BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-67. [PMID: 27718784 DOI: 10.1056/NEJMoa1602252] [Cited by in Crossref: 2749] [Cited by in F6Publishing: 2938] [Article Influence: 392.7] [Reference Citation Analysis]
Number Citing Articles
1 Pan C, Wu QV, Voutsinas J, Houlton JJ, Barber B, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Fromm JR, Rodriguez CP. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat. Head Neck 2023;45:391-7. [PMID: 36412064 DOI: 10.1002/hed.27252] [Reference Citation Analysis]
2 Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2023;41:790-802. [PMID: 36219809 DOI: 10.1200/JCO.21.02508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ho AL. Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol 2023;41:736-41. [PMID: 36223554 DOI: 10.1200/JCO.22.01408] [Reference Citation Analysis]
4 Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, Daud A, Behr SC. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol 2023;78:e131-6. [PMID: 36344282 DOI: 10.1016/j.crad.2022.09.127] [Reference Citation Analysis]
5 Roof L, Yilmaz E. Immunotherapy in HPV-Related Oropharyngeal Cancers. Curr Treat Options Oncol 2023;:1-14. [PMID: 36719604 DOI: 10.1007/s11864-023-01050-x] [Reference Citation Analysis]
6 Cossu Rocca M, Lorini L, Szturz P, Bossi P, Vermorken JB. Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope? Drugs Aging 2023. [PMID: 36715829 DOI: 10.1007/s40266-022-01000-6] [Reference Citation Analysis]
7 Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. Cancers 2023;15:852. [DOI: 10.3390/cancers15030852] [Reference Citation Analysis]
8 Pan X, Xu X, Wang L, Zhang S, Chen Y, Yang R, Chen X, Cheng B, Xia J, Ren X. BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1021262] [Reference Citation Analysis]
9 Yilmaz E, Ismaila N, Dabney R, Saba NF, Mell LK. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A. JCO Oncol Pract 2023;:OP2200802. [PMID: 36701647 DOI: 10.1200/OP.22.00802] [Reference Citation Analysis]
10 Williams KC, Gault A, Anderson AE, Stewart CJ, Lamb CA, Speight RA, Rajan N, Plummer R, Pratt AG. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1122430] [Reference Citation Analysis]
11 Verma A, Burtness B. Top advances of the year: Head and neck cancer. Cancer 2023. [PMID: 36692372 DOI: 10.1002/cncr.34654] [Reference Citation Analysis]
12 de Sousa LG, Lazar Neto F, Dal Lago EA, Sikora A, Hanna E, Moreno A, Phan J, Glisson BS, Bell D, Ferrarotto R. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol 2023;138:106311. [PMID: 36702015 DOI: 10.1016/j.oraloncology.2023.106311] [Reference Citation Analysis]
13 Han X, Sun Q, Lu C, Zhang M, Wang Y, Liu J, Guo Y, Mou Y, Li Y, Song X. Identification of novel ceRNA networks associated with PD- L1 in head and neck squamous cell carcinoma based on whole-transcriptome sequencing.. [DOI: 10.21203/rs.3.rs-2494934/v1] [Reference Citation Analysis]
14 Rao YJ, Goodman JF, Haroun F, Bauman JE. Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer. Cancers 2023;15:672. [DOI: 10.3390/cancers15030672] [Reference Citation Analysis]
15 Jin R, Hao J, Yu J, Wang P, Sauter ER, Li B. Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment. Cancers 2023;15:657. [DOI: 10.3390/cancers15030657] [Reference Citation Analysis]
16 Jimenez DG, Altunbulakli C, Swoboda S, Sobti A, Askmyr D, Ali A, Greiff L, Lindstedt M. Single-cell analysis of myeloid cells in HPV+ tonsillar cancer. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1087843] [Reference Citation Analysis]
17 Akbar S, Raza A, Mohsin R, Kanbour A, Qadri S, Parray A, Zar Gul AR, Philip A, Vijayakumar S, Merhi M, Hydrose S, Inchakalody VP, Al-abdulla R, Abualainin W, Sirriya SA, Al-bozom I, Uddin S, Khan OM, Mohamed Ibrahim MI, Al Homsi U, Dermime S. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1097117] [Reference Citation Analysis]
18 Kansal V, Burnham AJ, Kinney BLC, Saba NF, Paulos C, Lesinski GB, Buchwald ZS, Schmitt NC. Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. J Immunother Cancer 2023;11. [PMID: 36650022 DOI: 10.1136/jitc-2022-005940] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther 2023;8:31. [PMID: 36646686 DOI: 10.1038/s41392-022-01297-0] [Reference Citation Analysis]
20 Zhang W, Ling Y, Li Z, Peng X, Ren Y. Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. Cancer Med 2023. [PMID: 36645174 DOI: 10.1002/cam4.5590] [Reference Citation Analysis]
21 Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023. [PMID: 36645621 DOI: 10.1007/s40265-023-01835-2] [Reference Citation Analysis]
22 Li Y, Wang W, Hou X, Huang W, Zhang P, He Y, Wang B, Duan Q, Mao F, Guo D. Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth. Cell Death Dis 2023;14:28. [PMID: 36639372 DOI: 10.1038/s41419-023-05555-z] [Reference Citation Analysis]
23 Lee YG, Kang EJ, Keam B, Choi JH, Kim JS, Park KU, Lee KE, Lee KW, Kim MK, Ahn HK, Shin SH, Kim HR, Kim SB, Kim HJ, Yun HJ. Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01). Cancers (Basel) 2023;15. [PMID: 36672420 DOI: 10.3390/cancers15020471] [Reference Citation Analysis]
24 Lianova AA, Vladimirova LY, Abramova NA, Teplyakova MA, Popova IL, Tikhanovskaya NM, Storozhakova AE, Ryadinskaya LA, Udalenkova IA, Kalabanova EA, Trifanov D. Anti-PD‑1-induced type 1 diabetes mellitus in patient with recurrent oropharyngeal squamous cell cancer. Medicinskij alfavit 2023. [DOI: 10.33667/2078-5631-2022-31-28-34] [Reference Citation Analysis]
25 Wang N, Huang X, Cheng J. Identification of the function, immunological role and m6A modification of MYSM1 in head and neck squamous cell carcinoma.. [DOI: 10.21203/rs.3.rs-1734482/v1] [Reference Citation Analysis]
26 Mitchell AP, Goldstein DA. Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy. J Clin Oncol 2023;41:170-2. [PMID: 36265102 DOI: 10.1200/JCO.22.01711] [Reference Citation Analysis]
27 Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. J Clin Oncol 2023;41:222-32. [PMID: 36265101 DOI: 10.1200/JCO.22.01015] [Reference Citation Analysis]
28 Boss MK, Harrison LG, Gold A, Karam SD, Regan DP. Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. Front Oncol 2022;12:1033704. [PMID: 36698398 DOI: 10.3389/fonc.2022.1033704] [Reference Citation Analysis]
29 Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Challenges in neoantigen-directed therapeutics. Cancer Cell 2023;41:15-40. [PMID: 36368320 DOI: 10.1016/j.ccell.2022.10.013] [Reference Citation Analysis]
30 Dong H, Li M, Yang C, Wei W, He X, Cheng G, Wang S. Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. Cancer Cell Int 2023;23:1. [PMID: 36604694 DOI: 10.1186/s12935-022-02846-x] [Reference Citation Analysis]
31 William WN Jr, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, Gillenwater AM, Wistuba II, Myers JN, Gold KA, Ferrarotto R, Hwu P, Davoli T, Lee JJ, Heymach JV, Papadimitrakopoulou VA, Lippman SM. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer 2023. [PMID: 36597662 DOI: 10.1002/cncr.34607] [Reference Citation Analysis]
32 Matsubara Y, Toriyama K, Kadowaki S, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Masuishi T, Bando H, Ando M, Tajika M, Oze I, Hosoda W, Muro K. The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. Esophagus 2023. [PMID: 36595124 DOI: 10.1007/s10388-022-00978-7] [Reference Citation Analysis]
33 Lee A, Woods R, Mahfouz A, Kitpanit S, Cartano O, Mohamed N, Youssef I, Marqueen K, Sine K, Mah D, Neal B, Zakeri K, Kang JJ, Riaz N, Yu Y, McBride SM, Chen LD, Tsai CJ, Gelblum DY, Press RH, Michel LS, Sherman EJ, Pfister D, Dunn LA, Ho AL, Fetten J, Wong RJ, Boyle JO, Singh B, Cracchiolo JR, Ganly I, Cohen MA, Lee NY. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. JAMA Netw Open 2023;6:e2250607. [PMID: 36689229 DOI: 10.1001/jamanetworkopen.2022.50607] [Reference Citation Analysis]
34 Gao L, Yang F, Tang D, Xu Z, Tang Y, Yang D, Sun D, Chen Z, Teng Y. Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development. J Exp Clin Cancer Res 2023;42:1. [PMID: 36588153 DOI: 10.1186/s13046-022-02574-0] [Reference Citation Analysis]
35 Herter JM, Kiljan M, Kunze S, Reinscheid M, Ibruli O, Cai J, Niu L, Heßelmann I, Trommer M, Herter-Sprie GS, Köhler C, Marnitz S. Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlenther Onkol 2023;199:121-30. [PMID: 36251031 DOI: 10.1007/s00066-022-02007-z] [Reference Citation Analysis]
36 Mo DC, Huang JF, Luo PH, Chen L, Zou B, Wang HL. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2023;280:1-9. [PMID: 35907001 DOI: 10.1007/s00405-022-07571-9] [Reference Citation Analysis]
37 Pérez JMT, García-Cosío M, García-Castaño A, Gomà M, Mesia-Nin R, Ruiz-Bravo E, Soria-Rivas A, Castillo P, Braña-García I, Alberola-Ferranti M. Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Rev Esp Patol 2023;56:45-57. [PMID: 36599600 DOI: 10.1016/j.patol.2022.06.003] [Reference Citation Analysis]
38 Freudlsperger C, Moratin J, Hoffmann J. Tumoren im Kopf-Hals-Bereich. Mund-Kiefer-gesichtschirurgie 2023. [DOI: 10.1016/b978-3-437-24246-5.00021-4] [Reference Citation Analysis]
39 Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 2023;34:101-10. [PMID: 36522816 DOI: 10.1016/j.annonc.2022.10.006] [Reference Citation Analysis]
40 Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
41 Baudouin R, Badoual C, Lechien JR, Tartour E, Hans S. Peri-tumoral infiltrate in OSCC: “The simpler, the better” temptation. American Journal of Otolaryngology 2023;44:103666. [DOI: 10.1016/j.amjoto.2022.103666] [Reference Citation Analysis]
42 Freudlsperger C, Kühle R, Adeberg S, Moratin J, Fuchs J, Sandhu S, Regnery S, Hess J, Hoffmann J. Präzisionsmedizin in der Kopf-Hals-Onkologie durch den Einsatz innovativer Techniken. Onkologie 2023;29:12-23. [DOI: 10.1007/s00761-022-01252-2] [Reference Citation Analysis]
43 Gaipl US, Grosu AL, Frey B, Rückert M, Schäfer H, Popp I. Strahlentherapie und Immuntherapie. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-46764-0_177-1] [Reference Citation Analysis]
44 McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G Jr, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol 2023;9:102-11. [PMID: 36480191 DOI: 10.1001/jamaoncol.2022.5409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Razi S, Rezaei N. Introduction on Cancer Immunotherapy. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_180-1] [Reference Citation Analysis]
46 Weeks LD, Haddad RI. Head and neck cancers. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 2023. [DOI: 10.1016/b978-0-323-68135-3.00054-4] [Reference Citation Analysis]
47 Baldwin XL, Spanheimer PM, Downs-Canner S. A Review of Immune Checkpoint Blockade for the General Surgeon. J Surg Res 2023;281:289-98. [PMID: 36228339 DOI: 10.1016/j.jss.2022.08.040] [Reference Citation Analysis]
48 Liu S, Qin Z, Mao Y, Zhang W, Wang Y, Jia L, Peng X. Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma. OncoImmunology 2022;11:2130583. [DOI: 10.1080/2162402x.2022.2130583] [Reference Citation Analysis]
49 Saskova L, Tvrdy P, Melichar B, Pink R, Kral D, Michl P, Dvorak Z. Salivary and serum neopterin and interleukin 6 as biomarkers in patients with oral and oropharyngeal squamous cell carcinoma. Pteridines 2022;33:78-86. [DOI: 10.1515/pteridines-2022-0045] [Reference Citation Analysis]
50 Vigoda M, Mathieson C, Evans N, Hale C, Jennings J, Lucero O, Jeng S, Bottomly D, Clayburgh D, Andersen P, Li R, Petrisor D, Tyner JW, McWeeney S, Kulesz-Martin M. Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. Cancer Biol Ther 2022;23:310-8. [PMID: 35343367 DOI: 10.1080/15384047.2022.2055420] [Reference Citation Analysis]
51 Li HX, Liu TR, Tu ZX, Xie CB, Wen WP, Sun W. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma. Biomolecules 2022;13. [PMID: 36671475 DOI: 10.3390/biom13010090] [Reference Citation Analysis]
52 Kuba K, Inoue H, Matsumura S, Enoki Y, Kogashiwa Y, Ebihara Y, Nakahira M, Yamazaki T, Yasuda M, Kaira K, Kagamu H, Sugasawa M. A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. Sci Rep 2022;12:22557. [PMID: 36581686 DOI: 10.1038/s41598-022-27237-0] [Reference Citation Analysis]
53 Melo-Alvim C, Neves ME, Santos JL, Abrunhosa-Branquinho AN, Barroso T, Costa L, Ribeiro L. Radiotherapy, Chemotherapy and Immunotherapy-Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma. Diagnostics (Basel) 2022;13. [PMID: 36611391 DOI: 10.3390/diagnostics13010099] [Reference Citation Analysis]
54 Mehdi AM, Zhou C, Turrell G, Walpole E, Porceddu S, Frazer IH, Chandra J. HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer. Cancer Gene Ther 2022. [PMID: 36575316 DOI: 10.1038/s41417-022-00577-9] [Reference Citation Analysis]
55 Meyer R. Kopf-Hals-Tumoren: Checkpoint-Inhibitor verlängert Überleben bei erhaltener Lebensqualität. Deutsches Ärzteblatt Online 2022. [DOI: 10.3238/persdkk.2022.12.27.11] [Reference Citation Analysis]
56 Césaire M, Rambeau A, Clatot F, Johnson A, Heutte N, Thariat J. Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients. Eur Arch Otorhinolaryngol 2022. [PMID: 36564669 DOI: 10.1007/s00405-022-07800-1] [Reference Citation Analysis]
57 Fountzilas E, Vo HH, Mueller P, Kurzrock R, Tsimberidou A. Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials.. [DOI: 10.21203/rs.3.rs-2386222/v1] [Reference Citation Analysis]
58 Porciello N, Franzese O, D'Ambrosio L, Palermo B, Nisticò P. T-cell repertoire diversity: friend or foe for protective antitumor response? J Exp Clin Cancer Res 2022;41:356. [PMID: 36550555 DOI: 10.1186/s13046-022-02566-0] [Reference Citation Analysis]
59 Qin Z, Zhang W, Liu S, Wang Y, Peng X, Jia L. PVT1 Inhibition Stimulates Anti-tumor Immunity, Prevents Metastasis, and Depletes Cancer Stem Cells in Squamous Cell Carcinoma.. [DOI: 10.21203/rs.3.rs-2319966/v1] [Reference Citation Analysis]
60 Liu K, Huang T, Zhang H, Deng H, Tang M. Establishment and validation of a redox-related long non-coding RNAs prognostic signature in head and neck squamous cell carcinoma. Sci Rep 2022;12:22040. [PMID: 36543836 DOI: 10.1038/s41598-022-26490-7] [Reference Citation Analysis]
61 Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:579-97. [PMID: 36636451 DOI: 10.1016/j.jaccao.2022.09.004] [Reference Citation Analysis]
62 Liu H, Li Y. Potential roles of Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4) in head and neck squamous cell carcinoma. Cancer Biomark 2022;35:439-50. [PMID: 36404537 DOI: 10.3233/CBM-220143] [Reference Citation Analysis]
63 Ou Yamaguchi, Kazuyuki Atarashi, Kenichi Yoshimura, Ayako Shiono, Atsuhito Mouri, Fuyumi Nishihara, Yu Miura, Kosuke Hashimoto, Yoshiaki Miyamoto, Hitoshi Uga, Nobuo Seki, Tomoko Matsushima, Norihiro Kikukawa, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu. Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. BMC Cancer 2022;22:1325. [PMID: 36528575 DOI: 10.1186/s12885-022-10445-2] [Reference Citation Analysis]
64 Ono S, Suzuki S, Kondo Y, Okubo I, Goto M, Ogawa T, Kato H, Ito H, Takahara T, Satou A, Tsuzuki T, Yoshikawa K, Nagao T, Ueda R. Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma. Sci Rep 2022;12:21678. [PMID: 36522365 DOI: 10.1038/s41598-022-22773-1] [Reference Citation Analysis]
65 Wang Y, Du J, Gao Z, Sun H, Mei M, Wang Y, Ren Y, Zhou X. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer 2022. [DOI: 10.1038/s41416-022-02084-y] [Reference Citation Analysis]
66 Wang H, Xu Y, Zuo F, Liu J, Yang J. Immune-based combination therapy for esophageal cancer. Front Immunol 2022;13:1020290. [PMID: 36591219 DOI: 10.3389/fimmu.2022.1020290] [Reference Citation Analysis]
67 Yilmaz E, Ismaila N, Bauman JE, Dabney R, Gan G, Jordan R, Kaufman M, Kirtane K, McBride SM, Old MO, Rooper L, Saba NF, Sheth S, Subramaniam RM, Wise-Draper TM, Wong D, Mell LK. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. J Clin Oncol 2022;:JCO2202328. [PMID: 36521102 DOI: 10.1200/JCO.22.02328] [Reference Citation Analysis]
68 Stukan AI, Murashko RA, Tsygan NA, Goryainova AY, Nefedov ON, Porkhanov VA. Adaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender. Opuholi golovy i šei 2022;12:114-126. [DOI: 10.17650/2222-1468-2022-12-3-114-126] [Reference Citation Analysis]
69 von Witzleben A, Müller-Richter U, Maurus K, Brändlein S, Theodoraki MN, Brunner C, Laban S, Lennerz J, Möller P, Hoffmann TK, Doescher J, Schuler PJ. Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions. Int J Mol Sci 2022;23. [PMID: 36555474 DOI: 10.3390/ijms232415835] [Reference Citation Analysis]
70 Eichberger J, Spoerl S, Spanier G, Erber R, Taxis J, Schuderer J, Ludwig N, Fiedler M, Nieberle F, Ettl T, Geppert CI, Reichert TE, Spoerl S. TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma. Biomedicines 2022;10. [PMID: 36551992 DOI: 10.3390/biomedicines10123236] [Reference Citation Analysis]
71 Elias C, Zeidan YH, Bouferraa Y, Mukherji D, Temraz S, Charafeddine M, Al Darazi M, Shamseddine A. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). BMC Cancer 2022;22:1296. [PMID: 36503610 DOI: 10.1186/s12885-022-10373-1] [Reference Citation Analysis]
72 Willemsen ACH, De Moor N, Van Dessel J, Baijens LWJ, Bila M, Hauben E, van den Hout MFCM, Vander Poorten V, Hoeben A, Clement PM, Schols AMWJ. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients. Cancer Medicine 2022. [DOI: 10.1002/cam4.5522] [Reference Citation Analysis]
73 Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer 2022;22:1292. [PMID: 36494792 DOI: 10.1186/s12885-022-10398-6] [Reference Citation Analysis]
74 Yang Y, Ma B, Han L, Xu W, Du X, Wei W, Liao T, Ji Q, Qu N, Wang Y. Integrated single-cell and bulk RNA sequencing analyses reveal a prognostic signature of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Front Genet 2022;13:1028469. [PMID: 36568368 DOI: 10.3389/fgene.2022.1028469] [Reference Citation Analysis]
75 Liu Z, Meng X, Tang X, Zou W, He Y. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03310-5] [Reference Citation Analysis]
76 Kirtane K, St John M, Fuentes-Bayne H, Patel SP, Mardiros A, Xu H, Ng EW, Go WY, Wong DJ, Sunwoo JB, Welch JS. Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. J Clin Med 2022;11. [PMID: 36555876 DOI: 10.3390/jcm11247259] [Reference Citation Analysis]
77 Coordes A, Grund D, Mainka A, Olze H, Hanitsch L, von Bernuth H, Dommerich S. Rezidivierende Larynxpapillomatose. HNO 2022. [DOI: 10.1007/s00106-022-01250-1] [Reference Citation Analysis]
78 Cabezas-Camarero S, Merino-Menéndez S, Cabrera-Martín MN, Sotelo MJ, Plaza-Hernández JC, Falahat F, Iglesias-Moreno MC, Pérez-Segura P. Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. Oncol Lett 2023;25:37. [PMID: 36589672 DOI: 10.3892/ol.2022.13623] [Reference Citation Analysis]
79 Meliante PG, Barbato C, Zoccali F, Ralli M, Greco A, de Vincentiis M, Colizza A, Petrella C, Ferraguti G, Minni A, Fiore M. Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. Int J Mol Sci 2022;23. [PMID: 36499710 DOI: 10.3390/ijms232315384] [Reference Citation Analysis]
80 Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-richter U, Kiyota N, Roberts M, Khan TA, Miller-moslin K, Wei L, Argiris A. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. JCO 2022. [DOI: 10.1200/jco.22.00332] [Reference Citation Analysis]
81 Voronova V, Vislobokova A, Mutig K, Samsonov M, Peskov K, Sekacheva M, Materenchuk M, Bunyatyan N, Lebedeva S. Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. Front Oncol 2022;12:1035884. [PMID: 36544712 DOI: 10.3389/fonc.2022.1035884] [Reference Citation Analysis]
82 Xu J, Wang X, Zhu C, Wang K. A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers. Front Cell Dev Biol 2022;10:997633. [PMID: 36544907 DOI: 10.3389/fcell.2022.997633] [Reference Citation Analysis]
83 Wu C, Zhou K, Zheng Y, Lv D, Zhao M, Hu Y, Qi F, Wang X, Feng H. Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.969493] [Reference Citation Analysis]
84 Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
85 Zhou W, Zhang X, Feng Y, Zhang Y, Liu Z. The CC ligand chemokine family members CCL17/CCL22 predict the survival and response to immune checkpoint blockade therapy of patients with head and neck squamous cell carcinoma. Curr Probl Cancer 2022;46:100896. [PMID: 36167005 DOI: 10.1016/j.currproblcancer.2022.100896] [Reference Citation Analysis]
86 Sedano R, Cabrera D, Jiménez A, Ma C, Jairath V, Arrese M, Arab JP. Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. Am J Gastroenterol 2022;117:1917-32. [PMID: 36455219 DOI: 10.14309/ajg.0000000000001983] [Reference Citation Analysis]
87 Peissert F, Plüss L, Giudice AM, Ongaro T, Villa A, Elsayed A, Nadal L, Dakhel Plaza S, Scietti L, Puca E, De Luca R, Forneris F, Neri D. Selection of a PD-1 blocking antibody from a novel fully human phage display library. Protein Sci 2022;31:e4486. [PMID: 36317676 DOI: 10.1002/pro.4486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Chen X, Li J, Zhang R, Zhang Y, Wang X, Leung EL, Ma L, Wong VKW, Liu L, Neher E, Yu H. Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. J Extracell Vesicles 2022;11:e12279. [PMID: 36482876 DOI: 10.1002/jev2.12279] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Mehterov N, Sacconi A, Pulito C, Vladimirov B, Haralanov G, Pazardjikliev D, Nonchev B, Berindan-neagoe I, Blandino G, Sarafian V. A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1072579] [Reference Citation Analysis]
90 Murianni V, Cerbone L, Rescigno P, Catalano F, Damassi A, Cremante M, Gandini A, Puglisi S, Pesola G, Banna GL, Buti S, Signori A, Fornarini G, Rebuzzi SE. Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. Immunotherapy 2022;14:1419-27. [PMID: 36597723 DOI: 10.2217/imt-2022-0150] [Reference Citation Analysis]
91 Dennis MJ, Sacco AG, Qi Y, Bykowski J, Pittman E, Chen R, Messer K, Cohen EE, Gold KA. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncology 2022;135:106219. [DOI: 10.1016/j.oraloncology.2022.106219] [Reference Citation Analysis]
92 Li S, Sun Z. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. Cancer Letters 2022;550:215937. [DOI: 10.1016/j.canlet.2022.215937] [Reference Citation Analysis]
93 Schneidawind D, Frauenfeld L, Reinert CP, Lengerke C, Heidegger S. Plattenepithelkarzinom des Kopf-Hals-Bereichs: Palliative Systemtherapie. TumorDiagnostik & Therapie 2022;43:671-675. [DOI: 10.1055/a-1915-3411] [Reference Citation Analysis]
94 Karanam NK, Ding L, Vo DT, Giri U, Yordy JS, Story MD. miR-551a and miR-551b-3p target GLIPR2 and promote tumor growth in high-risk head and neck cancer by modulating autophagy. Advances in Cancer Biology - Metastasis 2022. [DOI: 10.1016/j.adcanc.2022.100085] [Reference Citation Analysis]
95 Qin X, Chen Y, Ma S, Shen L, Ju S. Immune-related gene TM4SF18 could promote the metastasis of gastric cancer cells and predict the prognosis of gastric cancer patients. Mol Oncol 2022;16:4043-59. [PMID: 36209368 DOI: 10.1002/1878-0261.13321] [Reference Citation Analysis]
96 Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer 2022. [PMID: 36456755 DOI: 10.1038/s41568-022-00531-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer 2022;177:175-85. [PMID: 36368251 DOI: 10.1016/j.ejca.2022.09.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Kao HF, Huang HC, Liao BC, Hong RL. Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. BMC Cancer 2022;22:1228. [PMID: 36443704 DOI: 10.1186/s12885-022-10343-7] [Reference Citation Analysis]
99 Lai C, Lin C, Su Y, Shih Y, Wang C, Teng CJ, Chou C. Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: An analysis from an endemic tertiary center. Cancer Medicine 2022. [DOI: 10.1002/cam4.5469] [Reference Citation Analysis]
100 Ma Y, Xin Y, Su D, Zhou Y, Li H, Zou H, Yu X, Yang Q, Cui J, Wang C, Zhang Y. Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.958783] [Reference Citation Analysis]
101 Pang L, Gan C, Xu J, Jia Y, Chai J, Huang R, Li A, Ge H, Yu S, Cheng H. Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. Cancers (Basel) 2022;14. [PMID: 36497209 DOI: 10.3390/cancers14235727] [Reference Citation Analysis]
102 Wang Z, Wang G, Lu H, Li H, Tang M, Tong A. Development of therapeutic antibodies for the treatment of diseases. Mol Biomed 2022;3:35. [PMID: 36418786 DOI: 10.1186/s43556-022-00100-4] [Reference Citation Analysis]
103 Daley JD, Olson AC, Bailey KM. Harnessing immunomodulation during DNA damage in Ewing sarcoma. Front Oncol 2022;12:1048705. [PMID: 36483025 DOI: 10.3389/fonc.2022.1048705] [Reference Citation Analysis]
104 Coray M, Göldi V, Schmid L, Benecke L, Figueiró F, Muller L. Differential Immunomodulatory Effects of Head and Neck Cancer-Derived Exosomes on B Cells in the Presence of ATP. Int J Mol Sci 2022;23. [PMID: 36430925 DOI: 10.3390/ijms232214446] [Reference Citation Analysis]
105 Okuda H, Shibata H, Watanabe T, Terazawa K, Mori K, Ueda N, Ohashi T, Ogawa T. Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. Cancers (Basel) 2022;14. [PMID: 36428780 DOI: 10.3390/cancers14225689] [Reference Citation Analysis]
106 Conway JW, Braden J, Wilmott JS, Scolyer RA, Long GV, Pires da Silva I. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1030147] [Reference Citation Analysis]
107 Nishikawa D, Suzuki H, Beppu S, Terada H, Sawabe M, Hanai N. Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer. Cancers (Basel) 2022;14. [PMID: 36428754 DOI: 10.3390/cancers14225662] [Reference Citation Analysis]
108 Ching-Yun Hsieh, Wei-Chao Chang, Ching-Chan Lin, Jong-Hang Chen, Chen-Yuan Lin, Chia-Hua Liu, Chen Lin, Mien-Chie Hung. Combination treatment of arsenic trioxide and osimertinib in recurrent and metastatic head and neck squamous cell carcinoma. Am J Cancer Res 2022;12. [PMID: 36504903] [Reference Citation Analysis]
109 Liu Z, Tian Y, Zhang X, Wang J, Yang J. Identification of a novel prognostic ADME-related signature associated with tumor immunity for aiding therapy in head and neck squamous cell carcinoma. Cancer Gene Ther 2022. [DOI: 10.1038/s41417-022-00557-z] [Reference Citation Analysis]
110 Fasaludeen A, Kumar RR, Rafi M, Nazeer F, Prakasan AM, Kumar N, George P, Ramadas K, Thommachan KC. Outcomes of organ preservation treatment in advanced laryngeal carcinoma: A retrospective analysis from a single institution. Mol Clin Oncol 2023;18:1. [PMID: 36545209 DOI: 10.3892/mco.2022.2597] [Reference Citation Analysis]
111 Murata D, Azuma K, Matama G, Zaizen Y, Matsuo N, Murotani K, Tokito T, Hoshino T. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer. Thorac Cancer 2023;14:73-80. [PMID: 36377039 DOI: 10.1111/1759-7714.14718] [Reference Citation Analysis]
112 Cillo AR, Mukherjee E, Bailey NG, Onkar S, Daley J, Salgado C, Li X, Liu D, Ranganathan S, Burgess M, Sembrat J, Weiss K, Watters R, Bruno TC, Vignali DAA, Bailey KM. Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. Clin Cancer Res 2022;28:4968-82. [PMID: 36074145 DOI: 10.1158/1078-0432.CCR-22-1471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
113 Zi M, Xingyu C, Yang C, Xiaodong S, Shixian L, Shicheng W. Improved antitumor immunity of chemotherapy in OSCC treatment by Gasdermin-E mediated pyroptosis. Apoptosis 2022. [DOI: 10.1007/s10495-022-01792-3] [Reference Citation Analysis]
114 Garcia-Mayea Y, Benítez-Álvarez L, Sánchez-García A, Bataller M, Companioni O, Mir C, Benavente S, Lorente J, Canela N, Fernández-Rozadilla C, Carracedo A, LLeonart ME. Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma. Cancers (Basel) 2022;14. [PMID: 36428603 DOI: 10.3390/cancers14225511] [Reference Citation Analysis]
115 Yamaguchi A, Saito Y, Narumi K, Furugen A, Takekuma Y, Shinagawa N, Shimizu Y, Dosaka-akita H, Sugawara M, Kobayashi M. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04425-z] [Reference Citation Analysis]
116 Zhou Q, Yuan O, Cui H, Hu T, Xiao GG, Wei J, Zhang H, Wu C. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.1007950] [Reference Citation Analysis]
117 Zhu Y, Zhang S, Lai Y, Pan J, Chen F, Wang T, Wang F, Xu Z, Yang W, Yu H. Self-Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer. Adv Sci (Weinh) 2022;9:e2203263. [PMID: 36344430 DOI: 10.1002/advs.202203263] [Reference Citation Analysis]
118 Wang F, Wei Q, Wu X. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.986357] [Reference Citation Analysis]
119 Hanada K, Tsunoda S, Nomura M, Fujimura S, Yutaka Y, Nishigori T, Hisamori S, Maekewa H, Hoshino N, Itami A, Tanaka E, Obama K. A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. surg case rep 2022;8:206. [DOI: 10.1186/s40792-022-01561-z] [Reference Citation Analysis]
120 Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A, Rossi E, Schinzari G, Tortora G, Di Pietro FR, Cerbelli B, Di Filippo A, Amirhassankhani S, Scala A, Zizzari IG, Cortesi E, Tomao S, Nuti M, Mezi S, Marchetti P. The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.974087] [Reference Citation Analysis]
121 Sato R, Kumai T, Ishida Y, Yuasa R, Kubota A, Wakisaka R, Komatsuda H, Yamaki H, Wada T, Harabuchi Y. The efficacy of PD-1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study. Laryngoscope Investig Otolaryngol 2022;7:1808-13. [PMID: 36544935 DOI: 10.1002/lio2.863] [Reference Citation Analysis]
122 Kenworthy C, Di M, Deshpande H. Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems in Cancer: Case Reports 2022. [DOI: 10.1016/j.cpccr.2022.100202] [Reference Citation Analysis]
123 Deng J, Yang J, Hou L, Wu J, He Y, Zhao M, Ni B, Wei D, Pfister H, Zhou C, Jiang T, She Y, Wu C, Chen C. Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. iScience 2022;25:105382. [DOI: 10.1016/j.isci.2022.105382] [Reference Citation Analysis]
124 Zhang L, Xu Q, Liu H, Li B, Wang H, Liu C, Li J, Yang B, Qin L, Han Z, Feng Z. The application of salvage surgery improves the quality of life and overall survival of extensively recurrent head and neck cancer after multiple operation plus radiotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1017630] [Reference Citation Analysis]
125 Suzuki S, Abe T, Endo T, Kaya H, Kitabayashi T, Kawasaki Y, Yamada T. Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab. CMAR 2022;Volume 14:3293-3302. [DOI: 10.2147/cmar.s382771] [Reference Citation Analysis]
126 Nishii N, Hirotsu Y, Takahashi Y, Takagawa Y, Amemiya K, Oyama T, Mochizuki H, Furusawa-nishii E, Harada H, Omata M. Observation of dynamic changes in neutrophil-to-lymphocyte ratio is useful for evaluating treatment response to nivolumab in PD-L1-negative advanced oral cancer. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 2022;34:833-841. [DOI: 10.1016/j.ajoms.2022.06.003] [Reference Citation Analysis]
127 Miao K, Zhang L. Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. Cancer Pathogenesis and Therapy 2022. [DOI: 10.1016/j.cpt.2022.11.003] [Reference Citation Analysis]
128 Zheng Y, Che J, Yuan M, Wu Z, Pang J, Zhou R, Li X, Dong C. A CT-Based Deep Learning Radiomics Nomogram to Predict Histological Grades of Head and Neck Squamous Cell Carcinoma. Academic Radiology 2022. [DOI: 10.1016/j.acra.2022.11.007] [Reference Citation Analysis]
129 Liu Z, Zheng Z, Dong L, Guo X, Jia X, Wang J, Meng L, Cui X, Jiang X. Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study. Sci Rep 2022;12:18327. [PMID: 36316341 DOI: 10.1038/s41598-022-20272-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Babyshkina NN, Dronova TA, Gervas PA, Popova NO, Dobrodeev AY, Kostromitsky DN, Afanasyev SG, Goldberg VE, Cherdyntseva NV. Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. Sib onkol ž 2022;21:135-141. [DOI: 10.21294/1814-4861-2022-21-5-135-141] [Reference Citation Analysis]
131 Yang H, Velmurugan BK, Chen M, Lin C, Lo Y, Chuang Y, Ho H, Hsieh M, Ko J. 7‐Epitaxol induces apoptosis in cisplatin‐resistant head and neck squamous cell carcinoma via suppression of AKT and MAPK signalling. J Cellular Molecular Medi 2022. [DOI: 10.1111/jcmm.17602] [Reference Citation Analysis]
132 Liu H, Wang D, Yang Z, Li S, Wu H, Xiang J, Kan S, Hao M, Liu W. Regulation of epigenetic modifications in the head and neck tumour microenvironment. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1050982] [Reference Citation Analysis]
133 Ma Y, Shi Y, Zhang G. Identification and Validation of a lipid metabolism-Immune-Based Prognostic Multiomics Signature for Oral Squamous Cell Carcinoma.. [DOI: 10.21203/rs.3.rs-2200774/v1] [Reference Citation Analysis]
134 Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, Falak R. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1018962] [Reference Citation Analysis]
135 Kang JJ, Yu Y, Chen L, Zakeri K, Gelblum DY, McBride SM, Riaz N, Tsai CJ, Kriplani A, Hung TKW, Fetten JV, Dunn LA, Ho AL, Boyle JO, Ganly IS, Singh B, Sherman EJ, Pfister DG, Wong RJ, Lee NY. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin 2022. [PMID: 36305841 DOI: 10.3322/caac.21758] [Reference Citation Analysis]
136 Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: Current therapeutics and emerging technologies. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1059133] [Reference Citation Analysis]
137 Olmos M, Lutz R, Büntemeyer T, Glajzer J, Nobis C, Ries J, Möst T, Eckstein M, Hecht M, Gostian A, Erdmann M, Foerster Y, Kesting M, Weber M. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck – a case series and review of literature. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.970823] [Reference Citation Analysis]
138 Nguyen NP, Kim L, Thariat J, Baumert BG, Mazibuko T, Gorobets O, Vinh-hung V, Giap H, Mehmood T, Vincent F, Chi A, Basu T, Loganadane G, Mohammadianpanah M, Karlsson U, Oboite E, Oboite J, Ali A, Page BR. Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group. Cancers 2022;14:5285. [DOI: 10.3390/cancers14215285] [Reference Citation Analysis]
139 Komatsuda H, Wakisaka R, Kono M, Kumai T, Hayashi R, Yamaki H, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Takahara M, Katada A, Kobayashi H. Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. Cancer Sci 2022. [PMID: 36285482 DOI: 10.1111/cas.15619] [Reference Citation Analysis]
140 Walker MD, Shane E. Hypercalcemia. JAMA 2022;328:1624. [DOI: 10.1001/jama.2022.18331] [Reference Citation Analysis]
141 Liu D, Zhou J, Wang Y, Li M, Jiang H, Liu Y, Yin X, Ge M, Xiang X, Ying J, Huang J, Zhang YQ, Cheng Y, Huang Z, Yuan X, Han W, Yan D, Wang X, Liu P, Wang L, Zhang X, Luo S, Liu T, Shen L. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. BMC Med 2022;20:408. [PMID: 36280870 DOI: 10.1186/s12916-022-02605-9] [Reference Citation Analysis]
142 Liu H, Zeng X, Ren X, Zhang Y, Huang M, Tan L, Dai Z, Lai J, Xie W, Chen Z, Peng S, Xu L, Chen S, Shen S, Kuang M, Lin S. Targeting tumour-intrinsic N(7)-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy. Gut 2022:gutjnl-2022-327230. [PMID: 36283801 DOI: 10.1136/gutjnl-2022-327230] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Menshikov KV, Sultanbaev AV, Musin SI, Izmailov AA, Lipatov ON, Menshikova IA, Sultanbaeva NI, Popova EV. Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). Kreativnaâ hirurgiâ i onkologiâ 2022;12:205-216. [DOI: 10.24060/2076-3093-2022-12-3-205-216] [Reference Citation Analysis]
144 Udagawa C, Nakano MH, Yoshida T, Ohe Y, Kato K, Mushiroda T, Zembutsu H. Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. Pharmacogenomics 2022. [PMID: 36268685 DOI: 10.2217/pgs-2022-0113] [Reference Citation Analysis]
145 Ye F, Wu P, Zhu Y, Huang G, Tao Y, Liao Z, Guan Y. Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma. Front Genet 2022;13:989081. [DOI: 10.3389/fgene.2022.989081] [Reference Citation Analysis]
146 Li Y, Goldberg EM, Chen X, Xu X, McGuire JT, Leuzzi G, Karagiannis D, Tate T, Farhangdoost N, Horth C, Dai E, Li Z, Zhang Z, Izar B, Que J, Ciccia A, Majewski J, Yoon AJ, Ailles L, Mendelsohn CL, Lu C. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell 2022;82:3901-3918.e7. [PMID: 36206767 DOI: 10.1016/j.molcel.2022.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Sanders C, Lau JF, Dietrich D, Strieth S, Brossart P, Kristiansen G. Nectin-4 is widely expressed in head and neck squamous cell carcinoma. Oncotarget 2022;13:1166-73. [PMID: 36268557 DOI: 10.18632/oncotarget.28299] [Reference Citation Analysis]
148 Mele D, Pessino G, Trisolini G, Luchena A, Benazzo M, Morbini P, Mantovani S, Oliviero B, Mondelli MU, Varchetta S. Impaired intratumoral natural killer cell function in head and neck carcinoma. Front Immunol 2022;13:997806. [DOI: 10.3389/fimmu.2022.997806] [Reference Citation Analysis]
149 John J, Woolaver RA, Popolizio V, Chen SMY, Ge H, Krinsky AL, Vashisht M, Kramer Y, Chen Z, Wang JH. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. Front Immunol 2022;13:992630. [DOI: 10.3389/fimmu.2022.992630] [Reference Citation Analysis]
150 Faur CI, Roman RC, Jurj A, Raduly L, Almășan O, Rotaru H, Chirilă M, Moldovan MA, Hedeșiu M, Dinu C. Salivary Exosomal MicroRNA-486-5p and MicroRNA-10b-5p in Oral and Oropharyngeal Squamous Cell Carcinoma. Medicina (Kaunas) 2022;58. [PMID: 36295638 DOI: 10.3390/medicina58101478] [Reference Citation Analysis]
151 Hata H, Matsumura C, Chisaki Y, Nishioka K, Tokuda M, Miyagi K, Suizu T, Yano Y. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. Cancer Control 2022;29:10732748221130576. [PMID: 36254804 DOI: 10.1177/10732748221130576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Chen Z, John J, Wang JH. Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors. Front Oncol 2022;12:995434. [DOI: 10.3389/fonc.2022.995434] [Reference Citation Analysis]
153 Yu X, Long Y, Chen B, Tong Y, Shan M, Jia X, Hu C, Liu M, Zhou J, Tang F, Lu H, Chen R, Xu P, Huang W, Ren J, Wan Y, Sun J, Li J, Jin G, Gong L. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. J Immunother Cancer 2022;10:e004590. [PMID: 36253000 DOI: 10.1136/jitc-2022-004590] [Reference Citation Analysis]
154 Zhang S, Zheng M, Nie D, Xu L, Tian H, Wang M, Liu W, Feng Z, Han F. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis. J Immunother Cancer 2022;10:e005158. [PMID: 36253001 DOI: 10.1136/jitc-2022-005158] [Reference Citation Analysis]
155 Khodadadi K, Moghimi M, Mansouri R. Cancer patients and targeted therapy during COVID-19 pandemic: A descriptive case series study. Clin Case Rep 2022;10:e6392. [PMID: 36267821 DOI: 10.1002/ccr3.6392] [Reference Citation Analysis]
156 Parmar K, Mohamed A, Vaish E, Thawani R, Cetnar J, Thein KZ. Immunotherapy in head and neck squamous cell carcinoma: An updated review. Cancer Treat Res Commun 2022;33:100649. [PMID: 36279709 DOI: 10.1016/j.ctarc.2022.100649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Yasumatsu R. The Role of Immune Checkpoint Inhibitors in Pharyngolaryngeal Cancer: A Current Review. The Journal of the Japan Broncho-esophagological Society 2022;73:318-324. [DOI: 10.2468/jbes.73.318] [Reference Citation Analysis]
158 Lin M, Sade-Feldman M, Wirth L, Lawrence MS, Faden DL. Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance. NPJ Precis Oncol 2022;6:71. [PMID: 36210388 DOI: 10.1038/s41698-022-00314-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Sánchez J, Nicolini V, Fahrni L, Waldhauer I, Walz AC, Jamois C, Fowler S, Simon S, Klein C, Umaña P, Friberg L, Frances N. Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1. AAPS J 2022;24:106. [PMID: 36207642 DOI: 10.1208/s12248-022-00755-5] [Reference Citation Analysis]
160 Galizia D, Minei S, Maldi E, Chilà G, Polidori A, Merlano MC. How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. Biomedicines 2022;10:2498. [PMID: 36289760 DOI: 10.3390/biomedicines10102498] [Reference Citation Analysis]
161 Sasaya T, Kubo T, Murata K, Mizue Y, Sasaki K, Yanagawa J, Imagawa M, Kato H, Tsukahara T, Kanaseki T, Tamura Y, Miyazaki A, Hirohashi Y, Torigoe T. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma. Cancer Med 2022. [PMID: 36200687 DOI: 10.1002/cam4.5310] [Reference Citation Analysis]
162 Hua Y, Sun X, Luan K, Wang C. Prognostic signature related to the immune environment of oral squamous cell carcinoma. Open Life Sci 2022;17:1135-47. [PMID: 36185403 DOI: 10.1515/biol-2022-0467] [Reference Citation Analysis]
163 Becker A, Zonnur S, Zimpfer A, Krause M, Schneider B, Strueder DF, Burmeister A, Erbersdobler A, Junghanss C, Maletzki C. CMTM6 and PD-L1 are independent prognostic biomarkers in head and neck squamous cell carcinoma.. [DOI: 10.21203/rs.3.rs-2111803/v1] [Reference Citation Analysis]
164 Som A, Rosenboom JG, Chandler A, Sheth RA, Wehrenberg-Klee E. Image-guided intratumoral immunotherapy: Developing a clinically practical technology. Adv Drug Deliv Rev 2022;189:114505. [PMID: 36007674 DOI: 10.1016/j.addr.2022.114505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
165 Shah JP, Wong RJ. Head and neck surgical oncology. J Surg Oncol 2022;126:860-4. [PMID: 36087078 DOI: 10.1002/jso.27029] [Reference Citation Analysis]
166 Gillison ML, Ferris RL, Harris J, Colevas AD, Mell LK, Kong C, Jordan RC, Moore KL, Truong M, Kirsch C, Chakravarti A, Blakaj DM, Clump DA, Ohr JP, Deeken JF, Gensheimer MF, Saba NF, Dorth JA, Rosenthal DI, Leidner RS, Kimple RJ, Machtay M, Curran WJ, Torres-saavedra P, Le QT. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Foundation 3504. International Journal of Radiation Oncology*Biology*Physics 2022. [DOI: 10.1016/j.ijrobp.2022.10.008] [Reference Citation Analysis]
167 Beck M, Semrau S, Haderlein M, Gostian AO, Hartwich J, Müller S, Kallies A, Geppert CI, Schonath M, Putz F, Gaipl U, Frey B, Saake M, Iro H, Uder M, Hartmann A, Kuwert T, Fietkau R, Eckstein M, Hecht M. Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer. Cancers (Basel) 2022;14:4811. [PMID: 36230733 DOI: 10.3390/cancers14194811] [Reference Citation Analysis]
168 Li X, Rui X, Li D, Wang Y, Tan F. Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma. Front Oncol 2022;12:994172. [DOI: 10.3389/fonc.2022.994172] [Reference Citation Analysis]
169 Taverna C, Franchi A. Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors in Head and Neck Cancer. Adv Anat Pathol 2022. [PMID: 36175939 DOI: 10.1097/PAP.0000000000000374] [Reference Citation Analysis]
170 Eshkiki ZS, Agah S, Tabaeian SP, Sedaghat M, Dana F, Talebi A, Akbari A. Neoantigens and their clinical applications in human gastrointestinal cancers. World J Surg Oncol 2022;20:321. [PMID: 36171610 DOI: 10.1186/s12957-022-02776-y] [Reference Citation Analysis]
171 Azuma T, Kano M, Iwata S, Honda S, Miyoshi Y, Nishiguchi J. Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. PLoS ONE 2022;17:e0274451. [DOI: 10.1371/journal.pone.0274451] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Kugimoto T, Oikawa Y, Kashima Y, Ohsako T, Kuroshima T, Hirai H, Tomioka H, Harada H. Prognostic impact of extended neck dissection in oral squamous cell carcinoma: a retrospective study.. [DOI: 10.21203/rs.3.rs-2101471/v1] [Reference Citation Analysis]
173 Marmonti E, Oliva-ramirez J, Haymaker C. Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. Cells 2022;11:3028. [DOI: 10.3390/cells11193028] [Reference Citation Analysis]
174 Azad A, Kong A. The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma. Cancers 2022;14:4694. [DOI: 10.3390/cancers14194694] [Reference Citation Analysis]
175 Becherini C, Banini M, Desideri I, Salvestrini V, Caprara L, Scotti V, Ganovelli M, Morelli I, Romei A, Livi L, Bonomo P. Clinical outcome of nivolumab in older and frail patients with recurrent/metastatic head and neck squamous cell carcinoma. J Geriatr Oncol 2022:S1879-4068(22)00228-4. [PMID: 36175350 DOI: 10.1016/j.jgo.2022.09.009] [Reference Citation Analysis]
176 Cao M, Shi E, Wang H, Mao L, Wu Q, Li X, Liang Y, Yang X, Wang Y, Li C. Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature. Int J Nanomedicine 2022;17:4293-306. [PMID: 36134201 DOI: 10.2147/IJN.S377816] [Reference Citation Analysis]
177 Kim CM, Lee JB, Shin SJ, Ahn JB, Lee M, Kim HS. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open 2022;7:100577. [PMID: 36156450 DOI: 10.1016/j.esmoop.2022.100577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
178 Luo H, Ye M, Hu Y, Wu M, Cheng M, Zhu X, Huang K. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. Aging (Albany NY) 2022;14. [PMID: 36152044 DOI: 10.18632/aging.204291] [Reference Citation Analysis]
179 Mesolella M, Evangelista A, Allosso S, Matano E, Motta G, Motta G. New Therapeutic Strategies in the Treatment of Stomal Recurrence After Total Laryngectomy: Role of Immunotherapy. Ear Nose Throat J 2022;:1455613221121237. [PMID: 36131507 DOI: 10.1177/01455613221121237] [Reference Citation Analysis]
180 Taneja N, Alam A, Patnaik RS, Taneja T. Current Trends in Anticancer Drug Delivery System for Oral Cancer- A PRISMA complaint Systematic Review. TODENTJ 2022;16:e187421062206275. [DOI: 10.2174/18742106-v16-e2206275] [Reference Citation Analysis]
181 Curry J, Alnemri A, Philips R, Fiorella M, Sussman S, Stapp R, Solomides C, Harshyne L, South A, Luginbuhl A, Tuluc M, Martinez-Outschoorn U, Argiris A, Linnenbach A, Johnson J. CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition. Laryngoscope 2022. [PMID: 36125263 DOI: 10.1002/lary.30389] [Reference Citation Analysis]
182 Tosi A, Parisatto B, Menegaldo A, Spinato G, Guido M, Del Mistro A, Bussani R, Zanconati F, Tofanelli M, Tirelli G, Boscolo-rizzo P, Rosato A. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors. J Exp Clin Cancer Res 2022;41:279. [DOI: 10.1186/s13046-022-02481-4] [Reference Citation Analysis]
183 近松 一. 頭頸部癌治療の最前線. Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 2022;125:1409-1413. [DOI: 10.3950/jibiinkotokeibu.125.9_1409] [Reference Citation Analysis]
184 Hermanns I, Kouka M, Schlattmann P, Guntinas-lichius O, Franco P. Mortality during In-Hospital Treatment for Head and Neck Cancer in Germany: A Diagnosis-Related Group-Based Nationwide Analysis, 2005–2018. Journal of Oncology 2022;2022:1-8. [DOI: 10.1155/2022/1387860] [Reference Citation Analysis]
185 Irabor OC, Nelson N, Shah Y, Niazi MK, Poiset S, Storozynsky E, Singla DK, Hooper DC, Lu B. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol 2022;12:940127. [DOI: 10.3389/fonc.2022.940127] [Reference Citation Analysis]
186 Bell RB, Gough M, Crittenden M, Young K. Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer. Journal of Clinical Investigation 2022;132:e162733. [DOI: 10.1172/jci162733] [Reference Citation Analysis]
187 He Y, Hu X, Su Y, Zeng J, Wei Z, Huang Y, Yang L, Peng X. Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis. Cancers 2022;14:4472. [DOI: 10.3390/cancers14184472] [Reference Citation Analysis]
188 Ju W, Xia R, Zhu D, Dou S, Zhu G, Dong M, Wang L, Sun Q, Zhao T, Zhou Z, Liang S, Huang Y, Tang Y, Wu S, Xia J, Chen S, Bai Y, Li J, Zhu Q, Zhong L. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-33080-8] [Reference Citation Analysis]
189 Hintzen G, Dulat HJ, Rajkovic E. Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. Front Oncol 2022;12:892212. [DOI: 10.3389/fonc.2022.892212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
190 De Azevedo J, Mourtada J, Bour C, Devignot V, Schultz P, Borel C, Pencreach E, Mellitzer G, Gaiddon C, Jung AC. The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells 2022;11:2866. [DOI: 10.3390/cells11182866] [Reference Citation Analysis]
191 Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 2022;13:964442. [DOI: 10.3389/fimmu.2022.964442] [Reference Citation Analysis]
192 Li Y, Huang X, Tong D, Jiang C, Zhu X, Wei Z, Gong T, Jin C. Relationships among microbiota, gastric cancer, and immunotherapy. Front Microbiol 2022;13:987763. [DOI: 10.3389/fmicb.2022.987763] [Reference Citation Analysis]
193 Okamoto I, Okada T, Tokashiki K, Tsukahara K. Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers (Basel) 2022;14:4413. [PMID: 36139573 DOI: 10.3390/cancers14184413] [Reference Citation Analysis]
194 Santiago-sánchez GS, Hodge JW, Fabian KP. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Front Immunol 2022;13:993624. [DOI: 10.3389/fimmu.2022.993624] [Reference Citation Analysis]
195 Seliger B, Al-samadi A, Yang B, Salo T, Wickenhauser C. In vitro models as tools for screening treatment options of head and neck cancer. Front Med 2022;9. [DOI: 10.3389/fmed.2022.971726] [Reference Citation Analysis]
196 Villanueva-fernández E, Hermsen MA, Suárez-fernández L, Vivanco B, Franchi A, García-marín R, Cabal VN, Codina-martínez H, Lorenzo-guerra SL, Llorente JL, López F. Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors. Biomedicines 2022;10:2205. [DOI: 10.3390/biomedicines10092205] [Reference Citation Analysis]
197 Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X, Li W. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front Pharmacol 2022;13:955701. [DOI: 10.3389/fphar.2022.955701] [Reference Citation Analysis]
198 Zhang T, Fang Q, Liu P, Wang P, Feng C, Wang J. Heme oxygenase 1 overexpression induces immune evasion of acute myeloid leukemia against natural killer cells by inhibiting CD48. J Transl Med 2022;20:394. [PMID: 36058936 DOI: 10.1186/s12967-022-03589-z] [Reference Citation Analysis]
199 Michikawa C, Gopalakrishnan V, Harrandah AM, Karpinets TV, Garg RR, Chu RA, Park YP, Chukkapallia SS, Yadlapalli N, Erikson-Carter KC, Gleber-Netto FO, Sayour E, Progulske-Fox A, Chan EKL, Wu X, Zhang J, Jobin C, Wargo JA, Pickering CR, Myers JN, Silver N. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia 2022;31:100813. [PMID: 35834946 DOI: 10.1016/j.neo.2022.100813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Takenaka Y, Takemoto N, Otsuka T, Nishio M, Tanida M, Fujii T, Hayashi K, Suzuki M, Mori M, Yamamoto Y, Uno A, Inohara H. Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study. Oral Oncol 2022;132:106018. [PMID: 35835055 DOI: 10.1016/j.oraloncology.2022.106018] [Reference Citation Analysis]
201 Desilets A, Soulières D. PI3K Inhibition for Squamous Cell Head and Neck Carcinoma. Cancer J 2022;28:369-76. [PMID: 36165725 DOI: 10.1097/PPO.0000000000000618] [Reference Citation Analysis]
202 Liu Y, Xue L, Xia Z, Zhang Q, Guo Y. Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study. Head Neck 2022;44:2040-5. [PMID: 35915862 DOI: 10.1002/hed.27085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Huang J, Huang Q, Xue J, Liu H, Guo Y, Chen H, Zhou L. Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade. J Int Med Res 2022;50:3000605221126874. [PMID: 36173010 DOI: 10.1177/03000605221126874] [Reference Citation Analysis]
204 Melssen MM, Fisher CT, Slingluff CL, Melief CJM. Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4 + and CD8 + T cells for immunotherapy of cancer. J Immunother Cancer 2022;10:e004709. [DOI: 10.1136/jitc-2022-004709] [Reference Citation Analysis]
205 Kadono T, Yamamoto S, Kato K. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Jpn J Clin Oncol 2022:hyac138. [PMID: 36047845 DOI: 10.1093/jjco/hyac138] [Reference Citation Analysis]
206 Jia Y, Cheng X, Liang W, Lin S, Li P, Yan Z, Zhang M, Ma W, Hu C, Wang B, Liu Z. CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis. Curr Res Transl Med 2022;70:103345. [PMID: 35487167 DOI: 10.1016/j.retram.2022.103345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
207 Yildirim HC, Guven DC, Aktepe OH, Taban H, Yilmaz F, Yasar S, Aksoy S, Erman M, Kilickap S, Yalcin S. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. JCM 2022;11:5171. [DOI: 10.3390/jcm11175171] [Reference Citation Analysis]
208 Pereira D, Martins D, Mendes F. Immunotherapy in Head and Neck Cancer When, How, and Why? Biomedicines 2022;10:2151. [DOI: 10.3390/biomedicines10092151] [Reference Citation Analysis]
209 Akdoğan O, Sütcüoğlu O, Öğüt B, Akyürek N, Özdemir N, Özet A, Yazıcı O. Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer. Immunotherapy 2022. [PMID: 36047777 DOI: 10.2217/imt-2021-0338] [Reference Citation Analysis]
210 Hagege A, Saada-bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. Cell Reports Medicine 2022;3:100659. [DOI: 10.1016/j.xcrm.2022.100659] [Reference Citation Analysis]
211 Wallington DG, Contessa JN, Hayman TJ. STING Agonists in Head and Neck Squamous Cell Carcinoma. Cancer J 2022;28:401-6. [PMID: 36165729 DOI: 10.1097/PPO.0000000000000620] [Reference Citation Analysis]
212 Long Z, Grandis JR, Johnson DE. Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opin Emerg Drugs 2022;27:333-44. [PMID: 36131561 DOI: 10.1080/14728214.2022.2125954] [Reference Citation Analysis]
213 Adkins D, Ley J, Cohen J, Oppelt P. The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma. Cancer J 2022;28:377-80. [PMID: 36165726 DOI: 10.1097/PPO.0000000000000617] [Reference Citation Analysis]
214 Liu Z, Meng X, Tang X, He Y. Intratumoral Tertiary Lymphoid Structures Promote Survival and Immunotherapy Response in Head Neck Squamous Cell Carcinoma.. [DOI: 10.21203/rs.3.rs-1987850/v1] [Reference Citation Analysis]
215 Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur J Cancer 2022:S0959-8049(22)00385-9. [PMID: 36038492 DOI: 10.1016/j.ejca.2022.06.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Yu C, Li Q, Zhang Y, Wen Z, Dong H, Mou Y. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front Cell Dev Biol 2022;10:941750. [DOI: 10.3389/fcell.2022.941750] [Reference Citation Analysis]
217 Chandrasekaran J, Elumalai S, Murugesan V, Kunjiappan S, Pavadai P, Theivendren P. Computational design of PD-L1 small molecule inhibitors for cancer therapy. Mol Divers 2022. [PMID: 36006501 DOI: 10.1007/s11030-022-10516-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Tang AL, O'Neil T, McDermott S, Tripathi S, Tikhtman R, Mark JR, Patil Y, Tabangin M, Altaye M, Wise-Draper TM, Zender CA. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients. JAMA Otolaryngol Head Neck Surg 2022. [PMID: 36006622 DOI: 10.1001/jamaoto.2022.2291] [Reference Citation Analysis]
219 Rao S, Jones M, Bowman J, Tian C, Spano J. POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Front Oncol 2022;12:935383. [DOI: 10.3389/fonc.2022.935383] [Reference Citation Analysis]
220 Kim S, Kim Y, Lee S, Kim Y, Jeon B, Kim H, Park H. Live Biotherapeutic Lactococcus lactis GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. Cancers 2022;14:4083. [DOI: 10.3390/cancers14174083] [Reference Citation Analysis]
221 Peng Q, Tan S, Xia L, Wu N, Oyang L, Tang Y, Su M, Luo X, Wang Y, Sheng X, Zhou Y, Liao Q. Phase separation in Cancer: From the Impacts and Mechanisms to Treatment potentials. Int J Biol Sci 2022;18:5103-22. [PMID: 35982902 DOI: 10.7150/ijbs.75410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Terazawa K, Ohashi T, Shibata H, Ishihara T, Ogawa T. Immune‐modified Glasgow prognostic score: A new prognostic marker for head and neck cancer. Head & Neck. [DOI: 10.1002/hed.27170] [Reference Citation Analysis]
223 Matoba T, Minohara K, Kawakita D, Takano G, Oguri K, Murashima A, Nakai K, Iwaki S, Tsuge H, Tanaka N, Imaizumi S, Hojo W, Matsumura A, Tsukamoto K, Esaki S, Iwasaki S. Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors. Sci Rep 2022;12:14319. [PMID: 35996017 DOI: 10.1038/s41598-022-18611-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Hempenius MA, Bisheshar SK, Slagter-Menkema L, van der Kamp MF, Halmos GB, Doff JJ, Willems SM, van der Vegt B. Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma. Oral Oncol 2022;134:106086. [PMID: 35995004 DOI: 10.1016/j.oraloncology.2022.106086] [Reference Citation Analysis]
225 Murata D, Azuma K, Matama G, Zaizen Y, Matsuo N, Murotani K, Tokito T, Hoshino T. Clinical Significance of Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor- Induced Interstitial Lung Disease in Patients with Non-Small Cell Lung Cancer.. [DOI: 10.21203/rs.3.rs-1961650/v1] [Reference Citation Analysis]
226 Guo T, Kang SY, Cohen EEW. Current perspectives on recurrent HPV-mediated oropharyngeal cancer. Front Oncol 2022;12:966899. [DOI: 10.3389/fonc.2022.966899] [Reference Citation Analysis]
227 Hobday SB, Brody RM, Kriegsman B, Basu D, Newman J, Cohen RB, Lukens JN, Singh A, D'Avella CA, Sun L. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors. JAMA Otolaryngol Head Neck Surg 2022. [PMID: 35980666 DOI: 10.1001/jamaoto.2022.2284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 B. Pathak A, Satyarthi S. Head Neck Squamous Cell Cancer Genomics: Oncogenes, Tumor Suppressor Genes and Clinical Implications. Molecular Mechanisms in Cancer 2022. [DOI: 10.5772/intechopen.101044] [Reference Citation Analysis]
229 Zhou X, Wang X. Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma. Biomedicines 2022;10:1990. [DOI: 10.3390/biomedicines10081990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Chiu W, Ou D, Tan C. Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer. IJMS 2022;23:9195. [DOI: 10.3390/ijms23169195] [Reference Citation Analysis]
231 Shen P, Qiao B, Jin N, Wang S. Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. Invest New Drugs 2022. [PMID: 35972629 DOI: 10.1007/s10637-022-01293-9] [Reference Citation Analysis]
232 Florez MA, Kemnade JO, Chen N, Du W, Sabichi AL, Wang DY, Huang Q, Miller-chism CN, Jotwani A, Chen AC, Hernandez D, Sandulache VC. Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access. Cancer Research Communications 2022;2:806-813. [DOI: 10.1158/2767-9764.crc-21-0143] [Reference Citation Analysis]
233 Jiang J, Ying H. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment. J Exp Clin Cancer Res 2022;41:244. [DOI: 10.1186/s13046-022-02457-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Li D, Li X, Zhao J, Tan F. Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. J Transl Med 2022;20:358. [PMID: 35962347 DOI: 10.1186/s12967-022-03559-5] [Reference Citation Analysis]
235 Rosenberg AJ, Agrawal N, Pearson AT, Gooi Z, Blair E, Portugal L, Cursio JF, Juloori A, Chin J, Rouse K, Villaflor VM, Seiwert TY, Izumchenko E, Lingen MW, Haraf DJ, Vokes EE. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer 2022. [PMID: 35945244 DOI: 10.1038/s41416-022-01941-0] [Reference Citation Analysis]
236 Zhang C, Liu H, Tan Y, Xu Y, Li Y, Tong S, Qiu S, Chen Q, Su Z, Tian D, Zhou W, Zhong C. MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. Front Immunol 2022;13:865020. [DOI: 10.3389/fimmu.2022.865020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
237 Gao L, Zhang A, Yang F, Du W. Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects. Vaccines (Basel) 2022;10:1272. [PMID: 36016159 DOI: 10.3390/vaccines10081272] [Reference Citation Analysis]
238 Konuthula N, Do OA, Gobillot T, Rodriguez CP, Futran ND, Houlton J, Barber BR. Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study. Head Neck 2022. [PMID: 35930296 DOI: 10.1002/hed.27162] [Reference Citation Analysis]
239 Xavier FCA, Silva JC, Rodini CO, Rodrigues MFSD. Mechanisms of immune evasion by head and neck cancer stem cells. Front Oral Health 2022;3. [DOI: 10.3389/froh.2022.957310] [Reference Citation Analysis]
240 Kiss I, Kuhn M, Hrusak K, Buchler B, Boublikova L, Buchler T. Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Front Oncol 2022;12:946307. [DOI: 10.3389/fonc.2022.946307] [Reference Citation Analysis]
241 Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol 2022;12:877594. [DOI: 10.3389/fonc.2022.877594] [Reference Citation Analysis]
242 Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, Navarro EA, Pasetto A, Nascimento Silva D, Ancarani V, Sambri V, Calabrò L, Martinelli G, Mazza M. T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. IJMS 2022;23:8590. [DOI: 10.3390/ijms23158590] [Reference Citation Analysis]
243 Lu HJ, Peng CY, Tseng HC, Hsin CH, Chuang CY, Chen CC, Huang WS, Chiu YW, Yang SF. Preoperative prediction model to evaluate salvage surgery in patients with recurrent or second primary oral cavity squamous cell carcinoma. Oral Oncol 2022;131:105951. [PMID: 35728414 DOI: 10.1016/j.oraloncology.2022.105951] [Reference Citation Analysis]
244 Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer 2022;10:e005036. [PMID: 35973745 DOI: 10.1136/jitc-2022-005036] [Reference Citation Analysis]
245 Pala L, Sala I, Oriecuia C, De Pas T, Queirolo P, Specchia C, Cocorocchio E, Ferrucci P, Patanè D, Saponara M, Pennacchioli E, Coppola S, Viale G, Giaccone G, Gelber RD, Bagnardi V, Conforti F. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5:e2226252. [PMID: 35972744 DOI: 10.1001/jamanetworkopen.2022.26252] [Reference Citation Analysis]
246 Ansary TM, Hossain MR, Komine M, Ohtsuki M. Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges. IJMS 2022;23:8530. [DOI: 10.3390/ijms23158530] [Reference Citation Analysis]
247 Ahmed KM, Veeramachaneni R, Deng D, Putluri N, Putluri V, Cardenas MF, Wheeler DA, Decker WK, Frederick AI, Kazi S, Sikora AG, Sandulache VC, Frederick MJ. Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer 2022;10:e004752. [PMID: 36002187 DOI: 10.1136/jitc-2022-004752] [Reference Citation Analysis]
248 Digkas E, Tabiim AJ, Smith D, Valachis A. Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis. Target Oncol 2022. [PMID: 35913645 DOI: 10.1007/s11523-022-00901-1] [Reference Citation Analysis]
249 Reis Ferreira M, Pasto A, Ng T, Patel V, Guerrero Urbano T, Sears C, Wade W. The microbiota and radiotherapy for head and neck cancer: what should clinical oncologists know? Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102442] [Reference Citation Analysis]
250 Søby S, Gothelf A, Gyldenkerne N, Bentzen J, Nowicka-Matus K, Tramm T, Eriksen JG. Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study. Acta Oncol 2022;:1-7. [PMID: 35913523 DOI: 10.1080/0284186X.2022.2103387] [Reference Citation Analysis]
251 Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer 2022;10:e005147. [PMID: 35940825 DOI: 10.1136/jitc-2022-005147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
252 Huang J, Xu Z, Yuan Z, Cheng L, Zhou C, Shen Y. Identification of cuproptosis‐related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Liu P, Ye M, Wu Y, Wu L, Lan K, Wu Z. Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes. Cancer Medicine. [DOI: 10.1002/cam4.5085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications 2022;2:739-753. [DOI: 10.1158/2767-9764.crc-22-0050] [Reference Citation Analysis]
255 Wakasaki T, Manako T, Yasumatsu R, Hara H, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, Nakagawa T. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study. PLoS ONE 2022;17:e0271907. [DOI: 10.1371/journal.pone.0271907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Righini M, Mollica V, Rizzo A, La Manna G, Massari F. Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. JCM 2022;11:4373. [DOI: 10.3390/jcm11154373] [Reference Citation Analysis]
257 Schlachtenberger G, Doerr F, Menghesha H, Lauinger P, Wolber P, Sabashnikov A, Popov AF, Macherey-Meyer S, Bennink G, Klussmann JP, Wahlers T, Hekmat K, Heldwein MB. Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review. Medicina (Kaunas) 2022;58:1000. [PMID: 35893115 DOI: 10.3390/medicina58081000] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Wu L, Jiang C, Zhu Z, Sun Y, Zhang T. Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis. PLoS ONE 2022;17:e0272080. [DOI: 10.1371/journal.pone.0272080] [Reference Citation Analysis]
259 Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang NA, Msari RA, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simon AB, Fox BA, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun 2022;13:4298. [PMID: 35879302 DOI: 10.1038/s41467-022-31941-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
260 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
261 Zhang S, Zhang W, Zhang J. 8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. Front Genet 2022;13:938611. [DOI: 10.3389/fgene.2022.938611] [Reference Citation Analysis]
262 Duhen T, Gough MJ, Leidner RS, Stanton SE. Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. Front Oral Health 2022;3. [DOI: 10.3389/froh.2022.902160] [Reference Citation Analysis]
263 Mukhopadhyay P, Ye J, Anderson KM, Roychoudhury S, Rubin EH, Halabi S, Chappell RJ. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis. JAMA Oncol 2022. [PMID: 35862037 DOI: 10.1001/jamaoncol.2022.2666] [Reference Citation Analysis]
264 Liu J, Ma J, Xing N, Ji Z, Li J, Zhang S, Guo Z. Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04201-z] [Reference Citation Analysis]
265 Noji R, Tohyama K, Kugimoto T, Kuroshima T, Hirai H, Tomioka H, Michi Y, Tasaki A, Ohno K, Ariizumi Y, Onishi I, Suenaga M, Mori T, Okamoto R, Yoshimura R, Miura M, Asakage T, Miyake S, Ikeda S, Harada H, Kano Y. Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. Cancers 2022;14:3476. [DOI: 10.3390/cancers14143476] [Reference Citation Analysis]
266 Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
267 Khalifa AM, Nakamura T, Sato Y, Sato T, Hyodo M, Hayakawa Y, Harashima H. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. Int J Pharm 2022;624:122034. [PMID: 35863595 DOI: 10.1016/j.ijpharm.2022.122034] [Reference Citation Analysis]
268 Ghosh S, Shah PA, Johnson FM. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2022;23:7889. [PMID: 35887235 DOI: 10.3390/ijms23147889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Baxi V, Lee G, Duan C, Pandya D, Cohen DN, Edwards R, Chang H, Li J, Elliott H, Pokkalla H, Glass B, Agrawal N, Lahiri A, Wang D, Khosla A, Wapinski I, Beck A, Montalto M. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Mod Pathol 2022. [PMID: 35840720 DOI: 10.1038/s41379-022-01119-2] [Reference Citation Analysis]
270 Issa M, Klamer BG, Mladkova N, Laliotis GI, Karivedu V, Bhateja P, Byington C, Dibs K, Pan X, Chakravarti A, Grecula J, Jhawar SR, Mitchell D, Baliga S, Old M, Carrau RL, Rocco JW, Blakaj DM, Bonomi M. Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort. BMC Cancer 2022;22:767. [PMID: 35836204 DOI: 10.1186/s12885-022-09809-5] [Reference Citation Analysis]
271 Shen DD, Bi YP, Pang JR, Zhao LJ, Zhao LF, Gao Y, Wang B, Liu HM, Liu Y, Wang N, Zheng YC, Liu HM. Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cell Mol Life Sci 2022;79:413. [PMID: 35819633 DOI: 10.1007/s00018-022-04431-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
272 Yu Y, Tian J, Hou Y, Zhang X, Li L, Cong P, Ji L, Wang X. A signature of immune-related gene pairs (IRGPs) for risk stratification and prognosis of oral cancer patients. World J Surg Oncol 2022;20:227. [PMID: 35804390 DOI: 10.1186/s12957-022-02630-1] [Reference Citation Analysis]
273 Huang Y, Liao J, Liang F, Lin P, Wu S, Ye Y, Gao M, Chen R, Zeng H, Yin X, Jiang Y, Ouyang N, Han P, Huang X. A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. Int Immunopharmacol 2022;110:108846. [PMID: 35816946 DOI: 10.1016/j.intimp.2022.108846] [Reference Citation Analysis]
274 Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E, Spindler KL, Tamberi S, Demols A, Guren MG, Arnold D, Fakih M, Kayyal T, Cornfeld M, Tian C, Catlett M, Smith M, Spano JP. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7:100529. [PMID: 35816951 DOI: 10.1016/j.esmoop.2022.100529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
275 Aristin Revilla S, Kranenburg O, Coffer PJ. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Front Immunol 2022;13:903564. [DOI: 10.3389/fimmu.2022.903564] [Reference Citation Analysis]
276 Wakasugi T, Nguyen TN, Takeuchi S, Ohkubo J, Suzuki H. Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck. Front Oncol 2022;12:876193. [DOI: 10.3389/fonc.2022.876193] [Reference Citation Analysis]
277 Choucair K, Naqash AR, Nebhan CA, Nipp R, Johnson DB, Saeed A. Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. Oncologist 2022:oyac119. [PMID: 35781739 DOI: 10.1093/oncolo/oyac119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Ziglari T, Claudio N, Nakayasu E, Kyle J, Guo Z, Pucci F. Senescent cell-derived extracellular vesicles recruit antigen presenting cells and limit squamous carcinoma recurrence.. [DOI: 10.1101/2022.06.30.498366] [Reference Citation Analysis]
279 Morimoto K, Yamada T, Morimoto Y, Ishikawa T, Asai J, Fujihara A, Arai A, Katoh N, Ukimura O, Hirano S, Itoh Y, Takayama K. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors. International Immunopharmacology 2022;108:108775. [DOI: 10.1016/j.intimp.2022.108775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Gameiro SR, Strauss J, Gulley JL, Schlom J. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status. Exp Biol Med (Maywood) 2022;247:1124-34. [PMID: 35473390 DOI: 10.1177/15353702221089910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. J Immunother Cancer 2022;10:e004610. [PMID: 35798536 DOI: 10.1136/jitc-2022-004610] [Reference Citation Analysis]
282 Ueda Y, Okano S, Enokida T, Fujisawa T, Ito K, Sato M, Tanaka H, Wada A, Tahara M. Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study. Oral Oncology 2022;130:105932. [DOI: 10.1016/j.oraloncology.2022.105932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Du K, Zou J, Wang B, Liu C, Khan M, Xie T, Huang X, Shen P, Tian Y, Yuan Y. A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. Front Immunol 2022;13:857934. [DOI: 10.3389/fimmu.2022.857934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Prajapati HP, Ansari A. Updates in the Management of Recurrent Glioblastoma Multiforme. J Neurol Surg A Cent Eur Neurosurg 2022. [DOI: 10.1055/s-0042-1749351] [Reference Citation Analysis]
285 Borse R, Ramakrishnan K, Gandhi J, Dhankhar P, Chirovsky D. Cost-Effectiveness of Pembrolizumab for the first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. J Med Econ 2022;:1-46. [PMID: 35765888 DOI: 10.1080/13696998.2022.2095826] [Reference Citation Analysis]
286 Lin Y, Liu T, Chen J, Wang C, Chen Y. Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. Front Public Health 2022;10:923619. [DOI: 10.3389/fpubh.2022.923619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Omura G, Honma Y, Matsumoto Y, Shinozaki T, Itoyama M, Eguchi K, Sakai T, Yokoyama K, Watanabe T, Ohara A, Kato K, Yoshimoto S. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. Auris Nasus Larynx 2022:S0385-8146(22)00167-5. [PMID: 35779979 DOI: 10.1016/j.anl.2022.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Huang J, Huo H, Lu R. A Novel Signature of Necroptosis-Associated Genes as a Potential Prognostic Tool for Head and Neck Squamous Cell Carcinoma. Front Genet 2022;13:907985. [PMID: 35754840 DOI: 10.3389/fgene.2022.907985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Tseha ST. Role of Adenoviruses in Cancer Therapy. Front Oncol 2022;12:772659. [PMID: 35756634 DOI: 10.3389/fonc.2022.772659] [Reference Citation Analysis]
290 Yu Y, Wang S, Su N, Pan S, Tu B, Zhao J, Shen Y, Qiu Q, Liu X, Luan J, Wang FS, Meng F, Shi M. Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. Front Oncol 2022;12:906824. [PMID: 35756643 DOI: 10.3389/fonc.2022.906824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Balachander K, Paramasivam A. Anti-PD-1 agent: A promising immunotherapy drug for oral cancer? Oral Oncol 2022;132:105997. [PMID: 35772187 DOI: 10.1016/j.oraloncology.2022.105997] [Reference Citation Analysis]
292 Ni L, Sun P, Ai M, Kong L, Xu R, Li J. Berberine inhibited the formation of metastasis by intervening the secondary homing of colorectal cancer cells in the blood circulation to the lung and liver through HEY2. Phytomedicine 2022;104:154303. [PMID: 35802997 DOI: 10.1016/j.phymed.2022.154303] [Reference Citation Analysis]
293 Trigo J, García-Cosío M, García-Castaño A, Gomà M, Mesia-Nin R, Ruiz-Bravo E, Soria-Rivas A, Castillo P, Braña-García I, Alberola-Ferranti M. Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2022. [PMID: 35739348 DOI: 10.1007/s12094-022-02856-1] [Reference Citation Analysis]
294 Shigefuku R, Yoshikawa K, Tsukimoto M, Owa H, Tamai Y, Tameda M, Ogura S, Sugimoto R, Tanaka H, Eguchi A, Sugimoto K, Hasegawa H, Iwasa M, Nakagawa H. A Case of Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab. Intern Med 2022. [PMID: 35732454 DOI: 10.2169/internalmedicine.9701-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Yu ZL, Liu JY, Chen G. Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns. NPJ Precis Oncol 2022;6:42. [PMID: 35729210 DOI: 10.1038/s41698-022-00287-3] [Reference Citation Analysis]
296 Bhatia S, Nguyen D, Darragh LB, Van Court B, Sharma J, Knitz MW, Piper M, Bukkapatnam S, Gadwa J, Bickett TE, Bhuvane S, Corbo S, Wu B, Lee Y, Fujita M, Joshi M, Heasley LE, Ferris RL, Rodriguez O, Albanese C, Kapoor M, Pasquale EB, Karam SD. EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. Nat Commun 2022;13:3535. [PMID: 35725568 DOI: 10.1038/s41467-022-31124-7] [Reference Citation Analysis]
297 Park BC, Jung S, Chen ST, Dewan AK, Johnson DB. Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. Am J Clin Dermatol 2022. [PMID: 35708849 DOI: 10.1007/s40257-022-00706-y] [Reference Citation Analysis]
298 Haist M, Mailänder V, Bros M. Nanodrugs Targeting T Cells in Tumor Therapy. Front Immunol 2022;13:912594. [PMID: 35693776 DOI: 10.3389/fimmu.2022.912594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
299 Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med 2022;20:271. [PMID: 35706041 DOI: 10.1186/s12967-022-03472-x] [Reference Citation Analysis]
300 Piersiala K, da Silva PFN, Lagebro V, Kolev A, Starkhammar M, Elliot A, Marklund L, Munck-Wikland E, Margolin G, Georén SK, Cardell LO. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. Transl Oncol 2022;23:101469. [PMID: 35714487 DOI: 10.1016/j.tranon.2022.101469] [Reference Citation Analysis]
301 Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, Albratty M, Meraya AM, Bungau SG. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules 2022;27:3798. [PMID: 35744922 DOI: 10.3390/molecules27123798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
302 Rad HS, Shiravand Y, Radfar P, Ladwa R, Perry C, Han X, Warkiani ME, Adams MN, Hughes BG, O'Byrne K, Kulasinghe A. Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clin Transl Immunology 2022;11:e1397. [PMID: 35686027 DOI: 10.1002/cti2.1397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Long Y, Yu X, Chen R, Tong Y, Gong L. Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. Front Immunol 2022;13:910704. [PMID: 35663968 DOI: 10.3389/fimmu.2022.910704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Wu Q, Luo S, Xie X. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75? J Immunother 2022. [PMID: 35674663 DOI: 10.1097/CJI.0000000000000426] [Reference Citation Analysis]
305 Mattoscio D, Ferri G, Miccolo C, Chiocca S, Romano M, Recchiuti A. Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer. Int J Mol Sci 2022;23:6473. [PMID: 35742918 DOI: 10.3390/ijms23126473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Kobayashi E, Kondo S, Dochi H, Moriyama-Kita M, Hirai N, Komori T, Ueno T, Nakanishi Y, Hatano M, Endo K, Sugimoto H, Wakisaka N, Yoshizaki T. Protein Farnesylation on Nasopharyngeal Carcinoma, Molecular Background and Its Potential as a Therapeutic Target. Cancers (Basel) 2022;14:2826. [PMID: 35740492 DOI: 10.3390/cancers14122826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Ascierto PA, Avallone A, Bhardwaj N, Bifulco C, Bracarda S, Brody JD, Buonaguro L, Demaria S, Emens LA, Ferris RL, Galon J, Khleif SN, Klebanoff CA, Laskowski T, Melero I, Paulos CM, Pignata S, Ruella M, Svane IM, Taube JM, Fox BA, Hwu P, Puzanov I. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. J Transl Med 2022;20:257. [PMID: 35672823 DOI: 10.1186/s12967-022-03471-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 Oyelakin A, Nayak KB, Glathar AR, Gluck C, Wrynn T, Tugores A, Romano RA, Sinha S. EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC. NAR Cancer 2022;4:zcac017. [PMID: 35664541 DOI: 10.1093/narcan/zcac017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
309 Staudte S, Klinghammer K, Jurmeister PS, Jank P, Blohmer JU, Liebs S, Rhein P, Hauser AE, Tinhofer I. Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers. Cancers (Basel) 2022;14:2810. [PMID: 35681790 DOI: 10.3390/cancers14112810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
310 Sauer AB, Daher GS, Lohse CM, Glasgow AE, Habermann EB, Douse DM, Moore EJ, Ighodaro ET, Van Abel KM, Yin LX. Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020: A Systematic Review. JAMA Otolaryngol Head Neck Surg 2022. [PMID: 35653143 DOI: 10.1001/jamaoto.2022.1028] [Reference Citation Analysis]
311 Wang W, Xie N, Yi C, Zhang M, Xiong G, Xu X, Hou J, Wang C. Prognostic and clinicopathological significance of cytocapsular tubes in oral squamous cell carcinoma. J Oral Pathol Med 2022. [PMID: 35652154 DOI: 10.1111/jop.13323] [Reference Citation Analysis]
312 McDowell L, Chua MLK, Beadle BM, Ma DJ, Mierzwa M, Thomson DJ, Margalit DN. A Bit More Here and a Little Less There: The Trials (and Tribulations) of Adjuvant and Neoadjuvant Head and Neck Studies in 2021. Int J Radiat Oncol Biol Phys 2022;113:243-51. [PMID: 35569469 DOI: 10.1016/j.ijrobp.2022.02.016] [Reference Citation Analysis]
313 Kiss I, Kuhn M, Hrusak K, Buchler T. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open 2022;7:100474. [DOI: 10.1016/j.esmoop.2022.100474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ, Lau D, Lesinski GB, Yarchoan M. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precis Oncol 2022;6:e2100510. [PMID: 35675577 DOI: 10.1200/PO.21.00510] [Reference Citation Analysis]
315 Alberti A, Lorini L, Ravanelli M, Perri F, Vinches M, Rondi P, Romani C, Bossi P. New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Vaccines 2022;10:885. [DOI: 10.3390/vaccines10060885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Chebib I, Mino-Kenudson M. PD-L1 immunohistochemistry: Clones, cutoffs, and controversies. APMIS 2022;130:295-313. [PMID: 35332576 DOI: 10.1111/apm.13223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
317 Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer. Clin Transl Med 2022;12:e901. [PMID: 35696531 DOI: 10.1002/ctm2.901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
318 Ebert MP, Meindl-Beinker NM, Gutting T, Maenz M, Betge J, Schulte N, Zhan T, Weidner P, Burgermeister E, Hofheinz R, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Gaiser T, Kather JN, Haertel N. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. Lancet Healthy Longev 2022;3:e417-27. [PMID: 36098320 DOI: 10.1016/S2666-7568(22)00116-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
319 Yue Q, Zhang Y, Wang F, Cao F, Bai J, Duan X, Huang J. Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. Journal of Immunology Research 2022;2022:1-17. [DOI: 10.1155/2022/8766735] [Reference Citation Analysis]
320 Nong C, Guan P, Li L, Zhang H, Hu H. Tumor immunotherapy: Mechanisms and clinical applications. MedComm – Oncology 2022;1. [DOI: 10.1002/mog2.8] [Reference Citation Analysis]
321 Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e004512. [PMID: 35676062 DOI: 10.1136/jitc-2022-004512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
322 Wiggins RH, Hoffman JM, Fine GC, Covington MF, Salem AE, Koppula BR, Morton KA. PET-CT in Clinical Adult Oncology-V. Head and Neck and Neuro Oncology. Cancers (Basel) 2022;14:2726. [PMID: 35681709 DOI: 10.3390/cancers14112726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Blatt S, Krüger M, Rump C, Zimmer S, Sagheb K, Künzel J. Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma. PLoS ONE 2022;17:e0269136. [DOI: 10.1371/journal.pone.0269136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Xiang Z, Li J, Zhang Z, Cen C, Chen W, Jiang B, Meng Y, Wang Y, Berglund B, Zhai G, Wu J. Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. Front Pharmacol 2022;13:883655. [DOI: 10.3389/fphar.2022.883655] [Reference Citation Analysis]
325 Petrillo A, Smyth EC. Immunotherapy for Squamous Esophageal Cancer: A Review. JPM 2022;12:862. [DOI: 10.3390/jpm12060862] [Reference Citation Analysis]
326 Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol 2022; 13(5): 388-411 [DOI: 10.5306/wjco.v13.i5.388] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
327 Cai Z, Tang B, Chen L, Lei W. Mast cell marker gene signature in head and neck squamous cell carcinoma. BMC Cancer 2022;22:577. [PMID: 35610596 DOI: 10.1186/s12885-022-09673-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Cui J, Chen Y, Ou Y, Liu G, Wen Q, Zhu W, Liang L, Chen Z, Yang H, Wang L, Wei M. Cancer germline antigen gene MAGEB2 promotes cell invasion and correlates with immune microenvironment and immunotherapeutic efficiency in laryngeal cancer. Clin Immunol 2022;:109045. [PMID: 35618211 DOI: 10.1016/j.clim.2022.109045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Uhara H, Tsuchida T, Kiyohara Y, Akamatsu A, Sakamoto T, Yamazaki N. Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance. J Dermatol 2022. [PMID: 35607248 DOI: 10.1111/1346-8138.16432] [Reference Citation Analysis]
330 Ma S, Wang F, Wang N, Jin J, Ba Y, Ji H, Du J, Hu S. Multiomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma. Front Neurol 2022;13:886913. [DOI: 10.3389/fneur.2022.886913] [Reference Citation Analysis]
331 Zhu Y, Liu K, Ding D, Wang K, Liu X, Tan X. Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. Front Pharmacol 2022;13:858207. [DOI: 10.3389/fphar.2022.858207] [Reference Citation Analysis]
332 Callejas-Valera JL, Vermeer DW, Lucido CT, Williamson C, Killian M, Vermeer PD, Spanos WC, Powell SF. Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2022;14:2499. [PMID: 35626103 DOI: 10.3390/cancers14102499] [Reference Citation Analysis]
333 Linxweiler M, Kühn JP, Neubert C, Khreish F, Balensiefer B, Wagner M, Schick B. Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma. J Otolaryngol Head Neck Surg 2022;51:21. [PMID: 35578359 DOI: 10.1186/s40463-022-00572-y] [Reference Citation Analysis]
334 De Keukeleire SJ, Vermassen T, Deron P, Huvenne W, Duprez F, Creytens D, Van Dorpe J, Ferdinande L, Rottey S. Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN. Cancers 2022;14:2431. [DOI: 10.3390/cancers14102431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
335 Yang CC, Lien CF, Hwang TZ, Wang CC, Wang CC, Shih YC, Yeh SA, Hsieh MC. Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa. Cancers (Basel) 2022;14:2351. [PMID: 35625956 DOI: 10.3390/cancers14102351] [Reference Citation Analysis]
336 Johnson L, McCune B, Locke D, Hedvat C, Wojcik JB, Schroyer C, Yan J, Johnson K, Sanders-Cliette A, Samala S, Dillon LM, Anderson S, Shuster J. Development of a LAG-3 immunohistochemistry assay for melanoma. J Clin Pathol 2022:jclinpath-2022-208254. [PMID: 35534200 DOI: 10.1136/jclinpath-2022-208254] [Reference Citation Analysis]
337 Bai Y, Pei Y, Xia L, Ma L, Deng S. A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. Front Pharmacol 2022;13:818170. [DOI: 10.3389/fphar.2022.818170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Nenclares P, Rullan A, Tam K, Dunn LA, St John M, Harrington KJ. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations. Am Soc Clin Oncol Educ Book 2022;42:1-16. [PMID: 35522916 DOI: 10.1200/EDBK_351336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
339 Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Front Pharmacol 2022;13:835510. [PMID: 35517794 DOI: 10.3389/fphar.2022.835510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
340 Borson S, Shuai Y, Branstetter BF, Nilsen ML, Hughes MA, Fenton M, Kubik M, Sridharan S, Clump DA, Skinner HD, Johnson JT, Chiosea SI, Ohr J, Duvvuri U, Kim S, Traylor KS, Ferris R, Zandberg DP. Definitive local therapy to head and neck squamous cell carcinoma with distant metastasis. Laryngoscope Investig Oto. [DOI: 10.1002/lio2.807] [Reference Citation Analysis]
341 Qiu MZ, Zhang Y, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X, Xue L, Tang W, Wu Y, Ren G, Wang L, Xi J, Jin Y, Li H, Hu C, Xu RH. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol 2022. [PMID: 35511148 DOI: 10.1001/jamaoncol.2022.0503] [Reference Citation Analysis]
342 Zhu C, Wu Q, Yang N, Zheng Z, Zhou F, Zhou Y. Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma. Front Genet 2022;13:848841. [DOI: 10.3389/fgene.2022.848841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Wusiman D, Guo L, Huang Z, Li Z, Liu S, Ying J, Li W, An C. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153934] [Reference Citation Analysis]
344 Michmerhuizen NL, Ludwig ML, Birkeland AC, Nimmagadda S, Zhai J, Wang J, Jewell BM, Genouw D, Remer L, Kim D, Foltin SK, Bhangale A, Kulkarni A, Bradford CR, Swiecicki PL, Carey TE, Jiang H, Brenner JC. Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma. Head Neck 2022;44:1192-205. [PMID: 35224804 DOI: 10.1002/hed.27018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Spoerl S, Gerken M, Chamilos C, Spoerl S, Fischer R, Vielsmeier V, Künzel J, Bohr C, Meier JK, Ettl T, Reichert TE, Spanier G. Clinical significance of panendoscopy in initial staging of oral squamous cell carcinoma and detection of synchronous second malignancies of the upper aerodigestive tract — Insights from a retrospective population-based cohort study. Journal of Cranio-Maxillofacial Surgery 2022. [DOI: 10.1016/j.jcms.2022.04.001] [Reference Citation Analysis]
346 Chen Y, Zheng X, Lin J, Gao X, Xiong J, Liu J, Fei Z, Chen C. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. Oral Oncology 2022;128:105860. [DOI: 10.1016/j.oraloncology.2022.105860] [Reference Citation Analysis]
347 Dreyfuss I, Frech FS, Hernandez L, Ramnot A, Rajabi-estarabadi A, Nouri K. Cells to Surgery Quiz: April 2022. Journal of Investigative Dermatology 2022;142:e51-7. [DOI: 10.1016/j.jid.2022.03.003] [Reference Citation Analysis]
348 Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro Jr G, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BG, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong R, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology 2022;128:105815. [DOI: 10.1016/j.oraloncology.2022.105815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
349 Neuenschwander B, Roychoudhury S, Wandel S, Natarajan K, Zuber E. The Predictive Individual Effect for Survival Data. Ther Innov Regul Sci 2022;56:492-500. [PMID: 35294767 DOI: 10.1007/s43441-022-00386-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Wei Z, Shen Y, Zhou C, Cao Y, Deng H, Shen Z. CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma. Bioengineered 2022;13:13784-800. [PMID: 35712757 DOI: 10.1080/21655979.2022.2084254] [Reference Citation Analysis]
351 Saada-bouzid E, Peyrade F, Guigay J. Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence? Current Opinion in Oncology 2022;34:196-203. [DOI: 10.1097/cco.0000000000000834] [Reference Citation Analysis]
352 Bedmutha A, Kaushal A. Pseudoprogression during Immunotherapy in Metastatic Head and Neck Squamous Cell Carcinoma. Radiology: Imaging Cancer 2022;4. [DOI: 10.1148/rycan.220037] [Reference Citation Analysis]
353 Wise-Draper TM, Bahig H, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. Am Soc Clin Oncol Educ Book 2022;42:1-14. [PMID: 35486888 DOI: 10.1200/EDBK_350442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
354 She L, Tian K, Han J, Zuo W, Wang Z, Zhang N. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis. Oral Oncol 2022;129:105871. [PMID: 35483156 DOI: 10.1016/j.oraloncology.2022.105871] [Reference Citation Analysis]
355 Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, Varricchi G. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol 2022;13:804597. [PMID: 35432346 DOI: 10.3389/fimmu.2022.804597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
356 Goel B, Tiwari AK, Pandey RK, Singh AP, Kumar S, Sinha A, Jain SK, Khattri A. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials. Transl Oncol 2022;21:101426. [PMID: 35460943 DOI: 10.1016/j.tranon.2022.101426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
357 Levy DA, Patel JJ, Nguyen SA, Nicholas Jungbauer W, Neskey DM, Cohen EEW, Paulos CM, Kaczmar JA, Knochelmann HM, Day TA. Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis. World j otorhinolaryngol -head neck surg . [DOI: 10.1002/wjo2.15] [Reference Citation Analysis]
358 Faraji F, Ramirez SI, Anguiano Quiroz PY, Mendez-Molina AN, Gutkind JS. Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer. Cells 2022;11:1370. [PMID: 35456049 DOI: 10.3390/cells11081370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
359 Le Naour J, Sztupinszki Z, Carbonnier V, Casiraghi O, Marty V, Galluzzi L, Szallasi Z, Kroemer G, Vacchelli E. A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. OncoImmunology 2022;11:2059878. [DOI: 10.1080/2162402x.2022.2059878] [Reference Citation Analysis]
360 Tsai YT, Strauss J, Toney NJ, Jochems C, Venzon DJ, Gulley JL, Schlom J, Donahue RN. Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. J Immunother Cancer 2022;10:e004601. [PMID: 35418484 DOI: 10.1136/jitc-2022-004601] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
361 Nguyen KA, Keith MJ, Keysar SB, Hall SC, Bimali A, Jimeno A, Wang XJ, Young CD. Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. Mol Carcinog 2022. [PMID: 35417043 DOI: 10.1002/mc.23409] [Reference Citation Analysis]
362 Chen C, Chen Y, Jin X, Ding Y, Jiang J, Wang H, Yang Y, Lin W, Chen X, Huang Y, Teng L. Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. Front Mol Biosci 2022;9:793403. [DOI: 10.3389/fmolb.2022.793403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, Zhang Z, Lu L, Zhang X. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol 2022;13:862084. [DOI: 10.3389/fimmu.2022.862084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
364 Zhang Y, Campbell BK, Stylli SS, Corcoran NM, Hovens CM. The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. Uro 2022;2:74-92. [DOI: 10.3390/uro2020010] [Reference Citation Analysis]
365 Yamazaki T. Clinical Use and Future Prospects of Immune Checkpoint Inhibitors in Head and Neck Carcinoma. The Journal of the Japan Broncho-esophagological Society 2022;73:80-82. [DOI: 10.2468/jbes.73.80] [Reference Citation Analysis]
366 Yasumatsu R. Effectiveness of Pembrolizumab in Patients with HNSCC in Japanese Real-World Clinical Practice. The Journal of the Japan Broncho-esophagological Society 2022;73:78-79. [DOI: 10.2468/jbes.73.78] [Reference Citation Analysis]
367 Kim JH, Ryu M, Park YS, Ma J, Lee SY, Kim D, Kang Y. Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09488-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Dou S, Zhang L, Wang C, Yao Y, Jiang W, Ye L, Li J, Wu S, Sun D, Gong X, Li R, Zhu G. EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma. Front Immunol 2022;13:813732. [PMID: 35371031 DOI: 10.3389/fimmu.2022.813732] [Reference Citation Analysis]
369 Wotman M, Gold B, Takahashi M, Draper L, Posner M. Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. Curr Otorhinolaryngol Rep. [DOI: 10.1007/s40136-022-00402-9] [Reference Citation Analysis]
370 Kondo Y, Suzuki S, Ono S, Goto M, Miyabe S, Ogawa T, Tsuchida H, Ito H, Takahara T, Satou A, Tsuzuki T, Yoshikawa K, Ueda R, Nagao T. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients. Int J Mol Sci 2022;23:4077. [PMID: 35456895 DOI: 10.3390/ijms23084077] [Reference Citation Analysis]
371 Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Noroozi-Aghideh A, Razeghian E. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 2022;20:44. [PMID: 35392976 DOI: 10.1186/s12964-022-00854-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 33.0] [Reference Citation Analysis]
372 Ishii R, Ohkoshi A, Kiyota N, Matsuura K, Yasuda K, Imamura Y, Saito Y, Homma A; Japan Clinical Oncology Group (JCOG) Head and Neck Cancer Study Group. Management of elderly patients with head and neck cancer. Jpn J Clin Oncol 2022;52:313-21. [PMID: 35165732 DOI: 10.1093/jjco/hyac013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Lu L, Zhang P, Cao X, Guan M, Vincenzi B. Prognosis and Characterization of Immune Microenvironment in Head and Neck Squamous Cell Carcinoma through a Pyroptosis-Related Signature. Journal of Oncology 2022;2022:1-19. [DOI: 10.1155/2022/1539659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
374 Huang Y, Lan Y, Zhang Z, Xiao X, Huang T. An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma. Front Oncol 2022;12:800315. [PMID: 35372036 DOI: 10.3389/fonc.2022.800315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Chen SMY, Popolizio V, Woolaver RA, Ge H, Krinsky AL, John J, Danis E, Ke Y, Kramer Y, Bian L, Nicklawsky AG, Gao D, Liu S, Chen Z, Wang XJ, Wang JH. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers. J Exp Clin Cancer Res 2022;41:123. [PMID: 35366939 DOI: 10.1186/s13046-022-02337-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
376 Jeon SM, Lim JS, Park SH, Kim HJ, Kim HR, Lee JH. Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation. Int J Oral Sci 2022;14:18. [PMID: 35365595 DOI: 10.1038/s41368-022-00168-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Tosello J, Borcoman E, Sedlik C, Piaggio E. Le rôle des ganglions lymphatiques drainant la tumeur à l’ère des immunothérapies. Bulletin de l'Académie Nationale de Médecine 2022;206:485-495. [DOI: 10.1016/j.banm.2021.11.025] [Reference Citation Analysis]
378 Farooq MZ, Aqeel SB, Lingamaneni P, Pichardo RC, Jawed A, Khalid S, Banskota SU, Fu P, Mangla A. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5:e227722. [PMID: 35438755 DOI: 10.1001/jamanetworkopen.2022.7722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
379 Kyriazoglou A, Beuselinck B. Equivocal evaluation of progressive disease in patients treated with immune checkpoint inhibitors: a challenge for clinical trials and biomarker research. Acta Clin Belg 2022;77:406-9. [PMID: 33308043 DOI: 10.1080/17843286.2020.1853886] [Reference Citation Analysis]
380 Ogiwara Y, Nakagawa M, Nakatani F, Uemura Y, Zhang R, Kudo-saito C. Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
381 Glazar DJ, Johnson M, Farinhas J, Steuer CE, Saba NF, Bonomi M, Chung CH, Enderling H. Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Oral Oncology 2022;127:105787. [DOI: 10.1016/j.oraloncology.2022.105787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
382 Suzuki S, Toyoma S, Abe T, Endo T, Kouga T, Kaswasaki Y, Yamada T. 18F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg 2022;51:13. [PMID: 35365214 DOI: 10.1186/s40463-022-00568-8] [Reference Citation Analysis]
383 Tagami M, Kakehashi A, Katsuyama-yoshikawa A, Misawa N, Sakai A, Wanibuchi H, Azumi A, Honda S. FOXP3 and CXCR4-positive regulatory T cells in the tumor stroma as indicators of tumor immunity in the conjunctival squamous cell carcinoma microenvironment. PLoS ONE 2022;17:e0263895. [DOI: 10.1371/journal.pone.0263895] [Reference Citation Analysis]
384 Park S, Kim CG, Kim D, Hong MH, Choi EC, Kim SH, Park YM, Kim J, Yoon SO, Kim G, Shin S, Kim K, Koh YW, Ha SJ, Kim HR. Disproportional enrichment of FoxP3+ CD4+ regulatory T cells shapes a suppressive tumour microenvironment in head and neck squamous cell carcinoma. Clin Transl Med 2022;12:e753. [PMID: 35343075 DOI: 10.1002/ctm2.753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Petitgas P, Lesouhaitier M, Boukthir S, Cattoir V, Tattevin P, Bénézit F. Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report. BMC Infect Dis 2022;22:306. [PMID: 35351017 DOI: 10.1186/s12879-022-07288-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
386 Zou Z, Li B, Wen S, Lin D, Hu Q, Wang Z, Fang J. The Current Landscape of Oral Squamous Cell Carcinoma: A Comprehensive Analysis from ClinicalTrials.gov. Cancer Control 2022;29:107327482210803. [DOI: 10.1177/10732748221080348] [Reference Citation Analysis]
387 Chalker C, Voutsinas JM, Wu QV, Santana-Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients. Cancer Med 2022. [PMID: 35349227 DOI: 10.1002/cam4.4722] [Reference Citation Analysis]
388 Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers (Basel) 2022;14:1710. [PMID: 35406483 DOI: 10.3390/cancers14071710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Someya M, Kondo T, Okimura A, Nakatsugawa M, Okubo M, Yunaiyama D, Takeda A, Kishida T, Yoshida S, Yonekura M, Ogawa Y, Tsukahara K. Tracheobronchial chondritis as an immune-related adverse event occurring during the administration of nivolumab for recurrent hypopharyngeal squamous cell carcinoma. Ear Nose Throat J 2022;:1455613221081912. [PMID: 35343278 DOI: 10.1177/01455613221081912] [Reference Citation Analysis]
390 Starzer AM, Heller G, Tomasich E, Melchardt T, Feldmann K, Hatziioannou T, Traint S, Minichsdorfer C, Schwarz-Nemec U, Nackenhorst M, Müllauer L, Preusser M, Berghoff AS, Fuereder T. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e003420. [PMID: 35338086 DOI: 10.1136/jitc-2021-003420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Goon P, Schürmann M, Oppel F, Shao S, Schleyer S, Pfeiffer CJ, Todt I, Brasch F, Scholtz L, Göerner M, Sudhoff H. Viral and Clinical Oncology of Head and Neck Cancers. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01263-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Saad AA. Targeting cancer-associated glycans as a therapeutic strategy in leukemia. All Life 2022;15:378-433. [DOI: 10.1080/26895293.2022.2049901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 2022;:JCO2102198. [PMID: 35333599 DOI: 10.1200/JCO.21.02198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
394 Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, Whittock H, Baker G, Kyula J, Guevara J, Melcher AA, Harper J, Ghadially H, Smith S, Pedersen M, McLaughlin M, Harrington KJ. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J Immunother Cancer 2022;10:e004306. [PMID: 35314434 DOI: 10.1136/jitc-2021-004306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
395 Li N, Xu T, Zhou Z, Li P, Jia G, Li X. Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review. Front Oncol 2022;12:837547. [DOI: 10.3389/fonc.2022.837547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
396 Lima Á, Sousa H, Medeiros R, Nobre A, Machado M. PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis. Discov Oncol 2022;13:19. [PMID: 35318527 DOI: 10.1007/s12672-022-00479-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Zidar N, Gale N. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hypopharynx, Larynx, Trachea and Parapharyngeal Space. Head Neck Pathol 2022. [PMID: 35312977 DOI: 10.1007/s12105-021-01405-6] [Reference Citation Analysis]
398 Kwon M. Treatment for Locoregionally Recurrent Head and Neck Cancers. Korean J Otorhinolaryngol-Head Neck Surg 2022;65:133-142. [DOI: 10.3342/kjorl-hns.2022.00087] [Reference Citation Analysis]
399 Powell SF, Mazurczak M, Dib EG, Bleeker JS, Geeraerts LH, Tinguely M, Lohr MM, Mcgraw SC, Jensen AW, Ellison CA, Black LJ, Puumala SE, Reed VJ, Miskimins WK, Lee JH, Spanos WC. Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. Invest New Drugs. [DOI: 10.1007/s10637-022-01235-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
400 Yamazaki T, Abue M, Itoh S, Sato I. A Case in which Mycophenolate Mofetil Administration Was Effective against Steroid-Refractory Liver Dysfunction Arising as a Nivolumab-Induced Immune-Related Adverse Event. Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 2022;125:285-290. [DOI: 10.3950/jibiinkotokeibu.125.3_285] [Reference Citation Analysis]
401 Peña-cardelles JF, Pozo-kreilinger JJ, Roncador G, Esteban-hernández J, Moro-rodríguez JE, Sastre-perona A, Castelo-fernández B, Cebrián-carretero JL. Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study. Biomedicines 2022;10:710. [DOI: 10.3390/biomedicines10030710] [Reference Citation Analysis]
402 Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. J Immunother Cancer 2022;10:e003917. [PMID: 35292516 DOI: 10.1136/jitc-2021-003917] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Ngan HL, Law CH, Choi YCY, Chan JY, Lui VWY. Precision drugging of the MAPK pathway in head and neck cancer. NPJ Genom Med 2022;7:20. [PMID: 35296678 DOI: 10.1038/s41525-022-00293-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
404 Ciraolo E, Althoff S, Ruß J, Rosnev S, Butze M, Pühl M, Frentsch M, Bullinger L, Na IK. Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. Int J Mol Sci 2022;23:3207. [PMID: 35328630 DOI: 10.3390/ijms23063207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
405 Hua Y, Dong R, Jin T, Jin Q, Chen X. Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment. Front Oncol 2022;12:781348. [PMID: 35280787 DOI: 10.3389/fonc.2022.781348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
406 Asai S, Koma A, Nohata N, Kinoshita T, Kikkawa N, Kato M, Minemura C, Uzawa K, Hanazawa T, Seki N. Impact of miR-1/miR-133 Clustered miRNAs: PFN2 Facilitates Malignant Phenotypes in Head and Neck Squamous Cell Carcinoma. Biomedicines 2022;10:663. [DOI: 10.3390/biomedicines10030663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
407 Liu Y, Zheng S, Wang T, Fang Z, Kong J, Liu J. Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:842220. [PMID: 35252205 DOI: 10.3389/fcell.2022.842220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
408 Chen Y, Huang H, Li Y, Xiao W, Liu Y, Chen R, Zhu Y, Zheng X, Wu C, Chen L. TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. Front Immunol 2022;13:832230. [DOI: 10.3389/fimmu.2022.832230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
409 Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer 2022. [PMID: 35254550 DOI: 10.1007/s10120-022-01286-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Clubb JHA, Kudling TV, Heiniö C, Basnet S, Pakola S, Cervera Carrascón V, Santos JM, Quixabeira DCA, Havunen R, Sorsa S, Zheng V, Salo T, Bäck L, Aro K, Tulokas S, Loimu V, Hemminki A. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. Front Immunol 2022;13:794251. [DOI: 10.3389/fimmu.2022.794251] [Reference Citation Analysis]
411 Chiang I, Lee Y, Tan Z, Hsu F, Tu H. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. Biomedicine & Pharmacotherapy 2022;147:112661. [DOI: 10.1016/j.biopha.2022.112661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
412 Abdalla AS, Sheybani ND, Khan SA. Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma. PET Clinics 2022. [DOI: 10.1016/j.cpet.2021.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
413 Chen L, Mo DC, Hu M, Zhao SJ, Yang QW, Huang ZL. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. Am J Otolaryngol 2022;43:103324. [PMID: 34923281 DOI: 10.1016/j.amjoto.2021.103324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
414 Cardin DB, Gilbert J, Whisenant JG, Ayers GD, Jalikis F, Dahlman KB, O'neal JF, Revetta F, Shi C, Berlin J. Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Routila J, Qiao X, Weltner J, Rantala JK, Carpén T, Hagström J, Mäkitie A, Leivo I, Ruuskanen M, Söderlund J, Rintala M, Hietanen S, Irjala H, Minn H, Westermarck J, Ventelä S. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Oral Oncol 2022;127:105772. [PMID: 35245886 DOI: 10.1016/j.oraloncology.2022.105772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
416 Wei B, Feng H, Wu H. Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment. IJGM 2022;Volume 15:3043-53. [DOI: 10.2147/ijgm.s349295] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
417 Shah H, Wang Y, Cheng SC, Gunasti L, Chen YH, Lako A, Guenette J, Rodig S, Jo VY, Uppaluri R, Haddad R, Schoenfeld JD, Jacene HA. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngol Head Neck Surg 2022;148:268-76. [PMID: 35050348 DOI: 10.1001/jamaoto.2021.4052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Li X, Duan J, Wang J, Qu Z, Ji M, Zhang B. Continuous particle separation of microfluidic chip with integrated inertial separation and dielectrophoresis separation. AIP Advances 2022;12:035148. [DOI: 10.1063/5.0075823] [Reference Citation Analysis]
419 Abdulrahman Z, Santegoets SJ, Sturm G, Charoentong P, Ijsselsteijn ME, Somarakis A, Höllt T, Finotello F, Trajanoski Z, van Egmond SL, Mustafa DAM, Welters MJP, de Miranda NFCC, van der Burg SH. Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. J Immunother Cancer 2022;10:e004346. [PMID: 35217577 DOI: 10.1136/jitc-2021-004346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
420 Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e003026. [PMID: 35217573 DOI: 10.1136/jitc-2021-003026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
421 Johnson L, Mccune B, Locke D, Hedvat C, Wojcik JB, Schroyer C, Yan J, Johnson K, Sanders-cliette A, Samala S, Dillon LM, Anderson S, Shuster J. Development of a LAG-3 Immunohistochemistry Assay for Melanoma.. [DOI: 10.1101/2022.02.25.481964] [Reference Citation Analysis]
422 Yang Q, Xu F, Jian A, Yu H, Ye T, Hu W. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Cell-Infiltration Characterization in Head and Neck Cancer. Front Cell Dev Biol 2021;9:803141. [PMID: 35198565 DOI: 10.3389/fcell.2021.803141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, William W, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer 2022;10:e004232. [PMID: 35193933 DOI: 10.1136/jitc-2021-004232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
424 Falco A, Leiva M, Blanco A, Cefarelli G, Rodriguez A, Melo J, Cayol F, Rizzo MM, Sola A, Rodríguez Montani H, Chacon M, Enrico D, Waisberg F. First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study. World J Clin Oncol 2022; 13(2): 147-158 [DOI: 10.5306/wjco.v13.i2.147] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
425 Yi K, Cui X, Liu X, Wang Y, Zhao J, Yang S, Xu C, Yang E, Xiao M, Hong B, Fang C, Kang C, Tan Y, Wang Q. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Front Immunol 2021;12:802795. [PMID: 35069587 DOI: 10.3389/fimmu.2021.802795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
426 Kataoka S, Moriguchi M, Okishio S, Takahashi A, Okuda K, Seko Y, Umemura A, Yamaguchi K, Miyagawa-Hayashino A, Itoh Y. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. Clin J Gastroenterol 2022. [PMID: 35201598 DOI: 10.1007/s12328-022-01590-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Qureshi HA, Zhu X, Yang GH, Steadele M, Pierce RH, Futran ND, Lee SM, Méndez E, Houghton AM. Impact of HPV status on immune responses in head and neck squamous cell carcinoma. Oral Oncol 2022;127:105774. [PMID: 35219073 DOI: 10.1016/j.oraloncology.2022.105774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
428 Solis RN, Silverman DA, Birkeland AC. Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer. Curr Treat Options Oncol 2022. [PMID: 35195839 DOI: 10.1007/s11864-022-00942-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
429 Suzuki S, Toyoma S, Kawasaki Y, Yamada T. Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma. PLoS One 2022;17:e0262549. [PMID: 35089951 DOI: 10.1371/journal.pone.0262549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
430 Rafael TS, Rotman J, Brouwer OR, van der Poel HG, Mom CH, Kenter GG, de Gruijl TD, Jordanova ES. Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. JCM 2022;11:1101. [DOI: 10.3390/jcm11041101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
431 Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol 2022. [PMID: 35172587 DOI: 10.2217/fon-2021-1634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
432 Bila M, Van Dessel J, Smeets M, Vander Poorten V, Nuyts S, Meulemans J, Clement PM. A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. Front Oncol 2022;12:761428. [PMID: 35155226 DOI: 10.3389/fonc.2022.761428] [Reference Citation Analysis]
433 Klinghammer K, Lorini L, Nevens D, Simon C, Machiels JP, Bossi P. Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. Front Oncol 2022;12:730785. [PMID: 35155222 DOI: 10.3389/fonc.2022.730785] [Reference Citation Analysis]
434 Aoki K, Hamamoto T, Chikuie N, Kono T, Taruya T, Ishino T, Ueda T, Takeno S. Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer. Auris Nasus Larynx 2022:S0385-8146(22)00034-7. [PMID: 35181217 DOI: 10.1016/j.anl.2022.02.002] [Reference Citation Analysis]
435 Wang D, Fang J, Wen S, Li Q, Wang J, Yang L, Dai W, Lu H, Guo J, Shan Z, Xie W, Liu X, Wen L, Shen J, Wang A, Chen Q, Wang Z. A comprehensive profile of TCF1+ progenitor and TCF1− terminally exhausted PD-1+CD8+ T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy. Int J Oral Sci 2022;14. [DOI: 10.1038/s41368-022-00160-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Deng H, Wei Z, Qiu S, Ye D, Gu S, Shen Y, Shen Z, Jin Y, Zhou C. Pyroptosis patterns and immune infiltrates characterization in head and neck squamous cell carcinoma. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
437 Allouchery M, Beuvon C, Pérault-Pochat MC, Roblot P, Puyade M, Martin M. Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers (Basel) 2022;14:955. [PMID: 35205703 DOI: 10.3390/cancers14040955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
438 Konwar M, Bose D, Maurya M, Ravi R. A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. J Oncol Pharm Pract 2022;:10781552221074315. [PMID: 35147454 DOI: 10.1177/10781552221074315] [Reference Citation Analysis]
439 Takenaka Y, Oya R, Takemoto N, Inohara H. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis. Head Neck 2022. [PMID: 35146824 DOI: 10.1002/hed.26997] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Okamoto I, Tsukahara K, Sato H. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. Sci Rep 2022;12:2025. [PMID: 35132165 DOI: 10.1038/s41598-022-06084-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 O'sullivan H, Conroy M, Power D, Bambury R, O’mahony D, Collins D, O’leary M, O’reilly S. Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study. J Palliat Care. [DOI: 10.1177/08258597221078391] [Reference Citation Analysis]
442 Lv S, Qian Z, Li J, Piao S, Li J, Guo J. Identification and Validation of a Hypoxia-Immune-Based Prognostic mRNA Signature for Oral Squamous Cell Carcinoma. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/5286251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
443 Heaton C. Oral Cavity. Essential Cases in Head and Neck Oncology 2022. [DOI: 10.1002/9781119775973.ch1] [Reference Citation Analysis]
444 Saddawi-konefka R, O’farrell A, Faraji F, Clubb L, Allevato MM, Anang NAS, Jensen SM, Wang Z, Wu VH, Yung BS, Msari RA, Pietryga IF, Molinolo AA, Mesirov JP, Simon AB, Fox BA, Bui JD, Sharabi A, Cohen EEW, Califano JA, Silvio Gutkind J. Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC.. [DOI: 10.1101/2022.02.01.478744] [Reference Citation Analysis]
445 Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu C, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang W, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 2022;386:449-62. [DOI: 10.1056/nejmoa2111380] [Cited by in Crossref: 64] [Cited by in F6Publishing: 90] [Article Influence: 64.0] [Reference Citation Analysis]
446 Kono M, Yamaki H, Komatsuda H, Kumai T, Hayashi R, Wakisaka R, Sato R, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Harabuchi Y. IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer. Transl Oncol 2022;18:101358. [PMID: 35123188 DOI: 10.1016/j.tranon.2022.101358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
447 Otsuki S, Hori R, Shinohara S, Kojima T, Tamaki H, Asato R, Kitamura M, Ichimaru K, Kitani Y, Kumabe Y, Honda K, Tsujimura T, Harada H, Ushiro K, Omori K. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Auris Nasus Larynx 2022. [DOI: 10.1016/j.anl.2022.02.006] [Reference Citation Analysis]
448 Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022. [PMID: 35105976 DOI: 10.1038/s41571-022-00603-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
449 Cw. Wong K, Johnson D, Hui EP, Ct. Lam R, By. Ma B, Tc. Chan A. Opportunities and Challenges in Combining Immunotherapy and Radiotherapy in Head and Neck Cancers. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
450 Decraene B, Yang Y, De Smet F, Garg AD, Agostinis P, De Vleeschouwer S. Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. Genes Immun 2022;23:1-11. [PMID: 35046546 DOI: 10.1038/s41435-021-00161-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
451 Wakasugi T, Takeuchi S, Ohkubo JI, Suzuki H. Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer. Acta Otolaryngol 2022;142:206-12. [PMID: 35148228 DOI: 10.1080/00016489.2022.2033317] [Reference Citation Analysis]
452 Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohnuma T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa T, Kochin V, Kawamura T, Matsue H, Hino M, Mano H, Suzuki Y, Nishikawa H, Togashi Y. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Cell Rep 2022;38:110331. [PMID: 35108529 DOI: 10.1016/j.celrep.2022.110331] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
453 Dormuth I, Liu T, Xu J, Yu M, Pauly M, Ditzhaus M. Which test for crossing survival curves? A user’s guideline. BMC Med Res Methodol 2022;22. [DOI: 10.1186/s12874-022-01520-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Kida W, Nakaya M, Ito A, Kozai Y, Bingo M. A Case of Acquired Factor V Inhibitor Following Nivolumab Administration. Cureus 2022. [DOI: 10.7759/cureus.21670] [Reference Citation Analysis]
455 Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK, Jha SK, Jha NK, Slama P, Roychoudhury S, Kumar D. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01503-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
456 Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB, Tamaskovics B, Hinke A, Zhou J, Frey B, Donaubauer A, Becker I, Semrau S, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Gostian A, Fietkau R. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. J Immunother Cancer 2022;10:e003747. [DOI: 10.1136/jitc-2021-003747] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
457 Xu S, Shi C, Xia R, Wang L, Tian Z, Ye W, Liu L, Liu S, Zhang C, Hu Y, Zhou R, Han Y, Wang Y, Zhang Z, Li J. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression. Front Immunol 2022;12:798424. [DOI: 10.3389/fimmu.2021.798424] [Reference Citation Analysis]
458 Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02251-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
459 de Bakker T, Journe F, Descamps G, Saussez S, Dragan T, Ghanem G, Krayem M, Van Gestel D. Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. Front Oncol 2021;11:799993. [PMID: 35071005 DOI: 10.3389/fonc.2021.799993] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
460 Basset-seguin N, Maubec E. Recent Advanced in the Treatment of Advanced SCC Tumors. Cancers 2022;14:550. [DOI: 10.3390/cancers14030550] [Reference Citation Analysis]
461 Lu HJ, Chiu YW, Lan WS, Peng CY, Tseng HC, Hsin CH, Chuang CY, Chen CC, Huang WS, Yang SF. Prediction Model of Distant Metastasis in Oral Cavity Squamous Cell Carcinoma With or Without Regional Lymphatic Metastasis. Front Oncol 2021;11:713815. [PMID: 35047382 DOI: 10.3389/fonc.2021.713815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Wondergem NE, Nijenhuis DNLM, Poell JB, Leemans CR, Brakenhoff RH, van de Ven R. At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma. Front Oral Health 2021;2:647980. [PMID: 35047999 DOI: 10.3389/froh.2021.647980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
463 Liu Y, Li G, Yang Y, Lu Z, Wang T, Wang X, Liu J. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Front Genet 2021;12:752025. [PMID: 35046996 DOI: 10.3389/fgene.2021.752025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Wildsmith S, Ye J, Franks A, Melillo G, Armstrong J, Whiteley J, Schnittker K, Lian F, Roland B, Sabalos C, Ahmadi P, Fayette J, Even C, Mesía R, Siu LL, Zandberg DP, Walker J. Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. Cancer Research Communications 2022;2:39-48. [DOI: 10.1158/2767-9764.crc-21-0032] [Reference Citation Analysis]
465 Zhou L, Zeng Z, Egloff AM, Zhang F, Guo F, Campbell KM, Du P, Fu J, Zolkind P, Ma X, Zhang Z, Zhang Y, Wang X, Gu S, Riley R, Nakahori Y, Keegan J, Haddad R, Schoenfeld JD, Griffith O, Manguso RT, Lederer JA, Liu XS, Uppaluri R. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. J Immunother Cancer 2022;10:e004034. [DOI: 10.1136/jitc-2021-004034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
466 Mclean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, Fox C, Kleid S, Rischin D. Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma. Front Oncol 2022;11:796197. [DOI: 10.3389/fonc.2021.796197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
467 van Duijvenvoorde M, Derks S, Bahce I, Leemans CR, van de Ven R, Fransen MF. Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy. Clin Transl Immunology 2022;11:e1363. [PMID: 35035956 DOI: 10.1002/cti2.1363] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
468 Cao R, Cui L, Zhang J, Ren X, Cheng B, Xia J. Immune-related lncRNA classification of head and neck squamous cell carcinoma. Cancer Cell Int 2022;22:25. [PMID: 35033066 DOI: 10.1186/s12935-022-02450-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
469 Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
470 Gameiro SF, Evans AM, Mymryk JS. The tumor immune microenvironments of HPV+ and HPV- head and neck cancers. WIREs Mech Dis 2022;14:e1539. [PMID: 35030304 DOI: 10.1002/wsbm.1539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
471 Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol 2022. [PMID: 35029519 DOI: 10.1080/17425255.2021.2029405] [Reference Citation Analysis]
472 Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol 2022;170:103596. [PMID: 35031442 DOI: 10.1016/j.critrevonc.2022.103596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Akashi K, Sakai T, Fukuoka O, Saito Y, Yoshida M, Ando M, Ito T, Murakami Y, Yamasoba T. Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer. Sci Rep 2022;12:572. [PMID: 35022425 DOI: 10.1038/s41598-021-04307-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
474 Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Kobayashi H, Harabuchi Y. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. Oncoimmunology 2022;11:2021619. [PMID: 35003900 DOI: 10.1080/2162402X.2021.2021619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
475 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
476 Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther 2022;236:108111. [PMID: 35016920 DOI: 10.1016/j.pharmthera.2022.108111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
477 Zhu C, Gu L, Yao M, Li J, Fang C. Prognostic Value of an Immune-Related Gene Signature in Oral Squamous Cell Carcinoma. Front Oncol 2021;11:776979. [PMID: 34993138 DOI: 10.3389/fonc.2021.776979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
478 Hwang GE, Lee JW, Jeon S, Cho IH, Kim HD. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer. Doc Ophthalmol 2022. [PMID: 34997406 DOI: 10.1007/s10633-021-09862-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
479 Ettl T, Schulz D, Bauer RJ. The Renaissance of Cyclin Dependent Kinase Inhibitors. Cancers (Basel) 2022;14:293. [PMID: 35053461 DOI: 10.3390/cancers14020293] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
480 Ma J, Hu X, Yao Y, Wu L, Sheng C, Chen K, Liu B. Characterization of Two Ferroptosis Subtypes With Distinct Immune Infiltration and Gender Difference in Gastric Cancer. Front Nutr 2021;8:756193. [PMID: 34977116 DOI: 10.3389/fnut.2021.756193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
481 Zhang S, Chen S, Wang Y, Zhan Y, Li J, Nong X, Gao B. Association of a Novel Prognosis Model with Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Thyroid Carcinoma. Front Genet 2021;12:744304. [PMID: 34976004 DOI: 10.3389/fgene.2021.744304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
482 Kumai T, Yamaki H, Kono M, Hayashi R, Wakisaka R, Komatsuda H. Antitumor Peptide-Based Vaccine in the Limelight. Vaccines (Basel) 2022;10:70. [PMID: 35062731 DOI: 10.3390/vaccines10010070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
483 Bunai K. Epidemiology of oral cancer and its relationship with inflammation. Inflammation and Oral Cancer 2022. [DOI: 10.1016/b978-0-323-88526-3.00001-4] [Reference Citation Analysis]
484 Low GMI, Thein KZ, Shah S, Chandra RA, Li RJ. Novel Multidisciplinary Paradigms: Surgery/Radiation, Immunotherapy, Organ Preservation. Multidisciplinary Management of Head and Neck Cancer 2022. [DOI: 10.1007/978-3-031-05973-5_2] [Reference Citation Analysis]
485 Bostan M, Ion G, Mihaila M, Roman V, Constantin C, Neagu MT. Oxidative Stress Player in Head and Neck Cancer Therapy Response. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_39] [Reference Citation Analysis]
486 Nguyen TT, Silva FN, Golemis EA. Aurora Kinases as Therapeutic Targets in Head and Neck Cancer. Cancer J 2022;28:387-400. [PMID: 36165728 DOI: 10.1097/PPO.0000000000000614] [Reference Citation Analysis]
487 Liu D, Gao S, Zhai Y, Yang X, Zhai G. Research progress of tumor targeted drug delivery based on PD-1/PD-L1. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
488 Romine PE, Rodriguez CP. Systemic Therapy Advances in Head and Neck Cancer. Multidisciplinary Management of Head and Neck Cancer 2022. [DOI: 10.1007/978-3-031-05973-5_5] [Reference Citation Analysis]
489 Polintan ET, Canicula SK, Catahay JA, Lo KB, Villalona-calero M, Loong HH. Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Ther Adv Med Oncol 2022;14:175883592211374. [DOI: 10.1177/17588359221137429] [Reference Citation Analysis]
490 Qian JM, Schoenfeld JD. Radiotherapy and Immunotherapy for Head and Neck Cancer. Multidisciplinary Management of Head and Neck Cancer 2022. [DOI: 10.1007/978-3-031-05973-5_7] [Reference Citation Analysis]
491 Müller-richter U, Hartmann S. Karzinome der Mundhöhle. Medikamentöse Tumortherapie von Kopf-Hals-Tumoren 2022. [DOI: 10.1007/978-3-662-62808-9_5] [Reference Citation Analysis]
492 Yoshioka Y, Hamana T, Mishima T, Tani R, Toratani S, Okamoto T. Nivolumab monotherapy after induction chemotherapy, bioradiotherapy, and cetuximab monotherapy leading to complete remission of locoregional advanced tongue cancer: A case report. Oral Science International 2022;19:72-76. [DOI: 10.1002/osi2.1114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
493 Oaks ZA, Shen CJ, Sheth SH, Gupta GP, Chera BS. Biomarkers in Head and Neck Cancer. Multidisciplinary Management of Head and Neck Cancer 2022. [DOI: 10.1007/978-3-031-05973-5_9] [Reference Citation Analysis]
494 Deschler-baier B, Hartmann S. Medikamentöse Tumortherapie des älteren Menschen. Medikamentöse Tumortherapie von Kopf-Hals-Tumoren 2022. [DOI: 10.1007/978-3-662-62808-9_11] [Reference Citation Analysis]
495 Campbell JS, Pai SI. Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer. Cancer J 2022;28:407-15. [PMID: 36165730 DOI: 10.1097/PPO.0000000000000621] [Reference Citation Analysis]
496 Kirtane K, Chung CH. Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer. Cancer Immunotherapy 2022. [DOI: 10.1007/13905_2022_34] [Reference Citation Analysis]
497 Mayer A, Schmidberger H. Tumoren im Kopf-Hals-Bereich. Therapie-Handbuch - Onkologie und Hämatologie 2022. [DOI: 10.1016/b978-3-437-23824-6.00032-8] [Reference Citation Analysis]
498 den bossche VV, Zaryouh H, Vara-messler M, Vignau J, Machiels J, Wouters A, Schmitz S, Corbet C. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Drug Resistance Updates 2022. [DOI: 10.1016/j.drup.2022.100806] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
499 Saniasiaya J, Mat Lazim N. Oropharyngeal and Hypopharyngeal Tumours and Their Treatment. Head and Neck Surgery : Surgical Landmark and Dissection Guide 2022. [DOI: 10.1007/978-981-19-3854-2_6] [Reference Citation Analysis]
500 Shafirstein G, Oakley E, Hamilton S, Habitzruther M, Chamberlain S, Sexton S, Curtin L, Bellnier DA. In Vivo Models for Studying Interstitial Photodynamic Therapy of Locally Advanced Cancer. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2099-1_11] [Reference Citation Analysis]
501 Kim M, Seo AN. Molecular Pathology of Gastric Cancer. J Gastric Cancer 2022;22:264. [DOI: 10.5230/jgc.2022.22.e35] [Reference Citation Analysis]
502 Tian T, Wang J, Yin F, Wu M, He W, Wang X, Zha Z, Wang H. Activation of Cascade-Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. Adv Healthc Mater 2022;11:e2102080. [PMID: 34655464 DOI: 10.1002/adhm.202102080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Wang Z, Anderson KS. Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer. Cancer J 2022;28:354-62. [PMID: 36165723 DOI: 10.1097/PPO.0000000000000615] [Reference Citation Analysis]
504 Tiwari RK, Ahmad A, Ansari IA, Bajpai P. Available immunotherapies and future opportunities to prevent HPV-associated cancers. Immunopathology, Diagnosis and Treatment of HPV Induced Malignancies 2022. [DOI: 10.1016/b978-0-323-91797-1.00001-6] [Reference Citation Analysis]
505 Iqbal MS, Smith E, Kelly CG. Head and Neck Cancer in Older Adults with Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_26] [Reference Citation Analysis]
506 Langer C, Wittekindt C. Oropharynx und Larynx. Medikamentöse Tumortherapie von Kopf-Hals-Tumoren 2022. [DOI: 10.1007/978-3-662-62808-9_6] [Reference Citation Analysis]
507 Wai K, Kang H. Epidemiology and Genomics of Head and Neck Squamous Cell Carcinoma. Multidisciplinary Management of Head and Neck Cancer 2022. [DOI: 10.1007/978-3-031-05973-5_8] [Reference Citation Analysis]
508 Olver I. Solid Tumours and Update on Modern Medical Oncology Interventions. Orofacial Supportive Care in Cancer 2022. [DOI: 10.1007/978-3-030-86510-8_3] [Reference Citation Analysis]
509 Enomoto N, Yamada K, Terayama M, Kato D, Yagi S, Wake H, Takemura N, Kiyomatsu T, Kokudo N. Current status of immune checkpoint inhibitor therapy for advanced esophageal squamous cell carcinoma. Glob Health Med 2021;3:378-85. [PMID: 35036619 DOI: 10.35772/ghm.2020.01112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
510 Pareek A, Patel AA, Kumar M, Kuttikat PG, Annadanam H, Pendse S, Mohammed N, Panchal HP. Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience. South Asian J Cancer. [DOI: 10.1055/s-0041-1733317] [Reference Citation Analysis]
511 Karukonda P, Odhiambo D, Mowery YM. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. Mol Carcinog 2021. [PMID: 34964992 DOI: 10.1002/mc.23384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
512 Chang JYF, Tseng CH, Lu PH, Wang YP. Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma. J Pers Med 2021;12:12. [PMID: 35055327 DOI: 10.3390/jpm12010012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
513 Tarantino P, Barroso-Sousa R, Garrido-Castro AC, McAllister SS, Guerriero JL, Mittendorf E, Curigliano G, Tolaney SM. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Rev Anticancer Ther 2021;:1-13. [PMID: 34919490 DOI: 10.1080/14737140.2022.2020650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
514 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
515 Vos JL, Zuur CL, Smit LA, de Boer JP, Al-mamgani A, van den Brekel MWM, Haanen JBAG, Vogel WV. [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-021-05610-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
516 Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
517 Joseph L, C Nickel A, Patel A, F Saba N, R Leon A, F El-Chami M, M Merchant F. Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors. J Atr Fibrillation 2021;13:2461. [PMID: 34950337 DOI: 10.4022/jafib.2461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
518 Hamada N, Maeda A, Takase-Minegishi K, Kirino Y, Sugiyama Y, Namkoong H, Horita N, Yoshimi R, Nakajima H; YCU irAE Working Group. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. Front Immunol 2021;12:803410. [PMID: 34938300 DOI: 10.3389/fimmu.2021.803410] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
519 Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden L, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, Blank CU, de Boer JP, Haanen JBAG, Zuur CL. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun 2021;12. [DOI: 10.1038/s41467-021-26472-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
520 Guven DC, Aktepe OH, Aksun MS, Sahin TK, Kavgaci G, Ucgul E, Cakir IY, Yildirim HC, Guner G, Akin S, Kertmen N, Dizdar O, Aksoy S, Erman M, Yalcin S, Kilickap S. The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors. Cancer Biomark 2021. [PMID: 34958005 DOI: 10.3233/CBM-210349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
521 Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao S, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun 2021;12. [DOI: 10.1038/s41467-021-27619-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
522 Chai LF, Hardaway JC, Heatherton KR, O'Connell KP, LaPorte JP, Guha P, Lopes MC, Rabinowitz BA, Jaroch D, Cox BF, Knight R, Katz SC. Regional Delivery of CAR-T Effectively Controls Tumor Growth in Colorectal Liver Metastasis Model. J Surg Res 2021;272:37-50. [PMID: 34929499 DOI: 10.1016/j.jss.2021.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
523 Shaikh H, McGrath JE, Hughes B, Xiu J, Brodskiy P, Sukari A, Darabi S, Ikpeazu C, Nabhan C, Korn WM, Wise-Draper TM. Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes. Cancers (Basel) 2021;13:6309. [PMID: 34944929 DOI: 10.3390/cancers13246309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
524 Calvo V, Fernández MA, Collazo-Lorduy A, Franco F, Núñez B, Provencio M. Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Manag 2021;10:LMT51. [PMID: 34899991 DOI: 10.2217/lmt-2021-0003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
525 Gupta S, Vanderbilt CM, Zhang Y, Tickoo SK, Fine SW, Gopalan A, Chen Y, Sirintrapun SJ, Teo MY, Funt SA, Iyer G, Rosenberg JE, Bajorin DF, Bochner BH, Pietzak EJ, Ross DS, Ladanyi M, Cheville JC, Solit DB, Reuter VE, Al-ahmadie HA. CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. BLC 2021;7:395-400. [DOI: 10.3233/blc-201532] [Reference Citation Analysis]
526 Omata J, Ueki Y, Takahashi T, Shodo R, Yamazaki K, Saijo K, Ota H, Togashi T, Sato Y, Horii A. Treatment Outcomes and the Safety of Chemoradiotherapy With High-Dose CDDP for Elderly Patients With Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Study. Front Surg 2021;8:753049. [PMID: 34888343 DOI: 10.3389/fsurg.2021.753049] [Reference Citation Analysis]
527 Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A, Safarpour H, Bernardini R, Brunetti O, Sonnessa M, Fasano R, Silvestris N, Baradaran B. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacother 2021;146:112516. [PMID: 34906767 DOI: 10.1016/j.biopha.2021.112516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
528 Li C, Chen X, Ren X, Chen JL, Chen H, Yu JJ, Ran QC, Kang S, Chen XM, Zhao ZJ. Identification of Hypoxia-Related Molecular Classification and Associated Gene Signature in Oral Squamous Cell Carcinoma. Front Oncol 2021;11:709865. [PMID: 34888229 DOI: 10.3389/fonc.2021.709865] [Reference Citation Analysis]
529 Qian J, Ding W, Jiang Y, Xu L. Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors. 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2021. [DOI: 10.1109/bibm52615.2021.9669586] [Reference Citation Analysis]
530 Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe A, Somasundaram AS, Shan F, Magnon GC, Kunning SR, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F, Buckanovich R, Schoen RE, Kim S, Duvvuri U, Zeh H, Edwards R, Kirkwood JM, Coffman L, Ferris RL, Bruno TC, Vignali DAA. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Sci Transl Med 2021;13:eabf8495. [PMID: 34878821 DOI: 10.1126/scitranslmed.abf8495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
531 Cavalieri S, Filippini DM, Ottini A, Bergamini C, Resteghini C, Colombo E, Lombardo R, Nuzzolese I, Alfieri S, Licitra L, Locati LD. Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00062] [Reference Citation Analysis]
532 Cabezas-Camarero S, Pérez-Segura P. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective. Crit Rev Oncol Hematol 2021;169:103569. [PMID: 34890800 DOI: 10.1016/j.critrevonc.2021.103569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
533 Gong W, Donnelly CR, Heath BR, Bellile E, Donnelly LA, Taner HF, Broses L, Brenner JC, Chinn SB, Ji RR, Wen H, Nör JE, Wang J, Wolf GT, Xie Y, Lei YL. Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion. Oncoimmunology 2021;10:1997385. [PMID: 34858725 DOI: 10.1080/2162402X.2021.1997385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
534 Schulz D, Wetzel M, Eichberger J, Piendl G, Brockhoff G, Wege AK, Reichert TE, Ettl T, Bauer RJ. Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2021;22:13087. [PMID: 34884892 DOI: 10.3390/ijms222313087] [Reference Citation Analysis]
535 Hermanns I, Ziadat R, Schlattmann P, Guntinas-Lichius O. Trends in Treatment of Head and Neck Cancer in Germany: A Diagnosis-Related-Groups-Based Nationwide Analysis, 2005-2018. Cancers (Basel) 2021;13:6060. [PMID: 34885170 DOI: 10.3390/cancers13236060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
536 Watanabe Y, Ogawa M, Tamura Y, Suda S, Kaneko M, Kumagawa M, Hirayama M, Matsumoto N, Yamamoto T, Moriyama M. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. J Investig Med High Impact Case Rep 2021;9:23247096211058489. [PMID: 34845921 DOI: 10.1177/23247096211058489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
537 Dietz A, Stöhr M, Zebralla V, Pirlich M, Wichmann G, Wiegand S. Immunonkologie bei Kopf-Hals-Tumoren. Onkologie up2date 2021;3:325-345. [DOI: 10.1055/a-1587-2499] [Reference Citation Analysis]
538 Haik L, Gonthier A, Quivy A, Gross-Goupil M, Veillon R, Frison E, Ravaud A, Domblides C, Daste A. The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta Oncol 2021;60:1597-603. [PMID: 34549686 DOI: 10.1080/0284186X.2021.1978540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
539 Liu S, Bellile E, Nguyen A, Zarins K, D'Silva N, Rozek L, Wolf GT, Sartor MA; INSPIRE Trial Clinical Investigators. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. Oral Oncol 2021;123:105587. [PMID: 34717154 DOI: 10.1016/j.oraloncology.2021.105587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
540 Beyaert S, Machiels JP, Schmitz S. Vaccine-Based Immunotherapy for Head and Neck Cancers. Cancers (Basel) 2021;13:6041. [PMID: 34885150 DOI: 10.3390/cancers13236041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
541 Keam B, Machiels JP, Kim HR, Licitra L, Golusinski W, Gregoire V, Lee YG, Belka C, Guo Y, Rajappa SJ, Tahara M, Azrif M, Ang MK, Yang MH, Wang CH, Ng QS, Wan Zamaniah WI, Kiyota N, Babu S, Yang K, Curigliano G, Peters S, Kim TW, Yoshino T, Pentheroudakis G. Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ESMO Open 2021;6:100309. [PMID: 34844180 DOI: 10.1016/j.esmoop.2021.100309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
542 Fuereder T, Minichsdorfer C, Mittlboeck M, Wagner C, Heller G, Putz EM, Oberndorfer F, Müllauer L, Aretin MB, Czerny C, Schwarz-Nemec U. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. Oral Oncol 2022;124:105634. [PMID: 34844042 DOI: 10.1016/j.oraloncology.2021.105634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
543 Lee S, Kim HR. What's New in Molecular Targeted Therapies for Head and Neck Cancer? Korean J Head Neck Oncol 2021;37:11-17. [DOI: 10.21593/kjhno/2021.37.2.11] [Reference Citation Analysis]
544 Misztal CI, Green C, Mei C, Bhatia R, Velez Torres JM, Kamrava B, Moon S, Nicolli E, Weed D, Sargi Z, Dinh CT. Molecular and Cellular Mechanisms of Perineural Invasion in Oral Squamous Cell Carcinoma: Potential Targets for Therapeutic Intervention. Cancers (Basel) 2021;13:6011. [PMID: 34885121 DOI: 10.3390/cancers13236011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
545 Jiang J, Ding Y, Chen Y, Lu J, Chen Y, Wu G, Xu N, Wang H, Teng L. Pan-cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. Cancer Med 2021. [PMID: 34841742 DOI: 10.1002/cam4.4456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
546 Florez M, Kemnade J, Chen N, Du W, Sabichi AL, Wang D, Huang Q, Miller-chism C, Jotwani A, Chen A, Hernandez D, Sandulache V. Persistent racial/ethnic associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.. [DOI: 10.1101/2021.11.26.21266821] [Reference Citation Analysis]
547 Jacquelot N, Ghaedi M, Warner K, Chung DC, Crome SQ, Ohashi PS. Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. Cancers (Basel) 2021;13:5967. [PMID: 34885076 DOI: 10.3390/cancers13235967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
548 Amin N, Maroun CA, El Asmar M, Alkhatib HH, Guller M, Herberg ME, Zhu G, Seiwert TY, Pardoll D, Eisele DW, Fakhry C, Gourin CG, Mandal R. Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review. Head Neck 2021. [PMID: 34825751 DOI: 10.1002/hed.26935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
549 Selvan SR, Brichetti JA, Thurber DB, Botting GM, Bertenshaw GP. Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response. Cancer Biother Radiopharm 2021. [PMID: 34846938 DOI: 10.1089/cbr.2021.0283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
550 Lonardi S, Prete AA, Morano F, Messina M, Formica V, Corsi DC, Orciuolo C, Frassineti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, Pietrantonio F. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer 2021;9:e002996. [PMID: 34815354 DOI: 10.1136/jitc-2021-002996] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
551 Raghavan P, Witek ME, Morales RE. Imaging of Complications of Chemoradiation. Neuroimaging Clin N Am 2022;32:93-109. [PMID: 34809846 DOI: 10.1016/j.nic.2021.08.012] [Reference Citation Analysis]
552 Gugnacki P, Sierko E. Is There an Interplay between Oral Microbiome, Head and Neck Carcinoma and Radiation-Induced Oral Mucositis? Cancers (Basel) 2021;13:5902. [PMID: 34885015 DOI: 10.3390/cancers13235902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
553 Huehn M, Gaebel J, Oeser A, Dietz A, Neumuth T, Wichmann G, Stoehr M. Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers (Basel) 2021;13:5890. [PMID: 34884998 DOI: 10.3390/cancers13235890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
554 Julian R, Savani M, Bauman JE. Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. Cancers (Basel) 2021;13:5889. [PMID: 34884999 DOI: 10.3390/cancers13235889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
555 Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
556 Fukumoto C, Oshima R, Sawatani Y, Shiraishi R, Hyodo T, Kamimura R, Hasegawa T, Komiyama Y, Izumi S, Fujita A, Wakui T, Kawamata H. Surveillance for Patients with Oral Squamous Cell Carcinoma after Complete Surgical Resection as Primary Treatment: A Single-Center Retrospective Cohort Study. Cancers (Basel) 2021;13:5843. [PMID: 34830994 DOI: 10.3390/cancers13225843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
557 安松 隆. Immuno-Oncology 時代における再発・転移頭頸部癌の治療戦略. Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 2021;124:1478-1484. [DOI: 10.3950/jibiinkotokeibu.124.11_1478] [Reference Citation Analysis]
558 Kheshtchin N, Hadjati J. Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy. J Cell Physiol 2021. [PMID: 34796969 DOI: 10.1002/jcp.30643] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
559 Han Y, Wang X, Xia K, Su T. A novel defined hypoxia-related gene signature to predict the prognosis of oral squamous cell carcinoma. Ann Transl Med 2021;9:1565. [PMID: 34790771 DOI: 10.21037/atm-21-4990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
560 Wang J, Hong J, Yang F, Liu F, Wang X, Shen Z, Wu D. A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. Cell Biol Toxicol 2021. [PMID: 34797429 DOI: 10.1007/s10565-021-09672-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
561 Sun X, Zhang L, Liu S. The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases. Comput Math Methods Med 2021;2021:1163250. [PMID: 34790249 DOI: 10.1155/2021/1163250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
562 Guller M, Herberg M, Amin N, Alkhatib H, Maroun C, Wu E, Allen H, Zheng Y, Gourin C, Vosler P, Tan M, Koch W, Eisele D, Seiwert T, Fakhry C, Pardoll D, Zhu G, Mandal R. Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer. Cancers (Basel) 2021;13:5772. [PMID: 34830929 DOI: 10.3390/cancers13225772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
563 Strait AA, Wang XJ. Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD-L1 inhibition to ongoing clinical studies. Mol Carcinog 2021. [PMID: 34793609 DOI: 10.1002/mc.23373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
564 Zhu G, Amin N, Herberg ME, Maroun CA, Wang H, Guller M, Gourin CG, Rooper LM, Vosler PS, Tan M, D'Souza G, Koch WM, Eisele DW, Seiwert TY, Fakhry C, Pardoll DM, Mandal R. Association of Tumor Site With the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers. JAMA Otolaryngol Head Neck Surg 2021. [PMID: 34792560 DOI: 10.1001/jamaoto.2021.3228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
565 Zhou C, Wang S, Shen Z, Shen Y, Li Q, Shen Y, Huang J, Deng H, Ye D, Zhan G, Li J. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma. J Clin Lab Anal 2021;:e24113. [PMID: 34783061 DOI: 10.1002/jcla.24113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
566 Burcher KM, Lantz JW, Gavrila E, Abreu A, Burcher JT, Faucheux AT, Xie A, Jackson C, Song AH, Hughes RT, Lycan T Jr, Bunch PM, Furdui CM, Topaloglu U, D'Agostino RB Jr, Zhang W, Porosnicu M. Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5733. [PMID: 34830888 DOI: 10.3390/cancers13225733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
567 Yoshimura K, Tsujikawa T, Mitsuda J, Ogi H, Saburi S, Ohmura G, Arai A, Shibata S, Thibault G, Chang YH, Clayburgh DR, Yasukawa S, Miyagawa-Hayashino A, Konishi E, Itoh K, Coussens LM, Hirano S. Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma. Front Immunol 2021;12:769534. [PMID: 34777389 DOI: 10.3389/fimmu.2021.769534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
568 Xing DT, Khor R, Gan H, Wada M, Ermongkonchai T, Ng SP. Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists. Cancers (Basel) 2021;13:5716. [PMID: 34830871 DOI: 10.3390/cancers13225716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
569 Kang NW, Tan KT, Li CF, Kuo YH. Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden. Curr Oncol 2021;28:4587-96. [PMID: 34898561 DOI: 10.3390/curroncol28060388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
570 Hellwig K, Ellmann S, Eckstein M, Wiesmueller M, Rutzner S, Semrau S, Frey B, Gaipl US, Gostian AO, Hartmann A, Iro H, Fietkau R, Uder M, Hecht M, Bäuerle T. Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Front Oncol 2021;11:734872. [PMID: 34745957 DOI: 10.3389/fonc.2021.734872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
571 Cheng Y, Li S, Gao L, Zhi K, Ren W. The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma. Front Oncol 2021;11:761379. [PMID: 34746001 DOI: 10.3389/fonc.2021.761379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
572 Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Clin Immunol 2021;232:108876. [PMID: 34740840 DOI: 10.1016/j.clim.2021.108876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
573 Ma B, Jiang H, Luo Y, Liao T, Xu W, Wang X, Dong C, Ji Q, Wang Y. Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma. Front Immunol 2021;12:692079. [PMID: 34737735 DOI: 10.3389/fimmu.2021.692079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
574 Qu Y, Wang C, Liu L, Li S, Zhang X, Ma Z, Bai H, Wang J. Predictive Value of Max's Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Cell Dev Biol 2021;9:728647. [PMID: 34733843 DOI: 10.3389/fcell.2021.728647] [Reference Citation Analysis]
575 Wang C, Zainal NS, Chai SJ, Dickie J, Gan CP, Zulaziz N, Lye BKW, Sutavani RV, Ottensmeier CH, King EV, Abraham MT, Ismail SMB, Lau SH, Kallarakkal TG, Mun KS, Zain RB, Abdul Rahman ZA, Thomas GJ, Cheong SC, Savelyeva N, Lim KP. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. Front Immunol 2021;12:763086. [PMID: 34733290 DOI: 10.3389/fimmu.2021.763086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
576 Porcheri C, Mitsiadis TA. New Scenarios in Pharmacological Treatments of Head and Neck Squamous Cell Carcinomas. Cancers (Basel) 2021;13:5515. [PMID: 34771677 DOI: 10.3390/cancers13215515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
577 Ren Z, Qin S, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Yan P, Zou J. A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer 2021;10:500-9. [PMID: 34721511 DOI: 10.1159/000516470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
578 Bauman J, El-Jawahri A. One Size Does Not Fit All: The Need for Population-Specific Palliative Care Interventions. J Natl Cancer Inst 2021;113:1449-50. [PMID: 33590003 DOI: 10.1093/jnci/djab021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
579 Zhou J, Mao Q, Li Y, Li Z, He H, Chen Q, Liu C. Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review. BMC Oral Health 2021;21:559. [PMID: 34727912 DOI: 10.1186/s12903-021-01901-9] [Reference Citation Analysis]
580 Clarke E, Eriksen JG, Barrett S. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis. Acta Oncol 2021;60:1534-42. [PMID: 34410881 DOI: 10.1080/0284186X.2021.1964699] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
581 Brix N, Dunn L, Seiwert T, Belka C, Lauber K. Immuntherapie bei Kopf-Hals-Plattenepithelkarzinomen. best practice onkologie 2021;16:520-527. [DOI: 10.1007/s11654-021-00347-3] [Reference Citation Analysis]
582 Boilesen DR, Nielsen KN, Holst PJ. Novel Antigenic Targets of HPV Therapeutic Vaccines. Vaccines (Basel) 2021;9:1262. [PMID: 34835193 DOI: 10.3390/vaccines9111262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
583 Naik PP. Cemiplimab in advanced cutaneous squamous cell carcinoma. Dermatol Ther 2021;:e15184. [PMID: 34716727 DOI: 10.1111/dth.15184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
584 Huguet F, Durand B, Atallah S, Prébet C, Richard S, Baujat B. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept? Cancer Radiother 2021;25:811-5. [PMID: 34711485 DOI: 10.1016/j.canrad.2021.08.018] [Reference Citation Analysis]
585 Shaw JW, Bennett B, Trigg A, DeRosa M, Taylor F, Kiff C, Ntais D, Noon K, King MT, Cocks K. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions. Value Health 2021;24:1651-9. [PMID: 34711366 DOI: 10.1016/j.jval.2021.05.022] [Reference Citation Analysis]
586 Kordbacheh F, Farah CS. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5471. [PMID: 34771633 DOI: 10.3390/cancers13215471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
587 Gavrielatou N, Vathiotis I, Economopoulou P, Psyrri A. The Role of B Cells in Head and Neck Cancer. Cancers (Basel) 2021;13:5383. [PMID: 34771546 DOI: 10.3390/cancers13215383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
588 de Sousa LG, Ferrarotto R. Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert Rev Anticancer Ther 2021;21:1321-31. [PMID: 34689660 DOI: 10.1080/14737140.2021.1996228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
589 Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X, Xu Q. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Front Oncol 2021;11:683502. [PMID: 34692475 DOI: 10.3389/fonc.2021.683502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
590 Saiz-Ladera C, Baliu-Piqué M, Cimas FJ, Manzano A, García-Barberán V, Camarero SC, Hinojal GF, Pandiella A, Győrffy B, Stewart D, Cruz-Hernández JJ, Pérez-Segura P, Ocana A. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. Front Oncol 2021;11:714550. [PMID: 34692491 DOI: 10.3389/fonc.2021.714550] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
591 Akhbariyoon H, Azizpour Y, Esfahani MF, Firoozabad MSM, Rad MR, Esfahani KS, Khoshavi N, Karimi N, Shirinisaz A, Abedi F, Rad MR, Sharifi P. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clin Immunol 2021;232:108873. [PMID: 34688855 DOI: 10.1016/j.clim.2021.108873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
592 Wang F, Su H, Xu D, Monroe MK, Anderson CF, Zhang W, Oh R, Wang Z, Sun X, Wang H, Wan F, Cui H. Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. Biomaterials 2021;279:121182. [PMID: 34688987 DOI: 10.1016/j.biomaterials.2021.121182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
593 Suzuki S, Toyoma S, Kawasaki Y, Koizumi K, Iikawa N, Shiina K, Endo T, Abe T, Kouga T, Yamada T. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Medicina (Kaunas) 2021;57:1151. [PMID: 34833369 DOI: 10.3390/medicina57111151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
594 Mizokami D, Kogashiwa Y, Kamide D, Maeda M, Nakamori Y, Shiotani A. Attempt at Outpatient Chemotherapy with Nivolumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Utilizing the Services of a Part-time Surgeon. Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 2021;124:1406-1412. [DOI: 10.3950/jibiinkotokeibu.124.10_1406] [Reference Citation Analysis]
595 Guigay J, Lee KW, Patel MR, Daste A, Wong DJ, Goel S, Gordon MS, Gutierrez M, Balmanoukian A, Le Tourneau C, Mita A, Vansteene D, Keilholz U, Schöffski P, Grote HJ, Zhou D, Bajars M, Penel N. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer 2021;9:e002998. [PMID: 34663640 DOI: 10.1136/jitc-2021-002998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
596 Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med 2021;2:100411. [PMID: 34755131 DOI: 10.1016/j.xcrm.2021.100411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
597 Ding Z, Dong Z, Chen Z, Hong J, Yan L, Li H, Yao S, Yan Y, Yang Y, Yang C, Li T. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Front Immunol 2021;12:733530. [PMID: 34659220 DOI: 10.3389/fimmu.2021.733530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
598 Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, Lentsch EJ, Hornig JD, Skoner J, Stalcup S, Spampinato MV, Garrett-Mayer E, O'Quinn EC, Timmers CD, Romeo MJ, Wrangle JM, Young MRI, Rubinstein MP, Day TA, Lo RS, Paulos CM, Neskey DM. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med 2021;2:100426. [PMID: 34755137 DOI: 10.1016/j.xcrm.2021.100426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
599 Sun J, Fang G, Zuo Z, Yu X, Xue L, Li C, Li S. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. Technol Cancer Res Treat 2021;20:15330338211045823. [PMID: 34657509 DOI: 10.1177/15330338211045823] [Reference Citation Analysis]
600 Takahashi M, Watanabe S, Suzuki R, Arita M, Sato K, Sato M, Sekiya Y, Abe Y, Fujisaki T, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Saida Y, Hokari S, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer. Cancer Immunol Immunother 2021. [PMID: 34657194 DOI: 10.1007/s00262-021-03078-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
601 Powell SF, Vu L, Spanos WC, Pyeon D. The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications. Cancers (Basel) 2021;13:5206. [PMID: 34680354 DOI: 10.3390/cancers13205206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
602 Zhang C, Guo L, Su Z, Luo N, Tan Y, Xu P, Ye L, Tong S, Liu H, Li X, Chen Q, Tian D. Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature. Front Cell Dev Biol 2021;9:717601. [PMID: 34650972 DOI: 10.3389/fcell.2021.717601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
603 Liu M, Gao Y, Yuan Y, Shi S, Wu J, Tian J, Zhang J. An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. Biomed Pharmacother 2021;143:112238. [PMID: 34649362 DOI: 10.1016/j.biopha.2021.112238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
604 Gruijs M, Ganzevles SH, Stigter-van Walsum M, van der Mast R, van Ostaijen-Ten Dam MM, Tuk CW, Schilham MW, Leemans CR, Brakenhoff RH, van Egmond M, van de Ven R, Bakema JE. NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. Int J Mol Sci 2021;22:11057. [PMID: 34681717 DOI: 10.3390/ijms222011057] [Reference Citation Analysis]
605 Bai Y, Boath J, White GR, Kariyawasam UGIU, Farah CS, Darido C. The Balance between Differentiation and Terminal Differentiation Maintains Oral Epithelial Homeostasis. Cancers (Basel) 2021;13:5123. [PMID: 34680271 DOI: 10.3390/cancers13205123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
606 Yang Z, Wang J, Chen C, Sun P, Yu Y. Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma. Technol Cancer Res Treat 2021;20:15330338211046432. [PMID: 34632870 DOI: 10.1177/15330338211046432] [Reference Citation Analysis]
607 Das S, Idate R, Regan DP, Fowles JS, Lana SE, Thamm DH, Gustafson DL, Duval DL. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. Commun Biol 2021;4:1178. [PMID: 34635775 DOI: 10.1038/s42003-021-02683-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
608 Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, Fidler MJ, Stenson K, Vasan NR, Razaq MA, Campana J, Ha P, Mann G, Ishida K, Garcia-Guzman M, Biel M, Gillenwater AM. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck 2021;43:3875-87. [PMID: 34626024 DOI: 10.1002/hed.26885] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
609 Saddawi-Konefka R, Simon AB, Sumner W, Sharabi A, Mell LK, Cohen EEW. Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Front Oncol 2021;11:738626. [PMID: 34621678 DOI: 10.3389/fonc.2021.738626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
610 Mochizuki K, Kobayashi S, Takahashi N, Sugimoto K, Sano H, Ohara Y, Mineishi S, Zhang Y, Kikuta A. Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice. J Exp Clin Cancer Res 2021;40:314. [PMID: 34625113 DOI: 10.1186/s13046-021-02102-6] [Reference Citation Analysis]
611 Zhu C, Li J, Yao M, Fang C. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma. BMC Oral Health 2021;21:506. [PMID: 34625078 DOI: 10.1186/s12903-021-01813-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
612 Oliva M, Chepeha D, Araujo DV, Diaz-Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, R Hansen A, Hope A, Goldstein D, Weinreb I, Smith S, Perez-Ordoñez B, Irish J, Torti D, Bruce JP, Wang BX, Fortuna A, Pugh TJ, Der-Torossian H, Shazer R, Attanasio N, Au Q, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu L. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer 2021;9:e003476. [PMID: 34599023 DOI: 10.1136/jitc-2021-003476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
613 Zhang P, Li S, Zhang T, Cui F, Shi JH, Zhao F, Sheng X. Characterization of Molecular Subtypes in Head and Neck Squamous Cell Carcinoma With Distinct Prognosis and Treatment Responsiveness. Front Cell Dev Biol 2021;9:711348. [PMID: 34595167 DOI: 10.3389/fcell.2021.711348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
614 Wang Y, Zhang X, Wang Y, Zhao W, Li H, Zhang L, Li X, Zhang T, Zhang H, Huang H, Liu C. Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. Acta Pharm Sin B 2021;11:2957-72. [PMID: 34729298 DOI: 10.1016/j.apsb.2021.03.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
615 Hung TKW, Ho AL, Pfister DG. Therapeutic strategies for systemic therapies of human papillomavirus-related oropharyngeal cancer. J Surg Oncol 2021;124:952-61. [PMID: 34585389 DOI: 10.1002/jso.26688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
616 Abbas W, Gupta S, Goel V, Rao RR, Pankaj P, Tripathi D, Patil PP, Popli S. Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer. South Asian J Cancer 2021;10:72-5. [PMID: 34568218 DOI: 10.1055/s-0041-1729443] [Reference Citation Analysis]
617 Clancy K, Hamill CS, O'Neill WQ, Vu B, Thuener J, Gui S, Li S, Fowler N, Rezaee R, Lavertu P, Wasman J, Patel M, Shaikh H, Vick E, Madabhushi A, Wise-Draper TM, Burkitt K, Teknos TN, Pan Q. Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. Cancers (Basel) 2021;13:4861. [PMID: 34638345 DOI: 10.3390/cancers13194861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
618 Huang H, Li S, Tang Q, Zhu G. Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma. Front Immunol 2021;12:680955. [PMID: 34566954 DOI: 10.3389/fimmu.2021.680955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
619 Hamada M, Inaba H, Nishiyama K, Yoshida S, Yura Y, Matsumoto-Nakano M, Uzawa N. Prognostic association of starvation-induced gene expression in head and neck cancer. Sci Rep 2021;11:19130. [PMID: 34580365 DOI: 10.1038/s41598-021-98544-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
620 Strojan P, Šifrer R, Ferlito A, Grašič-Kuhar C, Lanišnik B, Plavc G, Zidar N. Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study. Cancers (Basel) 2021;13:4813. [PMID: 34638312 DOI: 10.3390/cancers13194813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
621 Yuan J, Khilnani A, Brody J, Andtbacka RHI, Hu-Lieskovan S, Luke JJ, Diab A, Marabelle A, Snyder A, Cao ZA, Hodi FS. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. Eur J Cancer 2021;157:493-510. [PMID: 34561127 DOI: 10.1016/j.ejca.2021.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
622 Wu T, Tang C, Tao R, Yong X, Jiang Q, Feng C. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers. Front Immunol 2021;12:693881. [PMID: 34552581 DOI: 10.3389/fimmu.2021.693881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
623 Shibata H, Saito S, Uppaluri R. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. Front Oncol 2021;11:727433. [PMID: 34552878 DOI: 10.3389/fonc.2021.727433] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
624 Gao L, Chen R, Sugimoto M, Mizuta M, Kishimoto Y, Omori K. The Impact of m1A Methylation Modification Patterns on Tumor Immune Microenvironment and Prognosis in Oral Squamous Cell Carcinoma. Int J Mol Sci 2021;22:10302. [PMID: 34638642 DOI: 10.3390/ijms221910302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
625 Callahan SC, Divenko M, Barrodia P, Singh AK, Arslan E, Liu Z, Yang J, Anvar N, Amit M, Xie T, Jiang S, Schulz J, Tang M, Myers JN, Rai K. KMT2D Loss Promotes Head and Neck Squamous Carcinoma Through Enhancer Reprogramming and Modulation of Immune Microenvironment.. [DOI: 10.1101/2021.09.21.461314] [Reference Citation Analysis]
626 Hsieh RW, Borson S, Tsagianni A, Zandberg DP. Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol 2021;11:705614. [PMID: 34540672 DOI: 10.3389/fonc.2021.705614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
627 Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali DA. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer 2020;8:e000967. [PMID: 32675311 DOI: 10.1136/jitc-2020-000967] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
628 Leem G, Park J, Jeon M, Kim ES, Kim SW, Lee YJ, Choi SJ, Choi B, Park S, Ju YS, Jung I, Kim S, Shin EC, Lee JY, Park SH. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. J Immunother Cancer 2020;8:e001650. [PMID: 33335029 DOI: 10.1136/jitc-2020-001650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
629 Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, Ascierto PA, McEwan P, Wagner S, Borrill J, Wu E. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer 2020;8:e000648. [PMID: 32661115 DOI: 10.1136/jitc-2020-000648] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
630 Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Sater HA, Donahue RN, Jochems C, Lamping E, Burmeister A, Marté JL, Cordes LM, Bilusic M, Karzai F, Ojalvo LS, Jehl G, Rolfe PA, Hinrichs CS, Madan RA, Schlom J, Gulley JL. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer 2020;8:e001395. [PMID: 33323462 DOI: 10.1136/jitc-2020-001395] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
631 Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C, Rolfe PA, Gulley JL, Penel N. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer 2020;8:e000664. [PMID: 32641320 DOI: 10.1136/jitc-2020-000664] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
632 花井 信. 頭頸部癌に対する免疫チェックポイント阻害薬. Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 2021;124:1251-1255. [DOI: 10.3950/jibiinkotokeibu.124.9_1251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
633 Yao Y, Yan Z, Lian S, Wei L, Zhou C, Feng D, Zhang Y, Yang J, Li M, Chen Y. Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma. J Immunother Cancer 2020;8:e000444. [PMID: 32719094 DOI: 10.1136/jitc-2019-000444] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
634 Iida Y, Yoshikawa R, Murata A, Kotani H, Kazuki Y, Oshimura M, Matsuzaki Y, Harada M. Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells. J Immunother Cancer 2020;8:e000582. [PMID: 32675195 DOI: 10.1136/jitc-2020-000582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
635 Wei B, Yu M, Yao J, Jiang M, An J, Yang J, Lin J, Zhao Y, Zhu Y. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma. Front Immunol 2021;12:657951. [PMID: 34531849 DOI: 10.3389/fimmu.2021.657951] [Reference Citation Analysis]
636 Hu ZW, Wen YH, Ma RQ, Chen L, Zeng XL, Wen WP, Sun W. Ferroptosis Driver SOCS1 and Suppressor FTH1 Independently Correlate With M1 and M2 Macrophage Infiltration in Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:727762. [PMID: 34527677 DOI: 10.3389/fcell.2021.727762] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
637 Lee JH, Heo SG, Ahn BC, Hong MH, Cho BC, Lim SM, Kim HR. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Cancer Med 2021;10:7012-20. [PMID: 34528763 DOI: 10.1002/cam4.4231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
638 Gao L, Chen Y. Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). Biomed Rep 2021;15:84. [PMID: 34512972 DOI: 10.3892/br.2021.1460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
639 Koma A, Asai S, Minemura C, Oshima S, Kinoshita T, Kikkawa N, Koshizuka K, Moriya S, Kasamatsu A, Hanazawa T, Uzawa K, Seki N. Impact of Oncogenic Targets by Tumor-Suppressive miR-139-5p and miR-139-3p Regulation in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2021;22:9947. [PMID: 34576110 DOI: 10.3390/ijms22189947] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
640 Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath KV, Chandran UR, Chang A, Szymczak-Workman AL, Vujanovic L, Delgoffe GM, Ferris RL, Kane LP. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep 2021;36:109699. [PMID: 34525351 DOI: 10.1016/j.celrep.2021.109699] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
641 Das S, Shukla N, Singh SS, Kushwaha S, Shrivastava R. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis 2021;26:512-33. [PMID: 34510317 DOI: 10.1007/s10495-021-01687-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
642 Wang L, Liu F, Li J, Ma L, Feng H, Liu Q, Cho WC, Chen H, Chen H, Guo H, Li Z, Howard SC, Li M, Shan B, Gu W, Ji J. From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific? J Pers Med 2021;11:914. [PMID: 34575691 DOI: 10.3390/jpm11090914] [Reference Citation Analysis]
643 Wu YJ, Nai AT, He GC, Xiao F, Li ZM, Tang SY, Liu YP, Ai XH. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma. World J Surg Oncol 2021;19:274. [PMID: 34517904 DOI: 10.1186/s12957-021-02379-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
644 Dapash M, Castro B, Hou D, Lee-Chang C. Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. Cancers (Basel) 2021;13:4548. [PMID: 34572775 DOI: 10.3390/cancers13184548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
645 Sun J, Tang Q, Zhang J, Chen G, Peng J, Chen L. Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. Front Mol Biosci 2021;8:717038. [PMID: 34497832 DOI: 10.3389/fmolb.2021.717038] [Reference Citation Analysis]
646 Koh SA. An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam Univ J Med 2021. [PMID: 34496466 DOI: 10.12701/yujm.2021.01312] [Reference Citation Analysis]
647 Huang Y, Liang Y, Zhao W. Hypopharyngeal Cancer: Staging, Diagnosis, and Therapy. Pharynx - Diagnosis and Treatment 2021. [DOI: 10.5772/intechopen.97462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 Chan WY, Brown LJ, Reid L, Joshua AM. PARP Inhibitors in Melanoma-An Expanding Therapeutic Option? Cancers (Basel) 2021;13:4520. [PMID: 34572747 DOI: 10.3390/cancers13184520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
649 Rolles B, Gorgulho J, Tometten M, Roderburg C, Vieri M, Abels A, Vucur M, Heymann F, Tacke F, Brümmendorf TH, Luedde T, Beier F, Loosen SH. Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy. Front Oncol 2021;11:729207. [PMID: 34490122 DOI: 10.3389/fonc.2021.729207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
650 Nazeer F, Ravi Kumar R, Rafi M, M. Nair L, Cessal Thommachan K, Ramadas K. Role of Organ Preservation in Locally Advanced Hypopharyngeal Carcinoma. Pharynx - Diagnosis and Treatment 2021. [DOI: 10.5772/intechopen.98906] [Reference Citation Analysis]
651 Takahashi H, Kawabata-Iwakawa R, Ida S, Mito I, Tada H, Chikamatsu K. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma. Sci Rep 2021;11:17789. [PMID: 34493792 DOI: 10.1038/s41598-021-97292-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
652 Sekido K, Imaue S, Tomihara K, Tachinami H, Yamagishi K, Okazawa S, Ikeda A, Fujiwara K, Noguchi M. Durable complete response to immunotherapy with anti-PD-1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report. Clin Case Rep 2021;9:e04545. [PMID: 34484745 DOI: 10.1002/ccr3.4545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
653 Pialat PM, Mounie M, Podeur F, Gassa F, Suchaud JP, Fleury B, Racadot S, Serre AA, Pommier P. Salvage brachytherapy with or without external beam radiotherapy for oral or oropharyngeal squamous cell carcinomas in previously irradiated areas: carcinologic and toxicity outcomes of 25 patients. J Contemp Brachytherapy 2021;13:402-9. [PMID: 34484354 DOI: 10.5114/jcb.2021.108594] [Reference Citation Analysis]
654 Fleischmann M, Glatzer M, Rödel C, Tselis N. Radioimmunotherapy: future prospects from the perspective of brachytherapy. J Contemp Brachytherapy 2021;13:458-67. [PMID: 34484362 DOI: 10.5114/jcb.2021.108601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
655 Ueno S, Uenomachi M, Kusaba H, Ito M, Suzuki K, Ohmura H, Tsuchihashi K, Ariyama H, Akashi K, Baba E. Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. Mol Clin Oncol 2021;15:221. [PMID: 34476105 DOI: 10.3892/mco.2021.2379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
656 Mazilu L, Suceveanu AI, Stanculeanu DL, Gheorghe AD, Fricatel G, Negru SM. Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review). Exp Ther Med 2021;22:1128. [PMID: 34466142 DOI: 10.3892/etm.2021.10562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
657 Weber M, Ries J, Wehrhan F, Kesting M. Die Bedeutung des Immunsystems für maligne und entzündliche Erkrankungen in der Mund‑, Kiefer- und Gesichtschirurgie. MKG-Chirurg 2021;14:237-245. [DOI: 10.1007/s12285-021-00322-5] [Reference Citation Analysis]
658 Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH. PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy. J Immunother Cancer 2020;8:e000485. [PMID: 32238472 DOI: 10.1136/jitc-2019-000485] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
659 Lee MY, Allen CT. Immunotherapy for HPV Malignancies. Semin Radiat Oncol 2021;31:361-70. [PMID: 34455991 DOI: 10.1016/j.semradonc.2021.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
660 Roviello G, Catalano M, Santi R, Palmieri VE, Vannini G, Galli IC, Buttitta E, Villari D, Rossi V, Nesi G. Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. Cancers (Basel) 2021;13:4411. [PMID: 34503220 DOI: 10.3390/cancers13174411] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
661 Tada H, Takahashi H, Yamada K, Masuda K, Nagata Y, Uchida M, Shino M, Ida S, Mito I, Matsuyama T, Oyama T, Tatematsu KI, Sezutsu H, Takeda S, Chikamatsu K. Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. Cancer Immunol Immunother 2021. [PMID: 34463793 DOI: 10.1007/s00262-021-03042-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
662 DiNatale RG, Hakimi AA, Chan TA. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Hum Mol Genet 2020;29:R214-25. [PMID: 33029628 DOI: 10.1093/hmg/ddaa203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
663 Watters AL, Hansen HJ, Patel AA, Epstein J. Head and Neck Cancer. Burket's Oral Medicine 2021. [DOI: 10.1002/9781119597797.ch7] [Reference Citation Analysis]
664 Ge Y, Zhang H, Weygant N, Yao J. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021;12:640099. [PMID: 34447305 DOI: 10.3389/fphar.2021.640099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
665 Botticelli A, Cirillo A, Strigari L, Valentini F, Cerbelli B, Scagnoli S, Cerbelli E, Zizzari IG, Rocca CD, D'Amati G, Polimeni A, Nuti M, Merlano MC, Mezi S, Marchetti P. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Front Immunol 2021;12:705096. [PMID: 34434192 DOI: 10.3389/fimmu.2021.705096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
666 Missale F, Bugatti M, Mattavelli D, Lonardi S, Lombardi D, Nicolai P, Piazza C, Battocchio S, Bozzola AM, Calza S, Vermi W. Metavariables Resuming Host Immune Features and Nodal Involvement Are Associated with Oncological Outcomes in Oral Cavity Squamous Cell Carcinoma. Cells 2021;10:2203. [PMID: 34571850 DOI: 10.3390/cells10092203] [Reference Citation Analysis]
667 Strait AA, Woolaver RA, Hall SC, Young CD, Karam SD, Jimeno A, Lan Y, Raben D, Wang JH, Wang XJ. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol 2021;4:1005. [PMID: 34433873 DOI: 10.1038/s42003-021-02522-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
668 Laria A, Lurati A, Castelnovo L, Tamburello A, Faggioli PM, Mazzone A. Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series. Beyond Rheumatol 2021;3. [DOI: 10.4081/br.2021.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
669 Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B. Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Curr Oncol 2021;28:3227-39. [PMID: 34449592 DOI: 10.3390/curroncol28050280] [Reference Citation Analysis]
670 Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, Fuereder T, Zöchbauer-Müller S, Preusser M, Pabinger I, Ay C. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021;137:1669-78. [PMID: 33067632 DOI: 10.1182/blood.2020007878] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 33.0] [Reference Citation Analysis]
671 Prasad M, Zorea J, Jagadeeshan S, Shnerb A, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yagodayev K, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstei O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Hess J, Morris LG, Saintigny P, Elkabets M. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.. [DOI: 10.1101/2021.08.22.457244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
672 Zhan ZJ, Yao WY, Zhang F, Qiu WZ, Liao K, Feng JH, Tan JY, Liu H, Yuan TZ, Zheng RH, Yuan YW. The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis. Front Immunol 2021;12:719650. [PMID: 34413862 DOI: 10.3389/fimmu.2021.719650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
673 Minohara K, Matoba T, Kawakita D, Takano G, Oguri K, Murashima A, Nakai K, Iwaki S, Hojo W, Matsumura A, Ozaki S, Ozawa T, Harata I, Tanaka N, Maseki S, Tsuge H, Imaizumi S, Mitsuya S, Moribe K, Esaki S, Iwasaki S. Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. Sci Rep 2021;11:16992. [PMID: 34417539 DOI: 10.1038/s41598-021-96538-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
674 Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B, Guo H, Yang R. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clin Med Insights Oncol 2021;15:11795549211035540. [PMID: 34408525 DOI: 10.1177/11795549211035540] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
675 Shibata H, Xu N, Saito S, Zhou L, Ozgenc I, Webb J, Fu C, Zolkind P, Egloff AM, Uppaluri R. Integrating CD4+ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model. Oncoimmunology 2021;10:1958589. [PMID: 34408919 DOI: 10.1080/2162402X.2021.1958589] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
676 Webster AL, Sanders MA, Patel K, Dietrich R, Noonan RJ, Lach FP, White RR, Goldfarb A, Hadi K, Edwards MM, Donovan FX, Jung M, Sridhar S, Fedrigo O, Tian H, Rosiene J, Heineman T, Kennedy JA, Bean L, Rosti O, Tryon R, Gonzalez A, Rosenberg A, Luo J, Carrol T, Velleuer E, Rastatter JC, Wells SI, Surrallés J, Bagby G, Macmillan ML, Wagner JE, Cancio M, Boulad F, Scognamiglio T, Vaughan R, Koren A, Imielinski M, Chandrasekharappa S, Auerbach AD, Singh B, Kutler DI, Campbell PJ, Smogorzewska A. Fanconi Anemia Pathway Deficiency Drives Copy Number Variation in Squamous Cell Carcinomas.. [DOI: 10.1101/2021.08.14.456365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
677 Lyadova MA, Lyadov VK. Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. J Mod Onco 2021;23:319-326. [DOI: 10.26442/18151434.2021.2.200502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
678 Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, Muro K, Hida T. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer 2021;21:924. [PMID: 34399710 DOI: 10.1186/s12885-021-08661-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
679 Rocconi RP, Stanbery L, Madeira da Silva L, Barrington RA, Aaron P, Manning L, Horvath S, Wallraven G, Bognar E, Walter A, Nemunaitis J. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines (Basel) 2021;9:894. [PMID: 34452019 DOI: 10.3390/vaccines9080894] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
680 Matsui N, Kouda K, Ishihara N, Tamaki H, Yano T, Naora K, Kitahara T. Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. Jpn J Pharm Health Care Sci 2021;47:437-444. [DOI: 10.5649/jjphcs.47.437] [Reference Citation Analysis]
681 Mito I, Takahashi H, Kawabata-Iwakawa R, Ida S, Tada H, Chikamatsu K. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. Sci Rep 2021;11:16134. [PMID: 34373557 DOI: 10.1038/s41598-021-95718-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
682 Panagiotou E, Gomatou G, Trontzas IP, Syrigos N, Kotteas E. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. Clin Transl Oncol 2021. [PMID: 34363593 DOI: 10.1007/s12094-021-02688-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
683 Qiao Y, Liu C, Zhang X, Zhou Q, Li Y, Xu Y, Gao Z, Xu Y, Kong L, Yang A, Mei M, Ren Y, Wang X, Zhou X. PD-L2 based immune signature confers poor prognosis in HNSCC. Oncoimmunology 2021;10:1947569. [PMID: 34377590 DOI: 10.1080/2162402X.2021.1947569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
684 Bai Y, Zhao Z, Boath J, van Denderen BJ, Darido C. The functional GRHL3-filaggrin axis maintains a tumor differentiation potential and influences drug sensitivity. Mol Ther 2021;29:2571-82. [PMID: 33775911 DOI: 10.1016/j.ymthe.2021.03.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
685 Lan G, Yu X, Sun X, Li W, Zhao Y, Lan J, Wu X, Gao R. Comprehensive analysis of the expression and prognosis for TNFAIPs in head and neck cancer. Sci Rep 2021;11:15696. [PMID: 34344926 DOI: 10.1038/s41598-021-95160-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
686 Chen K, Sun B. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis]. Zhongguo Fei Ai Za Zhi 2020;23:927-40. [PMID: 33203196 DOI: 10.3779/j.issn.1009-3419.2020.103.14] [Reference Citation Analysis]
687 Shintani Y, Ueda H, Wada T, Mizobata N, Tojyo I. A Case of DILD Likely Induced by Molecular-Targeted Therapy Following Administration of an Immune Checkpoint Inhibitor Against Metastatic Lung Lesions from Tongue Cancer. SN Compr Clin Med 2021;3:1809-1812. [DOI: 10.1007/s42399-021-00905-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
688 Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int 2021;21:406. [PMID: 34332576 DOI: 10.1186/s12935-021-02024-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
689 Rhyner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galván JA, Lugli A, Zlobec I, Berger MD. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. J Pers Med 2021;11:749. [PMID: 34442393 DOI: 10.3390/jpm11080749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
690 Moratin J, Mock A, Obradovic S, Metzger K, Flechtenmacher C, Zaoui K, Fröhling S, Jäger D, Krauss J, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C. Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. Front Oncol 2021;11:712944. [PMID: 34395287 DOI: 10.3389/fonc.2021.712944] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
691 Khairil Anwar NA, Mohd Nazri MN, Murtadha AH, Mohd Adzemi ER, Balakrishnan V, Mustaffa KMF, Tengku Din TADA, Yahya MM, Haron J, Mokshtar NF. Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochim Biophys Sin (Shanghai) 2021;53:961-78. [PMID: 34180502 DOI: 10.1093/abbs/gmab077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
692 Lorini L, Bescós Atín C, Thavaraj S, Müller-Richter U, Alberola Ferranti M, Pamias Romero J, Sáez Barba M, de Pablo García-Cuenca A, Braña García I, Bossi P, Nuciforo P, Simonetti S. Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. Cancers (Basel) 2021;13:3696. [PMID: 34359597 DOI: 10.3390/cancers13153696] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
693 Matsuda A, Fujimoto N. Immunotherapy in Malignant Pleural Mesothelioma. Advances in Precision Medicine Oncology 2021. [DOI: 10.5772/intechopen.95823] [Reference Citation Analysis]
694 Chai LF, Hardaway JC, Heatherton KR, O'Connell KP, Lopes MC, Rabinowitz BA, Ghosh CC, Guha P, Jaroch D, Cox BF, Katz SC. Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. Vaccines (Basel) 2021;9:807. [PMID: 34451932 DOI: 10.3390/vaccines9080807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
695 Zimmermannova O, Caiado I, Ferreira AG, Pereira CF. Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Front Immunol 2021;12:714822. [PMID: 34367185 DOI: 10.3389/fimmu.2021.714822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
696 Zhu C, Gu L, Liu Z, Li J, Yao M, Fang C. Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma. BMC Cancer 2021;21:836. [PMID: 34284746 DOI: 10.1186/s12885-021-08547-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
697 松浦 一. 頭頸部癌の標準治療. Nippon Jibiinkoka Gakkai Kaiho 2021;124:1027-1029. [DOI: 10.3950/jibiinkoka.124.1027] [Reference Citation Analysis]
698 Sasaki A, Kawazoe A, Eto T, Okunaka M, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Akimoto T, Shitara K. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open 2020;4:e000775. [PMID: 32719002 DOI: 10.1136/esmoopen-2020-000775] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
699 Pharaon RR, Xing Y, Agulnik M, Villaflor VM. The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. Front Oncol 2021;11:649963. [PMID: 34336649 DOI: 10.3389/fonc.2021.649963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
700 Patel B, Saba NF. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancers (Basel) 2021;13:3545. [PMID: 34298761 DOI: 10.3390/cancers13143545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
701 Guo K, Xiao W, Chen X, Zhao Z, Lin Y, Chen G. Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. Biomed Res Int 2021;2021:1738932. [PMID: 34337000 DOI: 10.1155/2021/1738932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
702 Botticelli A, Pomati G, Cirillo A, Mammone G, Ciurluini F, Cerbelli B, Sciattella P, Ralli M, Romeo U, De Felice F, Catalano C, Vullo F, Della Monaca M, Amirhassankhani S, Tomao S, Valentini V, De Vincentiis M, Tombolini V, Della Rocca C, Polimeni A, di Gioia C, Corsi A, D'Amati G, Mezi S, Marchetti P. Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. J Transl Med 2021;19:303. [PMID: 34253248 DOI: 10.1186/s12967-021-02975-3] [Reference Citation Analysis]
703 Shen YT, Huang X, Zhang G, Jiang B, Li CJ, Wu ZS. Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis. Front Oncol 2021;11:636365. [PMID: 34322374 DOI: 10.3389/fonc.2021.636365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
704 Tian Y, Li R, Liu Y, Li M, Song Y, Zheng Y, Gao A, Wen Q, Su G, Sun Y. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:667650. [PMID: 34322382 DOI: 10.3389/fonc.2021.667650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
705 Wang Z, Zhang S. Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network. Biosci Rep 2021;41:BSR20211241. [PMID: 34212175 DOI: 10.1042/BSR20211241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
706 Miller KM, Filippova OT, Hayes SA, Abu-Rustum NR, Aghajanian C, Broach V, Ellenson LH, Selenica P, Jewell EL, Kyi C, Lakhman Y, Mueller JJ, O'Cearbhaill RE, Park KJ, Sonoda Y, Zamarin D, Weigelt B, Leitao MM Jr, Friedman CF. Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecol Oncol Rep 2021;37:100831. [PMID: 34345644 DOI: 10.1016/j.gore.2021.100831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
707 Botticelli A, Zizzari IG, Scagnoli S, Pomati G, Strigari L, Cirillo A, Cerbelli B, Di Filippo A, Napoletano C, Scirocchi F, Rughetti A, Nuti M, Mezi S, Marchetti P. The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. J Pers Med 2021;11:651. [PMID: 34357118 DOI: 10.3390/jpm11070651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
708 Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology 2021;10:1950411. [PMID: 34290909 DOI: 10.1080/2162402X.2021.1950411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
709 Wang H, Zhao Q, Zhang Y, Zhang Q, Zheng Z, Liu S, Liu Z, Meng L, Xin Y, Jiang X. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus. Front Immunol 2021;12:652054. [PMID: 34305889 DOI: 10.3389/fimmu.2021.652054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
710 Lundberg AP, Boudreau MW, Selting KA, Chatkewitz LE, Samuelson J, Francis JM, Parkinson EI, Barger AM, Hergenrother PJ, Fan TM. Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy. Neoplasia 2021;23:811-22. [PMID: 34246985 DOI: 10.1016/j.neo.2021.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
711 Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 2021. [PMID: 34236546 DOI: 10.1007/s10555-021-09976-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
712 Affolter A, Lammert A, Kern J, Scherl C, Rotter N. Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer. Front Cell Dev Biol 2021;9:666515. [PMID: 34307351 DOI: 10.3389/fcell.2021.666515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
713 Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
714 Fernandez A, O'Leary C, O'Byrne KJ, Burgess J, Richard DJ, Suraweera A. Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. Front Mol Biosci 2021;8:685440. [PMID: 34307454 DOI: 10.3389/fmolb.2021.685440] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
715 Veeramachaneni R, Yu W, Newton JM, Kemnade JO, Skinner HD, Sikora AG, Sandulache VC. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. J Immunother Cancer 2021;9:e002773. [PMID: 34230113 DOI: 10.1136/jitc-2021-002773] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
716 Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A, Thiery JP, Maslennikova A, Zvyagin AV, Ebrahimi Warkiani M. Emerging role of circulating tumor cells in immunotherapy. Theranostics 2021;11:8057-75. [PMID: 34335980 DOI: 10.7150/thno.59677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
717 Shen P, Han L, Ba X, Qin K, Tu S. Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. Front Pharmacol 2021;12:678409. [PMID: 34290608 DOI: 10.3389/fphar.2021.678409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
718 Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targ Oncol. [DOI: 10.1007/s11523-021-00824-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
719 Yatagai N, Hasegawa T, Amano R, Saito I, Arimoto S, Takeda D, Kakei Y, Akashi M. Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo. Biomed Res Int 2021;2021:5568428. [PMID: 34307656 DOI: 10.1155/2021/5568428] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
720 Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One 2021;16:e0252041. [PMID: 34197475 DOI: 10.1371/journal.pone.0252041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
721 Jia L, Wang Y, Wang CY. circFAT1 Promotes Cancer Stemness and Immune Evasion by Promoting STAT3 Activation. Adv Sci (Weinh) 2021;8:2003376. [PMID: 34258151 DOI: 10.1002/advs.202003376] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
722 Peña-Cardelles JF, Salgado-Peralvo AO, Garrido-Martínez P, Cebrián-Carretero JL, Pozo-Kreilinger JJ, Moro-Rodríguez JE. Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review. Med Oral Patol Oral Cir Bucal 2021;26:e494-501. [PMID: 33772569 DOI: 10.4317/medoral.24353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
723 Tin AW, Ali A, Jackson M, Aynsley E, Patil R, Kovarik J, Kelly C, Iqbal S. P-187 Regional Audit of the use of Nivolumab for Recurrent Head and Heck Squamous Cell Carcinoma. Oral Oncology 2021;118:4-5. [DOI: 10.1016/s1368-8375(21)00472-3] [Reference Citation Analysis]
724 Hui C, Chau B, Gan G, Stokes W, Karam SD, Amini A. Overcoming Resistance to Immunotherapy in Head and Neck Cancer Using Radiation: A Review. Front Oncol 2021;11:592319. [PMID: 34277390 DOI: 10.3389/fonc.2021.592319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
725 Coen O, Corrie P, Marshall H, Plummer R, Ottensmeier C, Hook J, Bell S, Sagoo GS, Meads D, Bestall J, Velikova G, Gallagher FA, Smith A, Howard H, Mason E, Katona E, Silva S, Collinson M, Rodwell S, Danson S. The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer 2021;21:761. [PMID: 34210290 DOI: 10.1186/s12885-021-08509-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
726 Mirghani H, Clatot F. Inmunoterapia en oncología de las vías aerodigestivas superiores. EMC - Otorrinolaringología 2021;50:1-20. [DOI: 10.1016/s1632-3475(21)45401-9] [Reference Citation Analysis]
727 Philips R, Han C, Swendseid B, Curry J, Argiris A, Luginbuhl A, Johnson J. Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. Front Oncol 2021;11:682075. [PMID: 34277428 DOI: 10.3389/fonc.2021.682075] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
728 Zhang SY, Ren XY, Wang CY, Chen XJ, Cao RY, Liu Q, Pan X, Zhou JY, Zhang WL, Tang XR, Cheng B, Wu T. Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy. Front Oncol 2021;11:587862. [PMID: 34277389 DOI: 10.3389/fonc.2021.587862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
729 Yokota C, Nakata J, Takano K, Nakajima H, Hayashibara H, Minagawa H, Chiba Y, Hirayama R, Kijima N, Kinoshita M, Hashii Y, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Kagawa N, Kishima H. Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. Neurooncol Adv 2021;3:vdab091. [PMID: 34355173 DOI: 10.1093/noajnl/vdab091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
730 Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Shimoda Y, Sano R, Oyama T, Saeki H, Shirabe K. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci 2021;112:3314-23. [PMID: 34080242 DOI: 10.1111/cas.15004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
731 Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Front Oncol 2021;11:641428. [PMID: 34268109 DOI: 10.3389/fonc.2021.641428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
732 Liu Q, Qi Y, Zhai J, Kong X, Wang X, Wang Z, Fang Y, Wang J. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. Front Immunol 2021;12:599207. [PMID: 34267742 DOI: 10.3389/fimmu.2021.599207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
733 Bouaoud J, Foy JP, Tortereau A, Michon L, Lavergne V, Gadot N, Boyault S, Valantin J, De Souza G, Zrounba P, Bertolus C, Bendriss-Vermare N, Saintigny P. Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival. Oncoimmunology 2021;10:1944554. [PMID: 34239777 DOI: 10.1080/2162402X.2021.1944554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
734 Li Y, Zhang Y, Cao G, Zheng X, Sun C, Wei H, Tian Z, Xiao W, Sun R, Sun H. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. J Hematol Oncol 2021;14. [DOI: 10.1186/s13045-021-01112-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
735 Su NW, Chen YJ. Metronomic Therapy in Oral Squamous Cell Carcinoma. J Clin Med 2021;10:2818. [PMID: 34206730 DOI: 10.3390/jcm10132818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
736 Arribas L, Plana M, Taberna M, Sospedra M, Vilariño N, Oliva M, Pallarés N, González Tampán AR, Del Rio LM, Mesia R, Baracos V. Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Oncol 2021;11:699668. [PMID: 34249760 DOI: 10.3389/fonc.2021.699668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
737 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 45.5] [Reference Citation Analysis]
738 Stern PL, Dalianis T. Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors. Viruses 2021;13:1234. [PMID: 34202255 DOI: 10.3390/v13071234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
739 Du Y, Ma Y, Zhu Q, Liu T, Jiao Y, Yuan P, Wang X. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Front Pharmacol 2021;12:707930. [PMID: 34248650 DOI: 10.3389/fphar.2021.707930] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
740 Brennan S, Baird AM, O'Regan E, Sheils O. The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma. Front Mol Biosci 2021;8:677900. [PMID: 34250016 DOI: 10.3389/fmolb.2021.677900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
741 Yang Z, Yan G, Zheng L, Gu W, Liu F, Chen W, Cui X, Wang Y, Yang Y, Chen X, Fu Y, Xu X. YKT6, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration. Oncoimmunology 2021;10:1938890. [PMID: 34221701 DOI: 10.1080/2162402X.2021.1938890] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
742 Okada R, Furusawa A, Inagaki F, Wakiyama H, Kato T, Okuyama S, Furumoto H, Fukushima H, Choyke PL, Kobayashi H. Endoscopic near-infrared photoimmunotherapy in an orthotopic head and neck cancer model. Cancer Sci 2021;112:3041-9. [PMID: 34101947 DOI: 10.1111/cas.15013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
743 Perrotti V, Caponio VCA, Mascitti M, Lo Muzio L, Piattelli A, Rubini C, Capone E, Sala G. Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review. Cancers (Basel) 2021;13:3126. [PMID: 34206707 DOI: 10.3390/cancers13133126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
744 Haring CT, Bhambhani C, Brummel C, Jewell B, Bellile E, Heft Neal ME, Sandford E, Spengler RM, Bhangale A, Spector ME, McHugh J, Prince ME, Mierzwa M, Worden FP, Tewari M, Swiecicki PL, Brenner JC. Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma. Oncotarget 2021;12:1214-29. [PMID: 34194620 DOI: 10.18632/oncotarget.27992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
745 Denis C, Sakalihasan S, Frères P, Withofs N, Sautois B. Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer. Case Rep Oncol 2021;14:972-6. [PMID: 34267641 DOI: 10.1159/000517008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
746 Borm FJ, Smit J, Oprea-Lager DE, Wondergem M, Haanen JBAG, Smit EF, de Langen AJ. Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Cancers (Basel) 2021;13:3083. [PMID: 34205572 DOI: 10.3390/cancers13123083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
747 Okada T, Okamoto I, Sato H, Ito T, Miyake K, Tsukahara K. Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma. In Vivo 2021;35:1253-9. [PMID: 33622928 DOI: 10.21873/invivo.12376] [Reference Citation Analysis]
748 Fushimi C, Baba D, Masubuchi T, Yamazaki M, Kitani Y, Kitajima T, Tanaka J, Hanyu K, Tanaka N, Miura K, Tada Y. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In Vivo 2020;34:2653-7. [PMID: 32871796 DOI: 10.21873/invivo.12084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
749 Suchan M, Wuerdemann N, Sharma SJ, Klussmann JP. [HPV-related oropharyngeal squamous cell carcinoma-Incidence steadily rising]. HNO 2021;69:599-608. [PMID: 34143237 DOI: 10.1007/s00106-021-01087-0] [Reference Citation Analysis]
750 Sato H, Fushimi C, Okada T, Matsuki T, Kondo T, Omura GO, Miura K, Yamashita T, Okamoto I, Tsukahara K. Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma. In Vivo 2020;34:2967-72. [PMID: 32871839 DOI: 10.21873/invivo.12127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
751 Cao W, Ma X, Fischer JV, Sun C, Kong B, Zhang Q. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res 2021;9:49. [PMID: 34134781 DOI: 10.1186/s40364-021-00301-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
752 Sliker BH, Campbell PM. Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. Vaccines (Basel) 2021;9:634. [PMID: 34200702 DOI: 10.3390/vaccines9060634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
753 Tahara M, Kiyota N, Nibu KI, Akamatsu A, Hoshino T, Hayashi R. Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. Int J Clin Oncol 2021;26:1619-27. [PMID: 34110532 DOI: 10.1007/s10147-021-01949-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
754 Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, Henson C, Sheqwara J, Mell LK, Sen N, Clump DA, Garg MK, Yilmaz E, Torres-Saavedra P, Le QT. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel) 2021;13:2882. [PMID: 34207599 DOI: 10.3390/cancers13122882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
755 Oshima S, Asai S, Seki N, Minemura C, Kinoshita T, Goto Y, Kikkawa N, Moriya S, Kasamatsu A, Hanazawa T, Uzawa K. Identification of Tumor Suppressive Genes Regulated by miR-31-5p and miR-31-3p in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2021;22:6199. [PMID: 34201353 DOI: 10.3390/ijms22126199] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
756 Nenclares P, Gunn L, Soliman H, Bover M, Trinh A, Leslie I, Wong KH, Melcher A, Newbold K, Nutting CM, Ap Dafydd D, Bhide SA, Harrington K. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. J Immunother Cancer 2021;9:e002718. [PMID: 34103355 DOI: 10.1136/jitc-2021-002718] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
757 Rosenberg AJ, Izumchenko E. Neoantigen evolution in head and neck cancer progression: where do we go from here? Oncotarget 2021;12:1124-5. [PMID: 34136081 DOI: 10.18632/oncotarget.27942] [Reference Citation Analysis]
758 Cowzer D, Mulligan K, Glennon K, Hegarty N, Walsh T, Mccaffrey JA. Clear cell urethral adenocarcinoma – a case report of an exceptional response to immunotherapy in a metastatic rare tumour. Journal of Clinical Urology. [DOI: 10.1177/20514158211022640] [Reference Citation Analysis]
759 Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, Lampenfeld C, Atiya HI, Abecassis I, Kürten CHL, Qi Z, Soose R, Duvvuri U, Kim S, Oesterrich S, Lafyatis R, Coffman LG, Ferris RL, Vignali DAA, Bruno TC. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun 2021;12:3349. [PMID: 34099645 DOI: 10.1038/s41467-021-23355-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 21.5] [Reference Citation Analysis]
760 Lai LT, Gu WG, Hu MB, Wang WJ, Wang SS, Huai YJ, Mei JH, Wang CL. Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. Aging (Albany NY) 2021;13:15413-32. [PMID: 34086601 DOI: 10.18632/aging.203100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
761 Fu JY, Zhang CP, Zhang ZY. Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer. BMC Cancer 2021;21:663. [PMID: 34078311 DOI: 10.1186/s12885-021-08420-4] [Reference Citation Analysis]
762 Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer 2021;9:e002568. [PMID: 34083421 DOI: 10.1136/jitc-2021-002568] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
763 Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl Med 2021;19:238. [PMID: 34078406 DOI: 10.1186/s12967-021-02895-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
764 Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U. The dark side of immunotherapy. Ann Transl Med 2021;9:1041. [PMID: 34277841 DOI: 10.21037/atm-20-4750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
765 Rachev B, Wilking N, Kobelt G, Spandonaro F, Rajer M, Roediger A, Normand R, Zielinski C. Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets. Journal of Cancer Policy 2021;28:100279. [DOI: 10.1016/j.jcpo.2021.100279] [Reference Citation Analysis]
766 Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med 2021;9:1040. [PMID: 34277840 DOI: 10.21037/atm-20-6396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
767 Gantner LF. Immuntherapien - Hoffnungsträger in der Therapie des Zervixkarzinoms. InFo Hämatol Onkol 2021;24:16-22. [DOI: 10.1007/s15004-021-8694-7] [Reference Citation Analysis]
768 Has C, South A, Uitto J. Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020. Mol Diagn Ther 2020;24:299-309. [PMID: 32328988 DOI: 10.1007/s40291-020-00466-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 16.5] [Reference Citation Analysis]
769 Suchan M, Wuerdemann N, Sharma SJ, Klussmann JP. Das HPV-positive Oropharynxkarzinom – eine Entität mit steigender Inzidenz. best practice onkologie 2021;16:286-295. [DOI: 10.1007/s11654-021-00314-y] [Reference Citation Analysis]
770 Nakano K. Progress of molecular targeted therapy for head and neck cancer in clinical aspects. Mol Biomed 2021;2:15. [PMID: 35006440 DOI: 10.1186/s43556-021-00032-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
771 Espinosa ML, Abad C, Kurtzman Y, Abdulla FR. Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers. Front Oncol 2021;11:605941. [PMID: 34123780 DOI: 10.3389/fonc.2021.605941] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
772 Pierik AS, Leemans CR, Brakenhoff RH. Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization. Cancers (Basel) 2021;13:2635. [PMID: 34071997 DOI: 10.3390/cancers13112635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
773 Li X, Fang Q, Du W, Zhang X, Dai L, Qiao Y. Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma. BMC Cancer 2021;21:622. [PMID: 34044810 DOI: 10.1186/s12885-021-08373-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
774 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
775 Tada H, Nagata Y, Takahashi H, Matsuyama T, Ida S, Mito I, Chikamatsu K. Systemic immune responses are associated with molecular characteristics of circulating tumor cells in head and neck squamous cell carcinoma. Mol Clin Oncol 2021;15:147. [PMID: 34094545 DOI: 10.3892/mco.2021.2309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
776 Chevalier T, Daste A, Saada-Bouzid E, Loundou A, Peyraud F, Lambert T, Le Tourneau C, Peyrade F, Dupuis C, Alfonsi M, Fayette J, Reure J, Huguet F, Fakhry N, Toullec C, Salas S. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. Cancer Med 2021;10:3952-63. [PMID: 34080776 DOI: 10.1002/cam4.3953] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
777 Liu W, Chen G, Zhang C, Liao X, Xie J, Liang T, Liao W, Song L, Zhang X. Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2021. [PMID: 34027599 DOI: 10.1007/s00405-021-06879-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
778 Zheng Y, Dou H, Li Q, Sun Y, Wang Y, Zhang W. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial. Cancer Control 2021;28:1073274821997444. [PMID: 34029149 DOI: 10.1177/1073274821997444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
779 Tian Y, Huang A, Yang Y, Dang Q, Wen Q, Wang L, Sun Y. Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:662392. [PMID: 34109117 DOI: 10.3389/fonc.2021.662392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
780 Borcoman E, Marret G, Le Tourneau C. Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:2573. [PMID: 34073885 DOI: 10.3390/cancers13112573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
781 Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer 2020;8:e000775. [PMID: 32554615 DOI: 10.1136/jitc-2020-000775] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 31.0] [Reference Citation Analysis]
782 Shi Y, Xie TX, Leach DG, Wang B, Young S, Osman AA, Sikora AG, Ren X, Hartgerink JD, Myers JN, Rangel R. Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model. Cancer Prev Res (Phila) 2021;14:767-78. [PMID: 34021022 DOI: 10.1158/1940-6207.CAPR-20-0607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
783 Ou X, Ma Q, Yin W, Ma X, He Z. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. Front Cell Dev Biol 2021;9:674467. [PMID: 34095145 DOI: 10.3389/fcell.2021.674467] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
784 Kanno H, Nagata H, Ishiguro A, Tsuzuranuki S, Nakano S, Nonaka T, Kiyohara K, Kimura T, Sugawara A, Okazaki Y, Takae S, Nakabayashi T, Arai H, Suzuki H. Designation Products: Boron Neutron Capture Therapy for Head and Neck Carcinoma. Oncologist 2021;26:e1250-5. [PMID: 33928712 DOI: 10.1002/onco.13805] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
785 Alghamri MS, McClellan BL, Hartlage MS, Haase S, Faisal SM, Thalla R, Dabaja A, Banerjee K, Carney SV, Mujeeb AA, Olin MR, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Front Pharmacol 2021;12:680021. [PMID: 34084145 DOI: 10.3389/fphar.2021.680021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
786 Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discov 2021;11:1896-912. [PMID: 33990345 DOI: 10.1158/2159-8290.CD-20-1760] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
787 Ionna F, Bossi P, Guida A, Alberti A, Muto P, Salzano G, Ottaiano A, Maglitto F, Leopardo D, De Felice M, Longo F, Tafuto S, Della Vittoria Scarpati G, Perri F. Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers (Basel) 2021;13:2371. [PMID: 34069092 DOI: 10.3390/cancers13102371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
788 Azuma T, Takeuchi T, Matayoshi Y, Namiki S, Obara T, Imamura K, Takamori M. Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. Sci Rep 2021;11:10264. [PMID: 33986326 DOI: 10.1038/s41598-021-88744-0] [Reference Citation Analysis]
789 Pogorzelski M, Hilser T, Ting SC, Kansy B, Gauler TC, Stuschke M, Schmid KW, Lang S, Grünwald V, Schuler M, Kasper S. Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. Front Oncol 2021;11:635096. [PMID: 34055606 DOI: 10.3389/fonc.2021.635096] [Reference Citation Analysis]
790 Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Int J Mol Sci 2021;22:5123. [PMID: 34066087 DOI: 10.3390/ijms22105123] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
791 Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
792 De Felice F, Musio D, Tombolini V. Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment. J Pers Med 2021;11:393. [PMID: 34068797 DOI: 10.3390/jpm11050393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
793 Kanno Y, Chen CY, Lee HL, Chiou JF, Chen YJ. Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. Front Oncol 2021;11:640392. [PMID: 34026617 DOI: 10.3389/fonc.2021.640392] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
794 Magnes T, Wagner S, Kiem D, Weiss L, Rinnerthaler G, Greil R, Melchardt T. Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2021;22:4981. [PMID: 34067112 DOI: 10.3390/ijms22094981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
795 Sanghavi K, Vuppala P, Ivaturi V, Hamuro L, Roy A, Suryawanshi S. Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology. CPT Pharmacometrics Syst Pharmacol 2021;10:748-59. [PMID: 33955714 DOI: 10.1002/psp4.12642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
796 Yan Q, Zheng W, Wang B, Ye B, Luo H, Yang X, Zhang P, Wang X. A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. BioData Min 2021;14:29. [PMID: 33962640 DOI: 10.1186/s13040-021-00261-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
797 Spaas M, Sundahl N, Hulstaert E, Kruse V, Rottey S, De Maeseneer D, Surmont V, Meireson A, Brochez L, Reynders D, Goetghebeur E, Van den Begin R, Van Gestel D, Renard V, Dirix P, Mestdagh P, Ost P. Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer 2021;21:514. [PMID: 33962592 DOI: 10.1186/s12885-021-08088-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
798 Mahmutović L, Bilajac E, Hromić-Jahjefendić A. Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials. Microorganisms 2021;9:1001. [PMID: 34066342 DOI: 10.3390/microorganisms9051001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
799 William WN Jr, Zhao X, Bianchi JJ, Lin HY, Cheng P, Lee JJ, Carter H, Alexandrov LB, Abraham JP, Spetzler DB, Dubinett SM, Cleveland DW, Cavenee W, Davoli T, Lippman SM. Immune evasion in HPV- head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. Proc Natl Acad Sci U S A 2021;118:e2022655118. [PMID: 33952700 DOI: 10.1073/pnas.2022655118] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
800 Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open 2021;4:e2111113. [PMID: 34019086 DOI: 10.1001/jamanetworkopen.2021.11113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
801 Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
802 Wurcel V, Chirovsky D, Borse R, Altuna JI, Carabajal F, Gandhi J. Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. Adv Ther 2021;38:2613-30. [PMID: 33855690 DOI: 10.1007/s12325-021-01656-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
803 Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Transl Cancer Res 2021;10:2571-85. [PMID: 35116571 DOI: 10.21037/tcr-20-2096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
804 Liu Z, Zhang D, Liu C, Li G, Chen H, Ling H, Zhang F, Huang D, Wang X, Liu Y, Zhang X. Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration. Front Immunol 2021;12:659184. [PMID: 33995379 DOI: 10.3389/fimmu.2021.659184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
805 Koucký V, Bouček J, Plzák J, Fialová A. Importance of immune cell infiltration in tumor microenvironment of head and neck cancer. Onkologie 2021;15:67-72. [DOI: 10.36290/xon.2021.013] [Reference Citation Analysis]
806 Ruiz de Porras V, Pardo JC, Notario L, Etxaniz O, Font A. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer? Int J Mol Sci 2021;22:4712. [PMID: 33946818 DOI: 10.3390/ijms22094712] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
807 Ribbat-Idel J, Dressler FF, Krupar R, Watermann C, Paulsen FO, Kuppler P, Klapper L, Offermann A, Wollenberg B, Rades D, Laban S, Reischl M, Bruchhage KL, Idel C, Perner S. Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma. Front Med (Lausanne) 2021;8:640515. [PMID: 33987192 DOI: 10.3389/fmed.2021.640515] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
808 Subramaniam N, Nambiar A, Dhar S, Thankappan K, Koyakutty M, Balasubramanian D, Das M, Iyer S. Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts Local Recurrence in Oral Squamous Cell Carcinoma. Indian J Surg Oncol 2021;12:408-14. [PMID: 34295087 DOI: 10.1007/s13193-021-01333-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
809 Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer 2021;21:360-78. [PMID: 33907315 DOI: 10.1038/s41568-021-00346-0] [Cited by in Crossref: 180] [Cited by in F6Publishing: 199] [Article Influence: 90.0] [Reference Citation Analysis]
810 Xiao L, Kang W, Liao J, Li Y. Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis. Braz J Otorhinolaryngol 2022;88 Suppl 1:S70-81. [PMID: 34045134 DOI: 10.1016/j.bjorl.2021.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
811 Yang B, Chen J, Teng Y. TNPO1-Mediated Nuclear Import of FUBP1 Contributes to Tumor Immune Evasion by Increasing NRP1 Expression in Cervical Cancer. J Immunol Res 2021;2021:9994004. [PMID: 33987449 DOI: 10.1155/2021/9994004] [Reference Citation Analysis]
812 Sobol RE, Menander KB, Chada S, Wiederhold D, Sellman B, Talbott M, Nemunaitis JJ. Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma. Front Oncol 2021;11:645745. [PMID: 33968744 DOI: 10.3389/fonc.2021.645745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
813 Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, Duvvuri U, Grandis JR, Califano JA, Cohen EEW, Gutkind JS. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun 2021;12:2383. [PMID: 33888713 DOI: 10.1038/s41467-021-22619-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
814 Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang YQ, Xie C. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:650292. [PMID: 33968750 DOI: 10.3389/fonc.2021.650292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
815 Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G, Laban S, Brunner T, Tamaskovics B, Frey B, Zhou JG, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl U, Iro H, Fietkau R, Hecht M. Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. Cancers (Basel) 2021;13:1959. [PMID: 33921668 DOI: 10.3390/cancers13081959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
816 Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, Huang D, Huang Z, Wu Z, Hu Y. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:562315. [PMID: 33937012 DOI: 10.3389/fonc.2021.562315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
817 Lim AM, Cavanagh K, Hicks RJ, McLean L, Goh MS, Webb A, Rischin D. Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. Front Oncol 2021;11:656611. [PMID: 33937066 DOI: 10.3389/fonc.2021.656611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
818 Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer 2021;9:e001752. [PMID: 33849924 DOI: 10.1136/jitc-2020-001752] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
819 Yu X, Long Y, Chen B, Tong Y, Jia X, Zhou J, Tang F, Xu P, Cao Y, Huang W, Ren J, Wan Y, Sun J, Jin G, Gong L. The PD-L1 and TLR7 dual-targeting nanobody-drug conjugate exerts potent antitumor efficacy by orchestrating innate and adaptive immune responses.. [DOI: 10.1101/2021.04.11.439388] [Reference Citation Analysis]
820 Ma B, Li H, Qiao J, Meng T, Yu R. Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas. Biosci Rep 2020;40:BSR20201820. [PMID: 33111959 DOI: 10.1042/BSR20201820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
821 Kikuchi M, Yamashita D, Hara S, Takebayashi S, Hamaguchi K, Mizuno K, Omori K, Shinohara S. Discordant Immune Marker Expression Between Preoperatively Biopsied and Matched Surgically Resected Specimens in Patients With Oral Squamous Cell Carcinoma. Cureus 2021;13:e14423. [PMID: 33996291 DOI: 10.7759/cureus.14423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
822 Wang T, Suita Y, Miriyala S, Dean J, Tapinos N, Shen J. Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics 2021;13:520. [PMID: 33918635 DOI: 10.3390/pharmaceutics13040520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
823 Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, Wu Y, Rajamanickam V, Bernard B, Hilgart-Martiszus I, Fountain CB, Morris G, Iwamoto N, Shimada T, Chang S, Traber PG, Zomer E, Horton JR, Shlevin H, Redmond WL. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. J Immunother Cancer 2021;9:e002371. [PMID: 33837055 DOI: 10.1136/jitc-2021-002371] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
824 Kariya S, Shimizu Y, Hanai N, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Fujiwara A, Yamada T, Homma A. Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. Int J Clin Oncol 2021;26:1049-56. [PMID: 33830342 DOI: 10.1007/s10147-021-01900-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
825 Cabezas-Camarero S, Cabrera-Martín MN, Merino-Menéndez S, Paz-Cabezas M, García-Barberán V, Sáiz-Pardo Sanz M, Iglesias-Moreno M, Alonso-Ovies A, Pérez-Segura P. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer. Oncologist 2021;26:e1018-35. [PMID: 33751752 DOI: 10.1002/onco.13754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
826 Wang JH, Wahid KA, van Dijk LV, Farahani K, Thompson RF, Fuller CD. Radiomic biomarkers of tumor immune biology and immunotherapy response. Clin Transl Radiat Oncol 2021;28:97-115. [PMID: 33937530 DOI: 10.1016/j.ctro.2021.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
827 De Keukeleire SJ, Vermassen T, Hilgert E, Creytens D, Ferdinande L, Rottey S. Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. Cancers (Basel) 2021;13:1714. [PMID: 33916646 DOI: 10.3390/cancers13071714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
828 Liu S, Tang Q, Huang J, Zhan M, Zhao W, Yang X, Li Y, Qiu L, Zhang F, Lu L, He X. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Aging (Albany NY) 2021;13:11257-80. [PMID: 33820866 DOI: 10.18632/aging.202811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
829 Meng Q, Lu YX, Ruan DY, Yu K, Chen YX, Xiao M, Wang Y, Liu ZX, Xu RH, Ju HQ, Qiu MZ. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. Mol Ther Nucleic Acids 2021;24:695-710. [PMID: 33996253 DOI: 10.1016/j.omtn.2021.03.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
830 Li G, Zhu X, Liu C. Characterization of Immune Infiltration and Construction of a Prediction Model for Overall Survival in Melanoma Patients. Front Oncol 2021;11:639059. [PMID: 33869027 DOI: 10.3389/fonc.2021.639059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
831 Abboodi F, Delva NC, Emmel J, Renrick A, Buckhaults P, Banister CE, Creek KE, Pirisi L. Human papillomavirus-mediated carcinogenesis and tumor progression. GENOME INSTAB DIS 2021;2:71-91. [DOI: 10.1007/s42764-021-00038-x] [Reference Citation Analysis]
832 Shiono S. The role of pulmonary metastasectomy for pulmonary metastasis from head and neck cancer. J Thorac Dis 2021;13:2643-8. [PMID: 34012613 DOI: 10.21037/jtd.2020.04.14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
833 Delafoy A, Uguen A, Lemasson G, Conan-Charlet V, Pradier O, Lucia F, Schick U. PD-L1 expression in recurrent head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2021. [PMID: 33796940 DOI: 10.1007/s00405-021-06777-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
834 Tian H, Chen X, Zhang Y, Wang Y, Fu X, Gu W, Wen Y. Dioscin inhibits SCC15 cell proliferation via the RASSF1A/MST2/YAP axis. Mol Med Rep 2021;23:414. [PMID: 33786612 DOI: 10.3892/mmr.2021.12053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
835 Patel JM, Enich M, Stephenson R, Groinsberg R, Girda E. Vaginal mucositis related to immunotherapy in endometrial cancer. Gynecol Oncol Rep 2021;36:100742. [PMID: 33948476 DOI: 10.1016/j.gore.2021.100742] [Reference Citation Analysis]
836 Hirshoren N, Al-Kharouf I, Weinberger JM, Eliashar R, Popovtzer A, Knaanie A, Fellig Y, Neuman T, Meir K, Maly A, Vainer GW. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma. Oncology 2021;99:464-70. [PMID: 33789303 DOI: 10.1159/000515441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
837 Nakamura K, Kiniwa Y, Okuyama R. CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses. J Cancer Res Clin Oncol 2021;147:1993-2001. [PMID: 33770254 DOI: 10.1007/s00432-021-03612-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
838 Altay-Langguth A, Balermpas P, Brandts C, Balster S, Ghanaati S, Winkelmann R, Burck I, Rödel F, Martin D, Rödel C, von der Grün J. Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. Clin Transl Radiat Oncol 2021;28:71-8. [PMID: 33889760 DOI: 10.1016/j.ctro.2021.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
839 Wang J, Hu Y, Escamilla-Rivera V, Gonzalez CL, Tang L, Wang B, El-Naggar AK, Myers JN, Caulin C. Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. Cancers (Basel) 2021;13:1471. [PMID: 33806894 DOI: 10.3390/cancers13061471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
840 Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer 2021;24:946-58. [PMID: 33743112 DOI: 10.1007/s10120-021-01173-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20]<